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ABSTRACT 
Cancer is the leading cause of death on the planet, killing an estimated 8.2 million people in 
the year of 2012.The disease is associated with two families of genes, namely oncogenes and 
tumour suppressor genes. The hallmarks of cancer pathogenesis include gene amplification, 
point mutations or chromosomal rearrangements within these genes. Kinases are responsible 
for the reversible phosphorylation of proteins, which plays a significant and extensive role in 
cellular signal transduction. Aberrant kinase activity provokes overexpression, mutations and 
chromosomal translocation and results in the onset of onco- and tumorogenesis, ultimately 
leading to cancer.  
Inactivation of this class of enzyme is thus critical as it would result in the suppression of 
these unwanted activities. For this, researchers have developed kinase inhibitors, specifically 
targeting these proteins and thus inhibiting signal transduction pathways and tumour growth. 
This has resulted in great successes, particularly in the case of the commercial inhibitor, 
imatinib. However, resistance to approved therapeutic agents through mutations has resulted 
in the search for more potent and selective inhibitors to overcome these obstacles.  
This project involved the synthesis of bioactive heterocycles linked to 1,2,3-triazoles using 
either a C-C or C-N bond forming strategy. The synthetic methodology followed included the 
use of Sonogashira coupling reactions between3-bromoquinoline, 7-chloro-4-iodoquinoline, 
4-bromoisoquinolineand5-bromoisoquinolineand trimethylsilylacetylene (TMSA), followed 
by deprotection of the TMS group to yield heterocycles bearing terminal alkynes. The 
synthesis of both benzyl azide and 2-(azidomethyl)pyridine as azide fragments, allowed for 
subsequent coupling of the synthesized azide and alkyne fragments through copper-mediated 
click chemistry, affording a library of 1,4-substituted 1,2,3-triazole based reversible kinase 
inhibitors. Synthesis of a second library of o-, m- and p-substituted nitro benzyl azides, 
allowed for both copper- and ruthenium-mediated click reactions, between the alkynes and 
nitro benzyl azides synthesized, to yield 1,4- and 1,5-substituted 1,2,3-triazoles, respectively. 
Finally, reduction of the incorporated o-, m- and p- substituted nitro group, and acylation of 
the resultant amine with acryloyl chloride, resulted in the incorporation of the important 
Michael acceptor moiety required for irreversible inhibition. This afforded a library of both 
reversible and potential irreversible triazole-based kinase inhibitors through efficient copper- 
and ruthenium-mediated click chemistry. 
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Biological screening and activity assays against the wildtype, and two mutated forms of the 
EGFR kinase, were undertaken with these synthesized compounds.A number of synthesized 
inhibitors showed good selectivity for the mutated forms of the EGFR kinase only.The most 
potent inhibitor N-{2-{[4-(isoquinolin-4-yl)-1H-1,2,3-triazol-1-
yl]methyl}phenyl}acrylamide,displayed efficacy in the low μM range - comparable to that of 
the FDA approved drug, gefitinib. 
The synthetic methodology derived in this project could be applied to the use of biological 
space probes with further investigatory research. Furthermore, from the biological screening 
results obtained, and the selectivity profile shown by these inhibitors, the synthesis of a 
second generation library of compounds is an additional research possibility.   
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UITTREKSEL 
Kanker is die hoof oorsaak van sterftes ter wêreld, wat verantwoordelik is vir die dood van 
ongeveer 8.2 miljoen mense in die jaar 2012. Die siekte word geassosieer met twee 
geenfamilies, naamlik onkogene en gewasonderdrukkingsgene. Die kenmerke van kanker 
pathiogene behels geenversterking, puntmutasies of chromosomale herrangskikking binne in 
die gene. Kinase is verantwoordelik vir die omkeerbare fosforilering van proteine wat n uiters 
belangrike rol in sellulere sein transduksie speel. Abnormale kinase aktiwiteit lei tot 
ooruitdrukking, mutasies en chromosomale translokasie wat tot die ontwikkeling van onko- 
en gewasgroei en wat eindelik tot kanker lei. 
Deaktivering van die klas van ensieme is dus krities want dit sal die ongewenste abnormale 
aktiwiteite onderdruk. As gevolg van die bogenoemde, het navorsers kinase inhibeerders 
ontwikkel wat die spesifieke protein teiken en hiermee die sein transduksie roete asook gewas 
groei inhibeer. Hiermee het die sukses van inhibeerders veral die kommersiele inhibeerder, 
imatinib, grootliks toegeneem. Oor die afgelope jare het die belangstelling in die 
ontwikkeling van meer selektiewe en kragtige inhibeerders toegeneem as gevolg van die 
weerstand wat goedgekeurde terapeutiese middels opbou.  
In hierdie projek is daar gebruik gemaak van „n C-C of C-N bindingsvorming strategie om 
bioaktiewe heterosikliese molekules te sintetiseer wat gekoppel is aan 1,2,3-triasool 
funksionele groepe. Die sintetiese metode maak gebruik van Sonogashira reaksies vir die 3-
bromo-kwinolien, 7-chloro-4-iodokwinolien, 4-bromoisokwinolien en 5-bromoisokwinolien 
met trimetielsilielasetileen (TMSA), gevolg met die ontskerming van die TMS-groep om die 
terminale alkyn op die heterosiklusse te ontbloot. Die asied fragmente, bensiel asied en 2-
(asidometiel)piridien, was toe gesintetiseer om met die gevormde heterosiklus alkyne „n 
koper ondersteunende kliek chemie te ondergaan. „n Reeks van 1,4-digesubstitueerde 1,2,3-
triasool gebaseerde omkeerbare kinase inhibitore is toe gevorm. „n Tweede reeks met o-, m-, 
en p- gesubtitueerde nitro bensiel asiede was gesintetiseer om 1,4- en 1,5- digesubtitueerde 
1,2,3-triasole te sintetiseer met behulp van koper- en ruthenium ondersteunende kliek chemie. 
Laastens was die o-, m-, en p- nitro groepe gereduseer om „n primêre amien te vorm.  Die 
gevormende amien het „n asileringsreaksie met akriloïel chloried ondergaan om die kern, die 
Michael akseptor, te inkorporeer. Die Michael akseptor word benodig om „n onomkeerbare 
inhibitoriese aktiwiteit te kan uitvoer.  Die projek het dus met behulp van kliek chemie, twee 
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1,2,3-triasool  reekse gelewer wat omkeerbare en onomkeerbare inhibitoriese aktiwiteit kan 
uitvoer. 
Die verbindings gesintetiseerd in hierdie projek het keuringstoetse ondergaan teen die wilde 
tipe en teen twee gemuteerde forme van die EGFR kinase ensiem. Van hierdie verbindings 
het goeie selektiwiteit vertoon teenoor die gemuteerde EGFR kinase ensiem. Die mees 
aktiewe inhibeerder, N-{2-{[4-isokwinolin-4-iel)-1H-1,2,3-triasool-1-iel]feniel}akrielamied, 
het aktiwiteit in die lae µM reeks vertoon. Dié inhibisie waarde is vergelykbaar met die FDA 
goedgekeurde medikasie, gefitinib.  
In hierdie projek is sintetiese metodes ontwikkel wat toegepas kan word op meer intensiewe 
biologiese ondersoeke en asook meer navorsing. Die resultate vekry van die biologiese 
aktiwiteit, asook die verbindings se selektiwiteit, gee die moontlikheid vir die ontwikkeling 
en sintese van „n tweede generasie verbindings. 
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CHAPTER 1 – CANCER AND TARGETED TREATMENT 
1.1CANCER 
1.1.1 Statistics, Definition and History 
Cancer is the chief cause of death worldwide, leading mortality causation in economically 
developed countries andsecondin developing countries.
1
 In 2002, the inaugural GLOBOCAN 
series of the International Agency for Research on Cancer (IARC) estimated that there were 
10.9 million new cases and 6.7 million deaths in the year due to cancer.
2
 In 2004, deaths due 
to cancer amounted to 12.6% of total deaths worldwide, coming second only to heart disease 
related deaths with 15.1%.
3
 In 2008, the number increased to an estimated 12.7 million new 
cases and 7.6 million deaths for the year. This translates to approximately 21000 deaths per 
day and 13% of all deaths worldwideper annum. Globally, cancer is the culprit for one in 
eight deaths and is the cause of more deaths than AIDS, tuberculosis and malaria combined.
4
 
 
Figure 1 
Illustration of worldwide statistics gathered from GLOBOCAN 2008.
5
 
Most recently, in 2012, 14.1 million new cases and 8.2 million deaths were estimated in the 
year – an 11% and 7.8% increase, respectively, since 2008. Prevalence estimates exhibited 
that there were 32.6 million people alive, above the age of 15, who had been diagnosed with 
cancer in the last 5 years. 57% (8 million) of new cancer cases, 65% (5.3 million) of the 
cancer deaths and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the less 
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developed regions.The most commonly diagnosed cancers worldwide illustrated in Figure 1, 
were those of the lung (1.8 million, 13.0% of the total), breast (1.7 million, 11.9%), and 
colorectum (1.4 million, 9.7%). The most common causes of cancer death were cancers of the 
lung (1.6 million, 19.4% of the total), liver (0.8 million, 9.1%), and stomach (0.7 million, 
8.8%).
6
Projections based on these estimationsdisplay a substantial increase to 19.3 million 
cases by the year 2025, and 21.4 million cases and 13.2 million deaths by 2030.
7
 These 
increases can largely be attributed tothe growth and aging of the human population, a 
consequence of reductions in childhood mortality and deaths due to infectious diseases in 
developing nations. As developing countries advance through accelerated societal and 
economic transitions, they are ultimately more likely to become “Westernized”. With 
Westernization and the adoption of Western lifestyles - which includes the use of tobacco, 
poor diet choice and lack of physical activity – it can be deduced that the pattern of cancer 
incidences, especially that of lung, breast and colorectal cancer,so evident in developed 
countries, will follow.
8
 
Closer to home, these predictions and evaluations are becoming a reality. With over 715 000 
newly recorded cancer cases and 542 000 deaths occurring in the year 2008 on the African 
continent due to cancer, a significant number which is estimated to double in the next 20 
years, the burden of cancer is becoming heavier every day.  
 
Figure 2 
Illustration of most common cancers by gender and country in Africa gathered from GLOBOCAN 2008.
9
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Furthermore, an increasing number of lung, female breast and prostate cancer cases are being 
documented as shown in Figure 2.
9
 In the face of these daunting statistics and harsh realities, 
opportunities for cancer prevention and control on our native soil, as well as worldwide, must 
be undertaken. 
Cancer, which is medically termed malignant neoplasm, is the collective name given to an 
expansive group of diseases which are mainly characterised by unregulated cellular division 
and growth. In cancer, the rapid division of abnormal cells leads to the formation of 
malignant tumours which grow beyond their usual capacity and boundaries. This results in 
the invasion of adjoining body parts and possibly vital organs.
10
Cancer may also spread via 
the lymphatic system and bloodstream to other remote areas of the body. This process is 
referred to as metastasis, and if the spread is not controlled or regulated it can result in death. 
Metastases are the major cause of death from cancer. Cancer can evolve from almost any type 
of cell and you can develop cancer in any organ of the body. There are over 200 different 
types of cancer known and over 60 different organs in the human body where cancer can 
grow.
11
 
 
Figure 3 
a) (left) The Edwin Smith Papyrus and b) (right) The printed collected writing of Hippocrates circa 1588 
in Venice.
12
 
 
It has been said that cancer is as old as the human race;however discoveries in the field of 
paleopathology indicate the existence of tumours in prehistoric animals, predating the advent 
of man. The oldest medical description of what we call cancer, dates back to approximately 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 1 – Cancer and Targeted Treatment 
_______________________________ 
17 
 
3000 BC and can be found written in the Edwin Smith Papyrus, an ancient Egyptian manual 
for surgery illustrated in Figure 3a. It recounts 8 incidents of tumours or ulcers in the breast 
area, with the writer concluding that there is no treatment or cure for the disease. The 
attempted treatment entailed cauterisation by making use of a fire drill. It is interesting to 
note that the Egyptian manner of remedy for tumours and cancerous growths using arsenic 
paste, known as “Egyptian ointment,” remained in use up until the 19th century.Fast 
forwarding approximately 2600 years brings us to the time of the Greek physician 
Hippocrates (460-375 BC), considered the “Father of Medicine.” Hippocrates is credited with 
the coining of the term “cancer” from the Greek words carcinos and carcinoma, names 
Hippocrates gave to describe non-ulcer- and ulcer- forming tumours respectively. The Greek 
words translate to crab - what the bulging, finger like protrusions of tumours reminded him 
of.Treatment at the time included salves and ointments and cautery for surface lesions, whilst 
deep tumours were removed by knife or regarded as untreatable.
12
A printed collection of his 
writings, still effective at the end of the 16
th
 century, is pictured in Figure 3b. 
With the incorporation of Greece into the Roman Empire in 146 BC, Greek physicians now 
became Roman citizens. Among these was Aulus Celsus (25 BC-AD 50), an authoritative 
physician who modelled Latin as the language of medicine and transcribed the Greek terms 
Hippocrates used, to the Latin name for crab – cancer. Another native of Greece, Claudius 
Galen (130-200), used the Greek term for swelling, oncos, to describe tumours. Both the 
terms that Hippocrates, Celsus and Galen brought into existence are still used today – to 
describe the study malignant growths and cancer specialists respectively, namely oncology 
andoncologists.
12,13
 
The Renaissance was a time of great development in scientific thinking and the application 
thereof. Thinkers such as Galileo Galilei (1564-1642) and Isaac Newton (1643-1727) 
introduced the use of scientific method which was later applied to study diseases. William 
Harvey (1578-1657), who shed light on human circulation by performing autopsies.
12
The 
pioneering work of Giovanni Batista Morgagni (1682-1771) also propelled cancer research 
forth. He is remembered as a giant of the time because of the relations he drew from patient‟s 
conditions and post-mortem conclusions derived from autopsies, and the importance of 
persuading his colleagues - and the medicinal field in general – that the further advancement 
of medicine lay in clinicopathologic correlation. His published work in 1761, De Sedibus, et 
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Causis Morborum, connected and linked analytic and post-mortem data from over 700 
autopsies.
14
 
Significant advances were made in anatomy, pathology and surgical techniques which served 
as a foundation for the modern advancements in the 18
th
 and 19
th
 centuries. Despite the 
innovation and improvement achieved at the time, surgery was used as a last ditch remedy to 
save the patient‟s life. This was predominately due to the pain subjects had to endure sans 
anaesthesia. It is noted that during these centuries most patients would rather die than go 
through the agony of surgery. William T.G. Morton (1819-1868) is considered the founder of 
modern anaesthesia, and administered the anaesthetic (sulphuric ether), in the first surgical 
operation under general anaesthetic. The surgery - removal of a large vascular tumour on the 
neck - was carried out by John Collins Warren on 16 October 1846 in the Massachusetts 
Hospital in Boston.
15
It is important to note that were it not for the introduction of “germ 
theory” by Louis Pasteur (1822-1895), and its ensuing utilization in the operating theatre by 
Joseph Lister (1827-1912), patients that survived operations would almost certainly have 
become stricken with infection, and death by sepsis would ensue. Lister was one of the first 
to see the link between Pasteur‟s findings on the fermentation and decomposition of meat by 
microscopic living organisms and the infection suffered by patients. Surgeons were now able 
to operate with a considerably diminished chance of infection.
16
The combination of these two 
milestones in medicine allowed surgery to flourish, leading to the development of long-
established cancer operations such as the radical mastectomy which was devised by William 
Stewart Halsted (1852-1922), the first to perform such an operation in the United States in 
1882. This revolutionary operation remained the standard for breast cancer treatment surgery, 
until the 1970s which ushered in the use of a modified radical mastectomy.
17
 
The19
th
 century saw the employment of the modern microscope in the field of oncology. 
Pathologists, or sometimes surgeons who assumed the role of pathologists, would perform 
preoperative and postoperative microscopic investigation on the tumours of their patients. 
From this was born the field of surgical pathology, of which Rudolf Virchow (1821-1902) 
ofGermany was a colossus. Rudolf coined a number of terms including chromatin and 
leukaemia, deduced that cancer cells are abnormal in comparison to benign cells and 
proposed that all cells arise from the division of pre-existing cells. He presented the first 
microscopic description of benign and malignant tumours and very importantly speculated 
that cancer in fluids of the body is caused by a growth-stimulating substance.
18
 In short, he 
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deciphered the cellular origin of cancer
19
 and like Morgagni before him, conceived a 
correlation between the microscopic pathology of the patient with cancer.This paradigm shift 
aided in the progression of cancer surgery and allowed for precise prognosis for patients and 
a way of knowing whether operations were successful in the removal of tumours. 
In the early decades of the 20
th
 century, two major breakthroughs provided impetus for the 
use of animals in cancer research.
20
 These were the discovery of the Rous sarcoma virus,
21
 a 
retrovirus that cause sarcoma in chickens and the first oncovirus to be described, by Francis 
Peyton Rous (1879-1970). There was also an important proposal by Theodor Boveri (1862-
1915) that cancerous tumours arise from chromosomal mutation, the causation of cells to 
grow and divide uncontrollably, which was later proved correct by Thomas Hunt Morgan in 
1915.
22
 
 
Figure 4 
Table illustrating the discoveries and events in the field of cancer and the effects on patient survival rates 
in the United States.
18
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Following the timeline illustrated in Figure 4, a number of colossal discoveries throughout 
the 20
th 
century, including the deciphering of structure of DNA, the breaking of the genetic 
code, and an array of advances in the understanding of molecular biology of cancer itself – 
which will be divulged in full - have led to an ever increasing survival rate and the first 
decrease in the total number of deaths from cancer in human history. Building on the path 
that brought us to this milestone, further scientific research and experimental evaluation will 
be paramount in bringing an end to the war on cancer. 
1.1.2 Causation of Cancer and Prevention 
Since the dawn of medicine and medical science, physicians were perplexed and pondered 
the causes of cancer. Humorism, or humoralism, was a theory postulated by the ancient 
Egyptians, but only established and adopted by Hippocrates, and the ancient Greek and 
Roman physicians and philosophers, circa 400 BC. This theory stated that the human body 
held within it four humours or bodily fluids, namely: black bile, yellow bile, phlegm and 
blood. For a healthy person, these humours would be in balance. Diseases and illness were 
believed to originate from an excess or deficiency of any one or more humours. Galen 
promulgated this theory and it is largely due to his influence and writings - and the religious 
prohibition of autopsies and studying of the body – that humorism remained undisputed for 
many years.
13
In 1858, Rudolf Virchow conclusively discredited this theory with his 
published work on cellular pathology.
18
 
Opposition to the humoral theory was founded by the discovery of lymph and the absence of 
black bile by numerous dissections of animals, conducted by Andreas Vesalius (1514-1564). 
His published work provoked rivalry antagonism from the devotees of Galen. Lymph 
eventually replaced black bile in the world of medicine and it was believed that the flow of 
blood and lymph throughout the body was essential for life. With this knowledge, the French 
philosopher and mathematician René Descartes (1596-1650) put forward his “lymphatic 
theory of cancer.” This theory hypothesized that leakage of lymph through the lymph ducts 
resulted in benign tumours, whilst local fermentation and deterioration of lymph resulted in a 
malignant tumour. Lymph theory was endorsed by the German duo of Georg Ernst Stahl 
(1659-1734) and Friedrich Hoffman (1660-1742), who further expounded that the etiology of 
cancer was as result of the degeneration of lymph, with variable density, acidity and 
alkalinity.
23
The renowned Scottish surgeon, John Hunter (1728-1793), a pioneer in work of 
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the lymphatic system,agreed that tumours were formed as a result of lymph being thrown out 
by the blood.
13
 
In 1838, the German pathologist Johannes Müller (1801-1858) determined the cellular nature 
of tumours. According to his research,cancerous growths did not consist of lymph but rather 
of cells and that the makeup of these growths was virtually identical to that of normal tissue. 
However, Müller speculated that the origin of cancer cells were not from normal tissue, but 
grew from blastema – analogues cells between normal tissue – giving rise to “Blastema 
Theory” as the cause of cancer. Müller also propounded that the basisfor cancer was the 
accumulation of cells in diseased organs that could be potentially harmful in growing and 
spreading to other organs. His student, Rudolf Virchow, later showed that all cells, including 
cancerous cells, are copied from other cells.
14, 23
 
In the 18
th
 century, the birth of the field of cancer epidemiology – the study of the patterns, 
causes, distribution and control of the disease - can be attributed to three major findings. The 
first was in 1713 by the Italian physician Bernardino Ramazzini (1633-1714), who noticed 
the almost entire absence of cervical cancer and higher frequency of breast cancer in nuns, in 
comparison to that of married woman at the time. He speculated whether this was due to their 
celibacy, an important observation in advancing the understanding the role of hormones, 
especially during pregnancy, as well as STDs and their contribution towards cancer risk.
24
His 
work also divulged the hazards of metals in certain occupations and dangers of occupational 
disease.
25
Secondly, in 1761 the London surgeon John Hill (1716-1775) confirmed in his 
book,Cautions against the Immoderate Use of Snuff,the correlation between the use of 
tobacco snuff and the formation of swellings and polyps in the nose. This confirmed the 
concerns of Thomas Venneron the threat of excessive use of tobacco 150 years 
earlier.
25
These conclusions eventually led to further research years later, which found that 
smoking causes lung cancer and the United States Surgeon General‟s warning of the hazards 
of tobacco usein 1964.
26
Lastly, Percival Pott (1714-1788) noticed a considerable number of 
cases of scrotal cancer in chimney sweeps, caused by the chronic exposure to soot collecting 
in the area of the scrotum. This is not surprising as chimney sweeps of the time would “buff 
it” or proceed to work in the nude. Pott identified the association between the soot being the 
causation of the cancer and in so doing, became the first scientist to demonstrate a work-
related link to cancer and that cancer may be caused by an environmentalcarcinogen.
14
 This 
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led to the induction of the Chimney Sweepers Act of 1788, which attempted to stop child 
labour.
27
 
In 1915, Katsusaburo Yamagiwa (1863-1930), a Tokyo pathologist, and his associates were 
the first to invoke cancer in laboratory animals. By applying a solution of crude tar to the 
rabbit‟s ears daily for two years, Yamagiwa and co-workers were able to induce invasive skin 
cancer in seven of the 137 rabbits – demonstrating for the first time experimentally that 
chemicals can be carcinogenic.
20
 
In the decades of, and following 1940, a nationwide fervour in researchers in the United 
States searching for chemical carcinogens was witnessed. Amongst others, oils, tar, 
petroleum, rubbers and other chemicals were irrefutably shown to lead to cancer. By the 
1960s, a lengthy list of organ-specific cancer-causing agents had been identified by 
experimental evaluation.
28
Preceding the 1950s, only a handful of viruses were known to 
cause malignant neoplasm in laboratory animals. In less than 20 years, the field of viral 
oncology exploded with the identification of a myriad of viruses being the causative agent of 
cancer. This included the discovery of the origin of Rous chicken sarcoma, the first cancer 
seen in animals, to be a virus through electron microscopy. Rous chicken sarcoma is shown 
on a hen in Figure 5, induced through the virus. In addition, an unusually high number of 
leukaemia cases in radiologists were attributed to continua exposure to X-rays.
28
 
 
Figure 5 
Rous sarcoma that was induced by a filterable virus is shown on a hen.
18 
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Diet and nutrition was determined to be the responsible factor in a large proportion of molar 
pregnancies in Asia.
28
 The discovery that external amounts of oestrogen were able to induce 
mammary cancer across a range of species of laboratory animals, and that oestrogen was 
responsible for breast cancer in both female and male humans, was also achieved in this 
period.
28
 
With the onset of the 1950s, scientists were far more capable of tackling the intricate enigmas 
of chemistry and biology, owing largely to a number of experiments carried out in the period 
of two decades. The misconception that genetic information was contained and transmitted 
by cell proteins was experimentally abolished by Oswald Avery (1877-1955) in 1944. His 
work with pneumococcal bacillus, indicated that DNA was the carrier of cellular information 
and contributed principally to the colossal revelation, that was the unravelling of the structure 
of DNA, by Francis Crick (1916-2004) and James Watson (1928- ) in 1953.
19
In the same 
year, the Finnish researcher CarlNordling (1919-2007), first postulated the multi-mutation 
theory of cancer in his publication in the British Journal of Cancer.
29
 Nordling observed that 
the occurrence of cancer in industrialised nations increased with age, and theorized that 
cancer cells contain mutations in a number of various genes which amass with age. This work 
was the first to associate cancer with ageing and would later become known as the“Knudson 
Hypothesis”, after Alfred G. Knudson‟s (1922- ) work confirming that the accumulation of 
mutationsin cellular DNA is a causation of cancer. His statistical analysis on instances of 
retinoblastoma in children, found that inherent retinoblastoma occurs at an earlier age and in 
both eyes of patients, in comparison to the sporadic disease. This was linked to a genetic 
propensity for cancer and Knudson further suggested that multiple mutations to DNA were 
necessary to induce cancer.
30
 
The discovery of two significant families of genes associated with cancer, namely oncogenes 
and tumour suppressor genes, occurred in the 1970s. With the proposal of the oncogene 
hypothesis of cancer and the coining of the term oncogene by Robert Huebner (1914-1998) 
and George Todaro (1937- ) in 1969,
31
it was postulated that oncogenes were genes that could 
cause uncontrolled cellular growth in other cells, resulting in cancer. The discovery of the 
first oncogene, Src (short for sarcoma), by J. Michael Bishop (1936- ) and Harold E. Varmus 
(1939- ), who found that DNA in normal chicken cells contained the gene responsible for 
avian sarcoma, a source for the causation of cancer in chickens, followed shortly thereafter in 
1976. This suggested that the gene that regulated cell growth and differentiation could also be 
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responsible for the formation of malignant tumours.
32
The origin of oncogenes was identified 
as the alteration or over expression of normal cellular genes called proto-oncogenes, a 
process known as activation. Proto-oncogenes provide the blueprint for their corresponding 
onco-proteins, which oversee cell growth and differentiation and play a role in cellular signal 
transduction pathways.
33
 Activation of proto-oncogenes to become oncogenes can occur 
through mutations, an increase in protein concentration or over expression and chromosomal 
translocations. These processes are illustrated in Figure 6. Bishop and Varmus‟ work on 
oncogenes led directly to the discovery of the first human proto-oncogene, c-Src, for which 
they were awarded the Nobel Prize in Physiology or Medicine in 1989.
32
 
Figure 6 
Representation of the various mechanisms of proto-oncogene activation.
34
 
Examples of proto-oncogenes include the protein subfamily rat sarcoma or RAS – found in 
~20-25% of all carcinomas and in up to 90% of pancreatic cancer tumours, myelocytomatosis 
viral oncogene homolog or MYC – a regulator gene that codes for transcription factors - and 
the WNT signal transduction pathways which are responsible for cell proliferation and 
embryonic development.
35
 
Genes that could inhibittumourigenicity were first reported to exist in experiments conducted 
by Stanbridge in 1976, and later confirmed by Klinger and co-workers.
36
Molecular genetic 
studies identified and subsequently characterized the role of tumour suppressor genes and 
their involvement in cancer. It is now known that these genes regulate an array of cellular 
activities including the retardation of cellular growth, repair of damaged DNA, differentiation 
and apoptosis.
37
 Defective tumour suppressor genes can lead to uncontrolled cellular growth 
and have been associated with the cause of multiple cancers.
33
 With the aid of research, a 
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number of tumour suppressor genes have been identified which include p53, RB, INK4a and 
ARF – all of which have been linked to the causation of many tumour types.37 
Scientists had now discovered that the causation of cancer by carcinogens or viruses was in 
fact damage by chemicals and radiation to DNA, or the addition of new DNA sequences by 
viruses respectively. It was understood that defective genes or mutated DNA in cells could be 
inherited, and that these hereditary anomalies were similar to mutations caused by 
carcinogens and could result in further instances of cancer with additional mutations. 
Regardless of the cause of mutation, inherent, sporadic or environmental, cells that arose 
through activation of proto-oncogenes to form oncogenes led to the growth of clusters of 
irregular cells named clones of the abnormal cell.Through cell differentiation and division, 
mutant clones would evolve and become more damaged with more mutations over time, 
causing the cancer to grow and spread. The most notable difference between normal cells and 
cancerous cells, is that regular cells with mutations undergo apoptosis whilst cancerous cells 
with damaged DNA do not, a discovery that shed light on the mystery that was the etiology 
of cancer. The 6 hallmarks of cancerous cells, what differentiates them from normal cells, is 
displayed in Figure 7.The identification of oncogenes and tumour suppressor genes is on-
going in genetic research and information from these findings can be used to identify people 
who are at a higher risk and more vulnerable to certain cancers.  
 
Figure 7 
The acquired and functional capabilities of cancer.
38
 
Today, we know that cancer is caused by both internal aspects such as inherent genetic 
mutations, hormones, immune conditions and metabolic mutations, as well as external or 
environmental factors.
39
 These external or environmental factors can be subdivided 
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intothreecategories, namely physical carcinogens such as UV radiation, chemical carcinogens 
such as tobacco, asbestos and arsenic and biological carcinogens, such as infectious 
organisms and viruses.
10
 
As is clearly evident in the graphic representations of Figure 8, tobacco is one of the main 
cancer risk factor in the world, increasing risk of developing at least 14 different types of 
cancer, containing at least 50 carcinogens and being the culprit for 22% of global cancer 
mortalities and 72% of lung cancer deathsworldwide. It has been estimated that poor diet can 
be linkedto 30-35% of all cancer deaths in United States, up to 70% of these being colorectal 
cancers. Chronic alcohol consumption has been connected to a multitude of cancers, 
including those of the upper aerodigestive tract, liver, pancreas and even breast. Persistent 
infections of amongst others, the Human Papilloma virus (HPV), hepatitis B (HBV), hepatitis 
C and HIV, have been related to cervical, anogential and skin cancer, as well as Hodgkin‟s 
Lymphoma and T-cell leukaemia to name a few. Infections are associated with 17.8% of all 
cancer cases internationally and in up to 20% in the United States as shown in Figure 8.
10, 39
 
 
Figure 8 
The role of genes and the environment in the development of cancer. A is the percentage contribution of 
each factor. B is familial risk ratios for certain cancers. C is the percentage contribution of each 
environmental factor.
37
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It is estimated that more than 30% of all cancer incidents can be prevented. This can be 
achieved by avoiding known carcinogens such as tobacco, alcohol and other chemical 
carcinogens, a healthy diet and lifestyle, vaccinations against HPV and HBV and reduced 
exposure to UV radiation. It is a case of cancer prevention is better than cure and if detected 
early and treated effectively a large number of cancers have a high probability of going into 
remission. Awareness of early signs and symptoms and undergoing screening at regular 
intervals when older, can both decrease the cancer mortality rate.
10
 As an important example, 
the invention of the “pap smear” or “pap test” by George Papanicolaou (1883-1962) and its 
implementation as test in the 1960s by the American Cancer Society (ACS) has led to a 
decline of about 70% in cervical cancer.
13
 A greater understanding of the pathogenesis and 
causation of malignant neoplasm has enabled researchers to develop effective therapeutic 
treatments for the disease. From humble beginnings, these treatments now make use of state 
of the art technology and cutting edge research techniques to halt the advance of cancer.  
1.1.3 The Evolution of Cancer Treatment 
Similar to ascertaining and understanding the cause and diagnosis of cancer, the progression 
and development of cancer treatment has been a slow endeavour. In antiquity, putting under 
the knife and cautery remained the best method for removal of tumours and remedy of 
cancer. Since 1500 BC, and for 300 years afterwards, various concoctions of herbal remedies 
containing boiled cabbage, tea or fruit amongst other things, as well as elixirs and pastes of 
assorted metals like mercury, lead, iron and copper, were made use of internally or externally 
in different concentrations. Galen, as Hippocrates did, held firm beliefs that cancer was 
incurable and considered the patient untreatable. With his prolific writings and influence at 
the time, progress in the comprehension and treatment of cancer was brought to a standstill 
for an age, as others throughout history adopted his approach.
12
 Surgery, the only real tool of 
cancer treatment at the time, was a primeval and ghastly affair with many complications, the 
main obstacle being blood loss. As discussed previously, it wasn‟t until the 19th and early 20th 
century with the pioneering introduction of antiseptic practice, use of anaesthesia and surgical 
pathology that cancer surgery, and surgery in general, blossomed. So much so, that the 
subsequent 100 years were named, “the century of the surgeon.”13 
A surge of surgical prototypes followed in this century, with a number of them being 
accomplished by Theodor Billroth (1829-1894). His repertoire included the first 
esophagectomy,laryngectomy and the first successful gastrectomy or treatment of gastric 
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cancer.
18
However, the most monumental moment in cancer surgery transpired in 1882, with 
the introduction of the radical mastectomy technique by William Halsted. Halsted believed 
that cancer radiated from the primarytumourto adjacent points.Figure 9 shows the en bloc 
abscission of all neighbouring tissue technique he endorsed, to ensure removal of all 
cancerous cells.
19
 The surgery entailed removal of the full breast, axillary lymph nodes 
andthe pectoralis major and minor in one piece under his recommendation.
 
 
Figure 9 
A diagram of Halsted’s showing his technique for the radical mastectomy.18 
Halsted‟s radical mastectomy remained the cream of the crop of cancer operations for a 
century with only slight alterations being made by others.
18
 Stephen Paget (1855-1926) made 
an important contribution to the knowledge of how cancer spreads by the bloodstream to all 
organs, but could only develop in particular organs, with his “seed and soil” theory of 
metastasis.
40
 This appreciation of metastasis was truthful andaided physicians in ascertaining 
the limits of cancer surgery and the development of systemic therapy – the future of cancer 
treatment. Cancer surgery eventually evolved into a combinational therapy with 
chemotherapy and radiation. With the vast escalation in superior technology of today, the use 
of ultrasound, computed tomography (CT scans), magnetic resonance imaging and positron 
emission tomography (PET scans) has become standard procedure and replaced the need for 
investigative surgery.In addition, through the use of fibre optic technology, the endoscope, 
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cryosurgery, radiofrequency ablation and laser technology, surgeons have been devising 
lesser invasive ways of eliminating tumours.
13
 
The foundation of hormone therapy, among the most prominent of modern approaches of 
cancer treatment, was laid by George Thomas Beatson (1848-1933) and his inquisitive 
nature. Beatson perceived, and concluded experimentally, that removal of the ovaries in 
rabbits led to fatty degeneration in normal cell division. In work he published in 1896, a 
paper entitled, “On Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions 
for a New Method of Treatment, with Illustrative Cases,” Beatson showed improvement of 
advanced breast cancer after bilateral oopherectomy (removal of the ovaries) in 3 patients. 
Beatson surmised that the ovaries were indeed the cause of breast cancer and had 
unknowinglycorrelated the hormone oestrogen and its complications in cancer causation even 
before it had been discovered. He has been the named the “father of endocrine ablation” in 
cancer treatment.
41
45 years later Charles Huggins (1901-1997) established the validity of this 
relationship with hormones and cancer, by experimental removal of the testicles 
(orchiectomy) in male patients with prostate cancer. Striking reversion of metastatic prostate 
cancer through this surgical procedure, as well as with dispensing of oestrogen, was 
witnessed by Huggins.
42
The combined work of these two giants in their field led to the use of 
modern hormonal therapy used to treat breast cancer today, such as tamoxifen and aromatase 
inhibitors. The development of new hormone therapeutic agents is on-going and this, 
combined with research in understanding how hormones manipulate cancer growth, has 
revolutionized cancer risk and treatment, especially in prostate and breast cancer.
13
 
The German physics professor Wilhelm Röntgen (1845-1923) became the first man to 
produce and detect X-rays in 1895, whilst experimenting with gaseous discharge tubes. In 
fact, the first x-ray image is that of his wife‟s hand. He later held a lecture disclosing his 
discovery, generating excitement worldwide. His work earned him the first Nobel Prize in 
physics in 1901,
43
and coupled with the discovery of the radioactive elements radium and 
polonium in 1898 by Pierre and Marie Curie, the era radiation therapy for cancer had 
emerged. The first physician to use X-rays to treat cancer was Emil Grubbe (1875-1960), 
only months after Röntgen‟s discovery, on Gordon Isaacs for retinoblastoma as pictured in 
Figure 10.
44
Radiotherapy showed marked success in skin cancer, as well breast cancer and 
cervical cancer.
20
 Fractionated radiation treatment, where the doses of radiation are spread 
out over time, became a landmark in the field, and in 1928 it was shown to treat head and 
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neck cancers.
19
 Modern radiation oncology can be traced back to the introduction of cobalt 
therapy and medical linear accelerator technology as treatment. The first patient that received 
radiotherapy from a clinical linear accelerator was in 1953.
45
 Henry Kaplan (1918-1984) was 
hugely influential in the design and development of these machines, which has become a 
cornerstone in cancer radiotherapy.
46
 As with surgery, breakthroughs in technology, 
especially in the field of computation, have in recent years allowed radiologists to deliver 
accurate and precise energy to tumours, limiting damage to adjacent regular tissue.
19
 
 
Figure 10 
The first patient treated with a linear accelerator for retinoblastoma, Gordan Isaacs, who lived to 
adulthood with normal vision after radiotherapy.
47 
It became clear to surgeons, radiologists and all individuals involved in the field of oncology 
that regardless of the quality of surgery or radiotherapy treatment, or the combination of the 
two, cure rates had levelled and progression had thus halted. In the 1950s only a third of 
cancers could be treated successfully with the methods and techniques available.
19
The closing 
of the 19
th
 century saw Paul Ehrlich (1854-1915) postulate his “side chain theory” of 1897 - 
the origin of targeted therapy and the introduction of the notion that chemicals could be used 
to fight cancer.
48
 Ehrlich coined the term “chemotherapy”19 and later won the Nobel Prize in 
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Physiology or Medicine in 1908, for his work on immunology, a field he brought into 
being.
48
His proposition that the human immune system stems tumour growth, gave impetus 
for research directed at exploiting the immune system in cancer treatment, as well as the 
widespread search for vaccines andchemicals to extinguish cancer. Animal models of 
transplantable tumourswere developed at the dawn of the 20
th
 century and a basis of being 
able to consistently predict the antitumour effect of these agents for humans from these 
models was thoroughly investigated. This research remained largely fruitless, mostly due to a 
restricted clinical trial for humans.
19
This changed however, after examination of soldiers 
exposed to mustard gas in World War I and II showed acute reduction and harmful changes 
in bone marrow that developed in blood cells. During this period, experimental evaluation 
showed that nitrogen mustard, an analogue of mustard gas, had beneficial effects in treating 
lymphoma, as well as leukaemia.Nitrogen mustard was the first of its kind, an alkylating 
agent that damaged the DNA of abnormal, rapidly growing cells, effectively killing them, and 
the blueprint for the design of a series of similar but more efficacious compounds.
49
In 
addition, folic acid, a vitamin present in leafy vegetable, was shown to be associated with 
bone marrow function andits associated deficiency in megaloblastic anaemia.
49
Sidney Farber 
(1903-1973) and colleagues, probed the effects it had on leukaemia patients, during which it 
surprisingly showed to accelerate proliferation of the cancerous cells. Joining forces with 
medicinal chemists at Lederle Laboratories, a series of similar compounds were generated 
which included aminopterin and amethopterin, now known as methotrexate, which acted as 
folate antagonists.
50
 Farber dispensed these drugs to children with acute lymphoblastic 
leukaemia (ALL) and remarkably, by blocking the folate-needing enzymes activity, induced 
remission of ALL. Methotrexate proved to show inhibition across a wide range of cancers, 
including breast, bladder and choriocarcinoma, a malignancy inherent in trophoblastic cells 
of the placenta, and formed the basis for the first cure for metastatic cancer.
49
With the 
knowledge that chemotherapeutic agents could act by inhibiting a vital chemical reaction for 
DNA duplication, researchers discovered inhibitors of other critical cellular functions. The 
early activity and success of nitrogen mustard and methotrexate, resulted in the founding of 
the National Cancer Chemotherapy Service Center (NCCSC) in 1955, of which Farber 
became a director.
28
This heralded the age of chemotherapy.  
The migration to the pioneering use of combination chemotherapy, where multiple drugs with 
different modes of action are used collectively, can be traced back to the long term remissions 
and even curing of ALL developed by Emil Frei (1924-2013) and colleagues, and the 
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extension of this to Hodgkin‟s and non-Hodgkin‟s lymphoma by Vincent DeVita (1935- ) 
and co-workers.
49In the case of Hodgkin‟s lymphoma, a combination of nitrogen mustard, 
oncovin, procarbazine and prednisone administered as treatment, lead to remission rates of 
effectively zero to 80%, with 60% of these patients never relapsing. Today, this cancer is 
curable 90% of the time, with treatment consisting of integration of radiotherapy and 
chemotherapy.
50
 
The success of combination therapyhad a positive effect use of chemotherapeutic agents as an 
adjuvant to surgery and radiotherapy.
19
 Physicians became more lenient and tolerable to 
using drugs after surgical resection, with no greater success than in that of breast and 
colorectal cancer. As a result of the long but ever improving methodology and techniques 
used in the treatment of cancer, shown in Figure 11, the breast cancer mortality rate began to 
fall in 1991 - a trend that has been maintained – and a drop of 40% in the mortality rate of 
colorectal cancer patients has been witnessed in the last 4 decades.
19
 
 
Figure 11 
Timeline of pivotal events in cancer treatment.
19 
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Research today in chemotherapy, mainly involves improving the activity and reducing the 
side effects these drugs have. This includes the search and use for new drugs and drug 
combinations, the development of liposomal therapy
51
 which increases selectivity towards 
cancer cells and decreases side effects, and chemo protective agents such as amifostine which 
reduces renal injury in chemo patients.
52
 
The great Paul Ehrlich did put forward the idea that the human immune system could halt and 
prevent tumour growth.
53
 With scientists growing understanding of the biology of cancer 
cells, biological agents that could imitate natural cellular signals that are responsible for cell 
growth, were developed and unveiled. The isolation, synthesis and application of these agents 
in treatment, is known biological response modifier (BRM) therapy or immunotherapy.These 
agents are administered to patients in order to either emulate or manipulate a natural immune 
response. This can be achieved by directly changing abnormal cellular growth or indirectly 
by aiding normal cells bring the cancer under control.
13
The first real embodiment of Ehrlich‟s 
vision was the production of monoclonal antibodies (mAbs) by Georges Köhler (1946-1995) 
and César Milstein (1927-2002), for which they won the Nobel Prize in Physiology or 
Medicine in 1984.
53
 Scientists recognized and identified certain tumour targets, name 
antigens, which bind specifically to certain antibodies. With technological advancements in 
the 1970s, mass production of mAbs could be undertaken and used to target specific 
antigens.
13
 With the accessibility to substantial amounts of mAbs with singular specificity, 
developments and enhancement of this method by making use of recombinant DNA 
technology improved efficacy and diminished side effects and resulted in the first Food and 
Drug Administration (FDA) approved monoclonal antibody, rituximab, in 1997, for the 
treatment of B-cell lymphoma.
19
 Since then eleven other antibodies have obtained approval 
for cancer immunotherapy for a wide variety of cancers, which include trastuzumab in 1998 
for the treatment of breast cancer.
53
 It became clear that cellular, rather than hormonal, 
immunity played a much larger role in the immunotherapy of cancer.A name synonymous 
with immunotherapy is that of Steven Rosenberg(1940- ) who first introduced immuno cell 
therapy in 1985, after the description of T-cell growth factor or interleukin-2 in 1976. By 
administering interleukin-2 to patients with metastatic melanoma and renal cancers, 
regression was witnessed in an invasive metastatic disease for the first time by immune 
therapy.
19
This became known as adoptive cell transfer treatment.
54
Immunotherapy has also 
been shown to increase survival probability, regress malignant tumour growth
55
 and result in 
regression and disease free periods.
56
 It has also been shown to be more efficacious as a 
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combination or adjuvant therapy.
57
Therapeutic vaccines that treat cancer by aiding the human 
body‟s immune system in attacking cancer cells - not unlike preventative vaccines which 
prevent infectious diseases - have been researched and developed.Sipuleucel-Tor Provenge, is 
an example of this, and received FDA approval in 2010 for treatment of metastatic hormone 
efractory prostate or prostate cancer that no longer responds to immunotherapy and is 
castration resistant.
58 
The signing of the National Cancer Act of 1971 by Richard Nixon and the subsequent 
declaration of the “war on cancer” was explosive for the development of chemotherapy. The 
act effectively quadrupled the budget of the National Cancer Institute (NCI) by the end of the 
decade.
19
 Clinical evaluation of novel drugs and innovative programs of chemotherapy 
improvement were broadened.
50
 This led to the development of a new series of screening 
techniques, as throughout the 1960s and 70s, screening was done strictly in vivo in mouse 
models. However, these screening evaluations proved inadequate and in 1976 human 
xenografts were introduced either by implantation or inoculation of mice. Today, over 300 
xenografts have been established, including all the key human tumour types. Regrettably, 
these newly implemented screening systems are yet to accurately predict the outcome of 
clinical trials correctly.
49
 
In the 1980s, chemotherapy research and development decelerated, due to extended periods 
of time required for trials which afforded only minor increases in efficacy against malignant 
tumours, coupled with the dismal performances of screening methods. Whilst endeavours to 
recover the development and progression of cytotoxic drugs continued, new insights in 
cellular biology revealed brand new cellular signal transduction pathways that regulate cell 
growth and differentiation. These new signal networks were also found to be fundamentally 
modified in cancerous cells. Researchers set out on amending these inherent flaws by 
targeting growth factors, signalling molecules, cell-cycle proteins, apoptosis regulators and 
angiogenesis catalysts.
49
Until the 1990s, virtually all drugs employed in cancer therapeutics - 
excluding that of hormonal therapy - operated by destroying proliferating abnormal cells. At 
this very time, an outbreak of novel drug targets revolutionized the cancer industry, from a 
government funded research program to a multi-billion dollar enterprise.
49
The last two 
decades has seen a transition from the use of cytotoxic agents and immunotherapy, to the 
rational design of anticancer drugs, which are mechanism based.
59
 This shift can best be 
described as the dawn of the era of targeted therapy.  
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1.2 TARGETED THERAPY 
1.2.1 The Revolution of Targeted Therapy 
The past two decades has witnessed a metamorphosis in our understanding of cancer 
epidemiology and our approach to the treatment thereof, a statement no more evidently 
substantiated with a recent study showing a 20% decline in cancer mortality in the United 
States since its peak in 1991. In the period from 1991-2010 this accounts for 1.3 million lives 
being saved, a decline of more than 30% in the death rate of colorectal cancer, breast cancer 
in woman and lung cancer in men, and more than 40% in prostate cancer. In the five year 
period of 2006-2010, an annual decrease of 1.8% in men and 1.4% in woman has been 
observed.
60
 These statistics can largely be attributed to tremendous advancements in the 
fields of molecular and cellular biology which has led to improved insight into the neoplastic 
cellular mechanisms of proliferation, differentiation, apoptosis, tumour immunology and 
causation of cancer in viral and chemical carcinogens.
61
 
The origin of identification of these novel signalling pathways, or molecular targets, can be 
traced back to the 1960s Special Virus Cancer Program (SVCP), a program dedicated to 
identifying viruses linked to cancer. When this project failed, it altered its research program 
to study genes that were co-opted by tumour viruses, which led to the description of 
numerous oncogenes, suppressor oncogenes and signal transduction pathways critical in 
formative biology.
50
 This scientific knowledge led to the identification of the majority of 
contemporary drug targets that are currently the focal point of targeted therapy.
50
 It also 
expedited the Human Genome Project (HGP) and the complete sequencing of the human 
genome in 2001,
62
 a milestone in advancing our understanding of cancer.
63
 A flash flood of 
small biotechnology firms were founded during this time, filled with researchers intent on 
rectifying the molecular faults in cancer cells. Today there are over 1300 of these enterprises, 
with more than half concerned with cancer research and treatment.
49
 In 2013, the worldwide 
market for oncology-related products was estimated to be approximately $77.3 billion and it 
is projected to reach an estimated $143.7 billion by 2023.
64
 The targeted cancer therapy 
market value is expected to double from $25 billion in 2008 to $51 billion by the year 2015.
65
 
Biochemist Stanley Cohen (1922- ) and neurologist Rita Levi-Montalcini (1909-2012) 
discovered and isolated nerve growth factor (NGF),for which they received the Nobel prize in 
1986.
66
 Cohen went on to discover epidermal growth factor (EGF),
67
 a fundamental discovery 
in our understanding of cancer for the design of modern cancer therapeutics. Research was 
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also beginning to reveal the importance of signal transduction in cancer translation.Signal 
transduction is the conversion of extracellular signalling such as hormones, growth factors, 
neurotransmitters and cytokines which elicit a specific internal cellular response such as gene 
expression, proliferation or even apoptosis.
68
The transformation of cancer treatment from 
sweeping, non-tailored, large dose chemotherapy with undesirable side effects, to the 
exploration and hunt for inhibitors that maintained negligible adverse effects with superlative 
anticancer activity was thus desired.
69
In addition the required features of auspicious drugs 
became apparent - a high metabolic stability which meant a long half-life and slow 
decomposition rate by enzymes such as cytochrome-P450, high specificity, good 
bioavailability and  low toxicity.
49
 
1.2.2 Molecular-Targeted Treatments – Successes and Challenges. 
Tamoxifen (Nolvadex; AstraZeneca) has been hailed as the foundation of targeted therapy 
and was the first of its kind - a selective oestrogen receptor modulator (SERM).
70
Tamoxifen 
was originally developed as a prospective contraceptive some 40 years ago in the era of 
discovery and application of chemotherapy.
71
 Prompting its failure as the post coital 
prophylactic ICI 46474, it was reinvented as tamoxifen – the first targeted therapeutic for 
breast cancer.
70
 Its first clinical trials in 1971 showed encouraging effects in advance breast 
cancer
72
 and subsequent oestrogen-assay evaluations and further experimentation shed light 
on its mechanism of action. It was found that tamoxifen itself was a prodrug, having little 
affinity for its target, the oestrogen receptor. Metabolic breakdown of tamoxifen in the liver 
yielded its active compound 4-hydroxytamoxifen, an anti-oestrogenic metabolite with a 100 
fold higher affinity for the oestrogen receptor.
71
 This metabolite acts as an antagonist of the 
oestrogen receptor in breast tissue, blocking gene transcription and preventing proliferation of 
cancerous cells.
73
 This breakthrough in the understanding of anti-oestrogen activity further 
advanced structure-activity relationship studies and led to the synthesis of nearly all other 
SERMs including raloxifene. It has been estimated that over 400 000 woman have their lives 
today because of tamoxifen therapy which has remained the benchmark in treatment for 
endocrine treatment of all stages of oestrogen-receptor positive breast cancer, and is one of 
the most widely used anticancer agents today. Although tamoxifen has been shown to have 
an excellent risk benefit ratio in midlife and older woman, it has also been shown to augment 
the risk of some positive events, such as prevention of osteoporosis, and others negative, such 
as an increased risk of endometrial cancer in woman.
71
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The first monoclonal antibody to match the criteria of a targeted therapeutic agent was 
trastuzumab(Herceptin; Genentech). Human epidermal growth factor receptor type 2 (HER2), 
also known as HER2/neu and ErbB-2, is over expressed in up to 30% of early stage invasive 
breast tumours and a noteworthy association between this aberrant gene activity and a 
diminished rate of survival in patients has been found.
74
 The receptor consists of an 
extracellular binding domain, a transmembrane lipophilic segment and a functional 
intracellular tyrosine kinase domain.
75
 HER2 signalling is responsible for certain cellular 
responses and processes which include cell proliferation, differentiation, apoptosis and 
migration. Activation of the tyrosine kinase domain occurs by homo- or heterodimerisation, 
usually brought about by ligand binding; however, in the case of HER2, dimerisation may 
occur without a ligand. Upon activation, the signal transduction pathways of HER2 stimulate 
cell growth and survival. In some types of cancer this mechanism is utilized, as mutations or 
over expression of this class of receptor has been known to result in uncontrolled cellular 
growth, ergo leading to tumour formation.
75
Trastuzumab prevents the activation and thus 
dimerisation of the HER2 receptor, thus inhibiting tumour growth and inducing cell death. It 
has also been suggested that trastuzumab may enlist immune effector cells accountable for 
antibody-dependant cytotoxicity, which results in increased tumour assault by lymphoid 
cells.
75
 Trastuzumab received FDA approval in 1998, shows mild adverse effects and when 
coupled with chemotherapy, has shown considerable improvements in response, duration and 
survival time of therapy in contrast to chemotherapy only. Furthermore, studies have shown 
that trastuzumab might enhance the effects of radiotherapy, as well as the action of 
tamoxifen.
74 
If tamoxifen and trastuzumab shed light on the capability and efficacy of these molecular 
targeted therapeutic agents in cancer treatment, imatinib mesylate (Glivec, Novartis) – used 
in the treatment of chronic myeloid leukaemia (CML) - was the monumental paradigm shift 
in exhibiting the potential and power of rationally designed inhibitors in a number of facets. It 
graced the cover of Time magazine as shown in Figure 12, hailed as the new cure for cancer. 
With tremendous advancements in technology, the first step to identifying the pathogenesis 
of CML was taken by Peter Nowell (1928- ) and David Hungerford (1927-1993) whilst 
studying human cellular mitosis. They detected a persistent chromosomal abnormality, 
namely a shortening in chromosome 22, which would later become known as the 
Philadelphia chromosome (Ph).  
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Figure 12 
Time magazine cover of 28 May 2001 detailing Glivec as a 'cure' for cancer.
76 
It was later deduced that the abnormality of the Ph chromosome arose from a reciprocal 
translation, which entailed the long arms of both chromosome 9 and 22 being exchanged, 
entitled t(9;22)(q34;q11).
63
 Chromosome 9 and 22 transmit the Abelson murine leukaemia 
viral oncogene homologue 1 (ABL or ABL1) and the breakpoint cluster region (BCR) gene 
respectively, which encode for a standard correctly formed tyrosine kinase.
69
 By utilizing 
cloned ABL oncogenes and genes, it was elucidated that a fusion of these two genes, termed 
BCR-ABL, was evident in the Ph chromosome.
77
 This union spawns a blueprint for the 
formation of a tyrosine kinase which signals unrestrained cellular proliferation and non-
apoptoticbehaviour in myeloid cells leading to tumour growth.
78
 Experimental evaluations 
later showed the presence of the chimeric BCR-ABL fusion gene in CML cells,
63
 as well as 
its demonstration as the singular oncogenic event that brought about CML in murine models, 
acknowledging the BCR-ABL gene to be the causation of CML.
78
CML is characterised by 
uncontrolled growth of myeloid cells and comprises of 3 phases, namely the chronic, 
accelerated and blastic phase.
69
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Figure 13 
Illustrative summary of the chemical optimization of imatinib.
78 
With the identification of the molecular pathogenic event for CML, an attractive drug target 
had been exposed in the BCR-ABL tyrosine kinase and its enzymatic activity.
78
 This 
resultedin CIBA–Geigy, now Novartis, establishing a kinase inhibitor development program 
in 1984.
63
 Following screening for inhibitors of protein kinase C (PKC), a lead compound 
was identified with a phenylaminopyrimidine backbone which can be seen in Figure 13a 
PKC inhibitions were markedly increased with the addition of a 3-pyridyl group at the 3 
position of the pyrimidine (Fig. 13a, blue).  Furthermore, tyrosine kinase inhibitory activity 
benefitted largely from the inclusion of an amide group on the phenyl ring of the lead 
structure (Fig. 13b, red). Interestingly, substitution at the 6 position of the diaminophenyl ring 
completely nullified any PKC inhibitory activity, but the addition of a methyl, increased 
activity against tyrosine kinases whilst sacrificing loss of PKC inhibition(Fig. 13c, pink). 
Lastly, to combat poor solubility and oral bioavailability, an extremely polar, hydrophilic side 
chain was attached (Fig. 13c, green). STI571, or what is now imatinib, was selected as the 
most encouraging candidate for further development. With the aid of molecular modelling 
and crystallographic data, the binding mode in the ATP active site was further understood. A 
crystal structure of imatinib in complex with the c-ABL kinase domain can be seen in Figure 
14. In vitroscreening of the candidate compound against a number of kinases showed 
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inhibitory activity of phosphorylation for three target kinases, namely BCR–ABL, c-KITand 
the platelet-derived growth factor (PDGF) receptor.
78
 
 
Figure 14 
Crystal structures of the kinase domain of c-Abl in complex with imatinib (PDB_ID:1IEP) 
The candidate compound was found to not only inhibit the growth of CML and BCR-ABL 
cells in cultures, but also in vitro.
63
 Following this, in vivo experiments with mouse models 
showed continuous inhibition of the fundamentally active p210
BCR–ABL
 tyrosine kinase 
phosphorylation, and resulted in tumour free existence of the mice. The first clinical trials 
carried out by Brian Druker (1955- ) showed a remarkable response of 98% of the patient‟s 
blood counts returning to normal.
78This propelled imatinib‟s FDA approval application 
forward and in 2001 it received FDA approval for treatment of CML. A disease that was 
regarded as untreatable, and thus inevitably fatal before –with an estimated survival of 15 
months for patients - is now treatable with a survival expectation of 15 years.
63
 In a 5 year 
evaluation of patients treated with imatinib, 89% of these patients survived with complete 
remission after 60 months.
79
 Imatinib is not as selective as previously thought, but fortunately 
this promiscuity extends to treatment and inhibition of other kinases as previously stipulated. 
Imatinib has undergone clinical trials for the inhibition of c-kit in which overexpression can 
lead to the formation of gastrointestinal stromal tumours (GIST), as well as being effective in 
treatment of proliferative premalignant hematopoietic diseases such as hypereosinophilia 
syndrome and chronic eosinophilia leukaemia, associated with the expression of an activated 
form of PDGFR.
63
Imatinib is a champion for targeted therapy and through its development 
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by identification of its molecular pathogen and drug target, medicinal chemistry endeavours, 
as well as biological assays and application to human clinical trials, has shown that is 
possible to produce a rationally designed, molecularly-targeted agent for the treatment of a 
specific cancer. Importantly, success was attained in the predictive quality of in vitro and 
animal model trials, as the results obtained in these trials agreed well and substantiated the 
results obtained in the clinical trials.
63
In its success; it presented a proof of principle and 
concept, following a more traditional route of drug discovery which had never before been 
successful for this target – cancer.  This was a definitive advancement in the campaign of 
targeted therapy.   
1.2.3 The Scope of Targeted Therapy and the 21
st
 Century. 
Although examples of growth factor receptor inhibitors - which target signal transduction 
pathways to bring a halt to aberrant and uncontrolled cellular growth - have been discussed, 
there are various other mechanisms that are focussed and exploited and different ways in 
which targeted therapeutic agents are implemented in the treatment of cancer. Angiogenesis 
is derived from the two Greek words angio, meaning “blood vessel,” and genesis, meaning 
“origin” or “beginning.” From this it is clearly deduced that the term describes the 
physiological process by which new blood vessels are created. The creator and titan of the 
field of angiogenesis, Judah Folkman (1933-2008), first postulated in 1971 that tumour 
growth is angiogenesis dependant and correctly predicted that the inhibition of angiogenesis 
or the concept of “antiangiogenesis” could be used as a possible future cancer therapeutic.80 
Whilst conducting research on different solutions of haemoglobin as possible blood 
transfusion substitutes, Folkman determined the viability of this hypothesis by perfusing 
canine thyroid glands in these solutions. The glands subsisted for up to two weeks. To 
ascertain whether or not these glands could support growth, they were implanted with murine 
melanomas. Tumour development was witnessed, but only to about 1-2mm in size 
whereupon growth was halted, even though both the tumour and thyroid gland remained 
alive. Upon transplantation back to the mice, the tumour underwent 
acceleratedvascularisation and swelled to sizes of up to 1cm
3
. It was on these experiments 
that Folkman based his deductions divulged in his landmark paper.
81
 The paper he wrote 
provided a schematic and the foundation for the rest of his research based on a number of 
observations. Folkman recognized that solid tumours were much more reliant and possibly 
dependant on the enlistment of new blood vessels for growth. Another crucial perception 
made during experimentation with resting endothelial cells of blood vessels was that tumours 
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were capable and readily made use of dispersing factors, termed tumour angiogenesis factor 
(TAF) by Folkman, which promoted and stimulated endothelial cell proliferation, a 
mechanism implemented by tumours for tumour angiogenesis.  
Figure 15 
The principle of anti-angiogenesis therapy.
82 
 
Logically, Folkman rationalized that antiangiogenesis therapy by inhibition of TAF, could 
provide control on the growth of malignant neoplasms, effectively cutting it off from 
resources for further proliferation – the principal of angiogenesis inhibitors as illustrated in 
Figure 15. This would not lead to complete tumour removal, but rather withdrawal to a 
dormant state and a diminutive size of the tumour. Folkman recognized this fragile 
instrument necessary for tumour growth and saw a target for future cancer therapeutics, 
foreseeing the evolution of anti-angiogenic antibodies in use today, decades prior to their 
arrival onto the scene.
82
 
Today, it is universally acknowledged that oncogene activation leads to carcinogenesis.
83
 The 
use of in vitro bioassays, which were later extended to murine models, displayed evidence 
that the conditional expression of activated oncogenes in cells resulted in a heightened rate of 
proliferation and a marked reduction in apoptosis, resulting in rapid tumour growth leading to 
the death of the host. Oncogene deactivation resulted in the tumours receding, leaving either 
shrunken malignancies or no trace of them at all. This verified the reliance of tumour 
proliferation and survival on oncogene activation, what is today known as oncogene 
addiction.
83, 84
 Further studies and experiments have been undertaken indicative that this is 
not the only requisite for the conceiving of a malignant tumour. The omission of angiogenesis 
in tumour growth results in inert, miniscule malignancies of ~ 1mm
3 
or less, in a dormant like 
state, shown to be innocuous to patients. In addition, transformation of oncogenes in tumour 
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cells have shown to considerably escalate angiogenic activity by means of abnormal 
expression of vascular endothelial growth factor (VEGF) – one of many signal proteins 
produced by cells that act as a mitogen for endothelial cells, promoting angiogenesis and 
vasculogenesis. A decrease in the expression of antiangiogenic proteins was also witnessed. 
Combined with experiments conducted by Fernandezet al.
85
, which showed tumour growth 
restriction by an angiogenesis inhibitor, led to the premise that formation of a malignant mass 
is unachievable without both tumour and endothelial cell proliferation, a requirement and 
component of angiogenesis.
83
 
The discovery of the existence of factors promoting endothelial cell proliferation, coupled 
with the notion of tumour growth dependency on angiogenesis, led to various scientific 
endeavours to identify and isolate these angiogenic mitogen factors. It was not until 1989 that 
Ferraraet al. became the first to isolate VEGF, an endothelial cell specific factor, from the 
follicular cells of bovine thyroids.
86
Arrays of in vivo and in vitro models have displayed 
VEGF to prompt a potent angiogenic reaction, as well as the dependency of cells of newly 
formed blood vessel on VEGF in malignancies. Overexpression of this factor has been 
documented in a myriad of cancers including lung, breast, gastrointestinal tract, renal and 
ovarian carcinomas.
87
It is estimated that in the order of 60% of the roughly 200 different 
types of human cancers express VEGF.
83
 This led to the development of bevacizumab 
(avastin, Genentech/Roche), a humanized monoclonal antibody which is known as a „direct‟ 
angiogenesis inhibitor. Its mode of action entails blocking signalling from the pro-angiogenic 
protein VEGF and thus thwarting vascular endothelial cell proliferation, migration and 
evasion of apoptosis.
88
Clinical trials of avastin ensued, where it passed with flying colours, 
showing great efficacy, especially in cases of colorectal cancer.
87
 In February 2004, FDA 
commissioner Mark McClellan declared that, in conjunction with surgery, radiotherapy and 
chemotherapy, „„antiangiogenic therapy can now be considered the fourth modality of cancer 
treatment.‟‟ Avastin subsequently received FDA approval for colorectal cancer.With the 
closing stages of 2007, 23 therapeutic agents with antiangiogenic activity were in phase III 
and 30 were in phase II clinical trials.
89
 The challenges faced with antiangiogenic therapy is 
mainly concerned with the recognition that tumours may generate a range of angiogenic 
molecules, and depending on the stage of development may be dependent on different factors 
for angiogenesis. Thus the inhibition of a singular angiogenic factor may have little to no 
effect of halting tumour growth. Antiangiogenic agents are now used in combination with 
other angiogenesis inhibitors, as well as in adjuvant therapy to greater effect.
81
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Apoptotic and non-apoptotic mechanisms of cellular death have been acknowledged to be 
conducive to the growth of cancer and the development of resistance to anticancer 
therapeutics.Irregularities in DNA maintenance and preservation facilitate genetic mutations 
and ultimately causation of cancer. Regular cells possess vital mechanisms to disrupt and 
ensure that these inherent anomalies do not perpetuate, leading to carcinogenesis. The tumour 
suppressor gene p53, aptly labelled the “guardian of the human genome”, plays an essential 
role in this defence of normal tissue and prevention of cancer. P53 stands sentry to cellular 
strain, hypoxia and DNA deterioration and following detection of any of the aforementioned 
stresses, the suppressor gene becomes stabilized, inducing cell cycle arrest or apoptosis.
90
 
The nature of this response is to destroy deviant cells undergoing uncontrolled cellular 
growth, discontinuing the progression to malignancies. It is now understood that cells can 
also be eradicated following DNA impairment by necrosis, mitotic catastrophe and 
autophagy.
90
 It is not surprising that researchers have found ways to utilize these processes in 
bringing about the programmed cellular death of tumours. An example would bebortezomib 
(Velcade, Millennium Pharmaceuticals), a boronic acid dipeptide and novel reversible 
proteasome inhibitor, which was shown to be effective amongst patients with multiple 
myeloma which was obstinate to conventional chemotherapy.
91
 It has been determined that 
the mechanism of action of this new class of anticancer therapeutic involves induction of 
apoptosis, the reversal of resistance to therapy of multiple myeloma cells, and blocking 
angiogenesis in vivo.
92
 The ubiquitin-proteasome signal transduction pathway is extensively 
involved in the removal of damaged or redundant proteins in the cells of eukaryotic 
organisms. It has been shown that proteasome inhibition is associated with sensitization to 
apoptosis and more importantly, that cancerous cells are significantly more receptive to 
proteasomal obstruction than are normal cells.
93
 Following success in clinical trials, 
bortezomib received FDA approval and it has been shown to be superior to other available 
treatments in cases of multiple myeloma.
92
 
In addition to the expansion of monoclonal antibodies and small molecule signal transduction 
pathway inhibitors available, researchers have identified new classes of molecules and 
therapies such as small interfering RNA (siRNA) and poly (ADP-ribose) polymerase enzyme 
(PARP) inhibitors. The involvement of siRNA in the RNA interference (RNAi) pathway, 
where the expression of specific genes can be tampered with or even dismantled, has led to 
sparks of interest in targeted therapy and more recently clinical trials of patients with 
advanced liver metastasized cancer through lipid nanoparticles targeting VEGF and kinesin 
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spindle protein (KSP). The trials were a success, halting the growth of the metastases or even 
promoting remission in certain patients.
94
PARP activation plays a critical role in DNA harm 
response processes or the ability of cells to maintain damaged DNA, and has been shown to 
enhance the cytotoxicity of anticancer therapeutics by tumour chemo and radio 
sensitization.
95
 The exploitation of defects in these DNA repair pathways has generated 
considerable interest in the targeted inhibition thereof, spawning a number of inhibitors in 
clinical phase III and phase II trials.
96
 
With the steady and continual innovation of state-of-the-art, superior technology and a 
greater understanding of the biological process of cancer at the molecular level, researchers 
will gain, and keep gaining, additional novel targets for promising therapeutic agents. The 
precise targeting of specific inhibitors to a distinct breed of tumour, increasing the 
effectiveness and lowering adverse events, has always been problematic. The use of gene 
expression profiling by DNA microarrays has facilitated in the comprehensive identification 
of new cancer classes (class discovery) and the classification and assignment of known 
tumours to classes (class prediction), a powerful new tool to be sharpened for use in target 
therapy.
97
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Figure 16 
Targeted therapeutic agents, their targets and mechanisms.
99 
Proteomics, or the extensive study of proteins structure and functions, has found its footing in 
cancer research as biomarkers for certain cancers and early cancer prognosis.
98
 Specificity, 
fewer and milder adverse effects, greater efficacy and lower toxicity is the trademark of 
targeted therapy. The future of research in this area will see the pursuit of improvement of 
these qualities as anticancer agents, as well as the identification and understanding of new 
therapeutic targets.  
The field of targeted therapy has grown enormously over the last twenty years, targeting a 
host of different cancer through an assortment of disease mechanisms. A few of these 
therapeutic agents with their corresponding targets are shown in Figure 16. Of all the targeted 
treatments, none have shown as much promise and delivered as many results, both clinically 
and in gaining an understanding of oncogenesis as that of the targeted inactivation of kinases 
through kinase inhibitors. With a collection of FDA approved drugs being used to treat 
cancer and a variety of other disorders, an impetus has been provided for further research in 
this area of cancer treatment and the development of new and improved kinase inhibitors.  
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CHAPTER 2 – KINASES AND KINASE INHIBITORS 
2.1 KINASES 
2.1.1 The Origins and Mechanism of Protein Phosphorylation 
The collaboration of spouses Carl (1896-1984) and Gerti Cori (1896-1957) and their work on 
carbohydrate metabolism, the discovery of the “Cori Cycle,” “Cori Ester” and glycogen 
synthesis earned them the Nobel Prize in physiology or medicine in 1947, as well as 
illuminating the presence of phosphorylation as a regulatory process. Experimentation with 
diced skeletal muscle tissue of frogs revealed an intermediate from glycogenolysis – the 
breakdown of glycogen – designated glucose-1-phosphate, which would later be termed the 
“Cori Ester.” Further studies elucidated its structure and the enzyme glycogen phosphorylase, 
which catalyses the rate-determining step of this process.
100,101
Phosphorylase was seen to 
have two forms, namely a and b, and the inter-conversion of these two enzymes from a to b, 
by another enzyme discovered in 1943 by Gerty Cori, was the first example of allosteric 
activation.
101
 However, it was not until many years later that the real significance of this 
reaction was grasped.  
It was in the middle of the 1950s thatEdwin Krebs (1918-2009) and Edmond Fischer (1920- ) 
determined that the processes of phosphorylation and dephosphorylation were implicated in 
the mutual conversion of phosphorylase a into phosphorylase b, work for which they received 
the Nobel Prize for physiology or medicine in 1992. They exposed that this interconversion, 
or more specifically the conversion of form b into form a, occurred readily in the presence of 
magnesium adenosine triphosphate (Mg-ATP or ATP) and phosphorylase kinase, an enzyme 
they discovered and coined.
101,102,103
This enzyme was later shown to facilitate the conversion 
from b into a by assignmentof a γ- phosphoryl group of ATP to an explicit serine residue of 
phosphorylase b, an example of phosphorylation.
104
 Dephosphorylation, or the reversion from 
a back to b, was activated by removal of thisγ- phosphorylgroup by a phosphate releasing 
(PR) enzyme known today as phosphatase 1.
101
 The first example of a protein kinase cascade 
-the activation of one protein kinase by another – was identified with the revealing of 3′, 5′- 
cyclic adenosine monophosphate (cAMP) dependant protein kinase A (PKA) and its 
activation of phosphorylase kinase. PKA was subsequently shown to suppress another 
enzyme, namely glycogen synthase, the first example to display the inhibitory activity of 
phosphorylation.
101
Phosphorylation however, remained dormant in research – owing to the 
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belief that it was exclusive to the regulation of only the glycogen metabolic pathway – until 
the 1970s and 80s. 
A number of the most notable serine/threonine specific protein phosphatases and their 
regulatory mechanisms were identified during decades of the 1970s and 80s.
105
 The 
unravelling of the amino-acid sequence for the first protein kinase PKA was accomplished in 
1981.
106
 The amalgamation of these and other discoveries, led to insight into the target of 
cyclosporin, the immunosuppressant drug that made organ transplants possible. Multisite 
phosphorylation, the phosphorylation of two or more residues by two or more protein 
kinases, was observed in the 1970s.
101
Perhaps the greatest milestone in these 20 years was the 
discovery by Ray Erikson (1936- )that v-Src, a gene found in Rous sarcoma virus, encoded 
aprotein kinase.
107
 This led Tony Hunter (1943- ), or the “kinase king,” to uncover that the v-
Src gene was responsible for phosphorylation of tyrosine kinase residues in 1980.
108
  Within 
a year, the realization that tyrosine phosphorylation played a role in regular cellular 
preservation was grasped, and in the following years the magnitude of phosphorylation as an 
extensive, complex and crucial cellular activity regulatory mechanism was revealed.
109
The 
discovery of epidermal growth factor receptor (EGFR) as a protein kinase,
110
 shed light on its 
activation by epidermal growth factor (EGF) interacting with the receptor itself.  The 
exposure that this was the case with a number of other growth factor receptors provided an 
impetus for researchers to find the natural substances these enzymes acted upon.
101
 This led 
to the peculiar finding that the receptors themselves were becoming repeatedly 
phosphorylated at multiple tyrosine residues - being the most prominent suitable cellular 
substrates themselves - and the discovery of receptor autophosphorylation, which today is 
recognized as pivotal in downstream signal transduction and mediation of these signals.
101
 It 
was not long thereafter that the first protein tyrosine phosphatase(PTP1B) was purified, as 
well as the cloning of the family of “just another kinase” (JAK) which were shown to play a 
role in signal transduction and activation of transcription.
101
The 1990s have been conferred 
the title of “decade of protein kinase cascades”101 and the unearthing of an insulin activated 
protein kinase that phosphorylates microtubule-associated protein 2 (MAP2), later changed to 
mitogen-activated kinase (MAP) kinase - a family of protein kinases that are activated in 
response to diverse mitogens, stresses and developmental signals.
111
 Both tyrosine and 
threonine residues are phosphorylated – activated by a dual specific MAP kinase. Further 
experimental evaluation on these MAP kinases showed their importance in cellular protection 
against stress, damaging agents and infection.
101
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Figure 17 
The basic catalytic cycle for substrate reversible phosphorylation by a kinase and its regulation in aspects 
of cellular processes and life.
111, 112 
 
Our comprehension of reversible protein phosphorylation today, recognizes its central and 
essential role encompassing almost every regulatory process in cells and proteins. Philip 
Cohen captures it quite eloquently in his review on the subject,with the statement that “the 
reversible phosphorylation of proteins regulates nearly every aspect of cell life”.101 Copious 
volumes of published works have either paraphrased or echoed these words in one way or 
another.
111, 113
 Phosphorylation by protein kinases is the most extensive mechanism for 
cellular signal transduction. Referring to Figure 17, protein kinases activate the transfer of a 
γ- phosphoryl group from ATP to generate phosphate monoesters, using a specific residuein 
proteins in eukaryotes, namely protein alcohol groups on serine (Ser) and threonine 
(Thr)and/or protein phenolic groups on tyrosine (Tyr) amino acidsas phosphate acceptors.
114
 
This is accomplished by ATP binding to the active site of the protein kinase, after which the 
substrate follows suit. Once constrained, the γ- phosphate of ATP (red) is transferred to an 
explicit residue of the substrate, changing its enzymaticactivity, cellular location, or 
association with other proteins. The substrate and adenosine diphosphate (ADP) is then 
released.
111
 Reversible phosphorylation, or the dephosphorylation of these specific substrates, 
would be undertaken by protein phosphatases in a similar manner. This would catalyse 
removal of the γ-phosphate group, yielding the unmodified substrate once again available for 
phosphorylation.
113c
 As can be seen in Figure 17, phosphorylation and dephosphorylation can 
alter the activity or behaviour of a protein in essentially every imaginable way, thus playing a 
cardinal role in virtually all cellular process and every aspect of cell life. This includes 
metabolism, proliferation, differentiation, motility, membrane transport, apoptosis, immunity, 
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learning and memory.
101,111
The selection of reversible phosphorylation as the universal 
cellular regulative mechanism utilized by eukaryotic cells lies in its simplicity, adaptability 
and the large concentration of ATP as a γ-phosphate donor.101It has been predicted that 
phosphorylation takes place on at least one suitable residue of up to 30% of all proteins. If 
there are approximately 10000 different proteins in a normal cell, with an average length of 
roughly 400 amino acids, of which 17% are Ser (8.5%), Thr (5.7%) and Tyr (3.0%) residues, 
then there are a staggering 700 000 potential locations for phosphorylation to take place for 
any given kinase.
111, 115,116
 The knowledge of phosphorylation, and its role, propelled 
extensive research into protein kinases to answer questions pertaining to the specificity of 
phosphorylation and its regulatory roles and its involvement in disease. 
2.1.2 The Eukaryotic Protein Kinase Superfamily and the Protein Kinase Complement 
of the Human Genome 
With the last piece of the human genome sequence puzzle fitted in 2001, an opportunity to 
determine the completeaccompaniment of human protein kinases presented itself. 
Bioinformaticians at SUGEN, Inc. -a drug discovery company focused on development of 
protein kinase inhibitors - led by Gerard Manning and Sucha Sudarsanam and including Tony 
Hunter and Greg Plowman, embarked on a comprehensive effort to classify, characterise and 
describe the full eukaryotic protein kinase (ePK) complement from genomic sequence 
data.
113a
 The group exhausted all available human genome sequence sources - including all 
those publicly available, Celera genomic databases, Genbank and many others not publicly 
available - with a hidden Markov model profile to detect fragments bearing any similarity to 
any known kinase.  Following this, the use of homology modelling, predictive software and 
verification of the accuracy of these techniques by DNA cloning, resulted in a complete 
catalogue of 518 putative protein kinase genes. This eukaryotic superfamily, or kinome, 
consisted of 478 ePK and 40 atypical protein kinases (aPK) – that is a variety of protein 
kinases that do not share a substantial sequence overlap to the ePK domain, but have proven 
kinase activity – approximating to 1.7% of all predicted human genes. Their efforts also 
identified 106 kinase pseudogenes.
113d
Classification of an extensive and intricate group such 
as the human kinome, and the addition of model organism‟s kinases, meant division into a 
hierarchy of groups, families and sub-families as can be seen in Fig 16.Thereare two main 
subdivisions within the superfamily:the protein-serine/threonine kinases and theprotein-
tyrosine kinases.
114
 This superfamily contains 9 broad groups including tyrosine kinase (TK), 
tyrosine kinase like (TKL), calcium/calmodulin-dependent protein kinase (CMCK), and 
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others shown in large on Figure 18. The 9
th
 group is not displayed and contains the aPK 
family.Each of these broad groups is further sub-divided into a total of 134 families and 196 
subfamilies. The classification of these kinases was carried out according to a number of 
fundamental criteria, by sequence correlation of the active catalytic domains, supported by 
sequence similarity outside the catalytic domain and physiological function.
113d
The 
knowledge acquired with the full complement of the ePK superfamily provided a 
colossalimpact on further research on kinases and kinase inhibitors.
113a
 
 
Figure 18 
An overview of the human kinome.
117 
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Figure 19 
3D and 2D representation of the kinase ATP binding site, illustratingstructure and nomenclature.
118
 
 
 
Most ePKs are structurally similar and are analogous by their canonical, homologous 
catalytic domains consisting of approximately 250 – 300 amino acid residues.114 The majority 
of kinasespossess a common fold composed of two lobes, a smaller N-terminus lobe 
consisting of 5 antiparallel β-sheets and 1 helix and the C-terminus lobe consisting of α-
helices as can be seen in Figure 19a.
111,118
 A cleft or narrow hydrophobic pocket situated 
between these two lobes houses the ATP binding site, where ATP resides with its phosphate 
backbone protruding into the solvent tail – the area of the protein exposed to the solvent. The 
ATP binding site is linked by a flexible hinge region which commonly consists of one 
hydrogen bond donor flanked by two hydrogen bond acceptors arising from the protein spine 
as can be seen in a 2D schematic inFigure 19c.
118
The activation loop of the kinase represents 
Ser, Thr and Tyr residues which may be phosphorylated and occupy a sector of the binding 
site when not phosphorylated. After activation, this hydrophilic charged loop moves into the 
solvent to expose the ATP catalytic domain allowing the protein or substrate to bind along 
the cleft of the active site whereby transfer of the terminal γ-phosphate of ATPto the 
hydroxyl oxygen of the Ser, Thr or Tyr residue of the substrate occurs.
111
 These substrates 
can be seen in Figure 20. A large role in this phosphate transfer is played by the aspartate 
residue which typically engages in a salt bridge interaction with a conserved lysine residue 
shown in Figure 19c. The gatekeeper (gk) residue plays a significant role in defining kinase 
inhibitor selectivity with the specificity pocket shown in Figure 19b. The size/volume of this 
side chain governs entrance to the hydrophobic pocket located behind it as seen in Figure 19b 
and c.
118
 
a b c 
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Figure 20 
Chemical structures of amino acids and ATP involved in protein phosphorylation. 
Although protein kinases share a common fold and many structural affinities, differences in 
relation to charge and hydrophobicity in the surface area of the active site result in distinct 
kinase specificity.
111
 A number of structural relationships kinases have in common with one 
another reflect in related cell regulatory functions.
114
 Neighbouring determinants in and 
around the ATP binding site play a large role in determining substrate specificity and 
particular phosphorylation sequences which take place in the protein 
kinase.
114
Exemplification of this is the difference in the depth of the catalytic cleft between 
the two major classes of kinases namely the Ser/Thr - specific kinases, which constitute about 
80% of protein kinases, and the Tyr-specific kinases.
114
 The difference in depth allows a Tyr 
residue to traverse the length amid the protein backbone and the γ-phosphate of ATP, whilst 
Ser/Thr residues cannot. This attribute is instrumental not only for the specificity of Tyr and 
Ser/Thr kinases, but also their phosphatase counterparts.
114
 Distal binding motifs and docking 
sites or additional binding sites, which are often spatially isolated from the catalytic domain, 
provide supplementary binding interactions and sometimes allosteric regulation and 
localization – leading to an increase in the affinity of kinases for particular substrates.Various 
other mechanisms, such as competition and multisite phosphorylation, ensure proper 
phosphorylation of corresponding substrates selectively to maintain the specificity that is 
observed in signalling pathways.
114
An understanding of these differences in selectivity and 
specificity of phosphorylation and the regulatory effects thereof, as well as the catalytic 
domain of the vast number of kinases, has increased the understanding in designing 
increasingly efficacious and selective kinase inhibitors.  
Stellenbosch University  http://scholar.sun.ac.za
Chapter 2 – Kinases and Kinase Inhibitors 
_______________________________ 
54 
 
2.1.3 Oncogenic Kinase Signalling 
Work undertaken by Stanley Cohen in the 1980s with EGF responsive malignant cells 
indicated anoperative relationship between oncoprotein activity and receptor phosphorylation 
signalling.
110, 119
Shortly thereafter, the successful cloning of the first oncogene - cellular 
homologues of the ras genes – and subsequent molecular genetic studies, showed a single 
amino acid change in the c-Ha-RAS1 gene and its malignant analogue, namely a 
transformation from glycine to valine. Further experimental evaluation showed that this 
single alteration transformed the RAS protein, promoting aberrant activity. Not only was the 
first cellular oncogene identified and confirmed, its active mutation was also singled out and 
recognized. This was a monumental step in our understanding of genetic mutations, 
oncogenes, oncoproteins and their involvement in cancer.
120
 
 
Figure 21 
Kinases implicated in human cancer, their variety and oncogenic role .
121 
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Fast forward 20 years – with the unravelling of the full human kinome complement and 
chromosomal mapping, 244 protein kinases were revealed to map to disease loci or cancer 
amplicons.
113d
 164 of these were seen to be implicated with tumour amplicons - or replicative 
genes, whilst 80 kinases mapped to loci associated with other diseases.
113d
 Figure 21 
illustrates known kinase targets that has been intensely investigated and shown to be involved 
in carcinogenesis, where RTK is receptor tyrosine kinase, CTK is cytoplasmic tyrosine 
kinase, S/T Kinase is serine/threonine kinase and LK is lipid kinase.
121
With the incredible 
amount of regulatory activity and responsibility protein kinases have with regards to all 
cellular processes, it is not surprising that perturbations of these signal transduction pathways 
by mutations and other genetic alterations results in deregulation of kinase activity and 
malignant neoplasm transformation.
122
Certain classes of signalling proteins,i.e. those that 
oversee cellular proliferation, differentiation and development, are targeted much more 
sporadically by oncogenic mutations.
122
 Receptor protein tyrosine kinases (RPTK) represent 
a significant allocation of all oncoproteins that are responsible for causation of a variety of 
cancers as can be seen in Figure 21. Protein tyrosine kinases (PTK) phosphorylation activity 
in resting, untransformed cells is usually tightly controlled by the antagonizing effect of 
tyrosine kinase andphosphatases.
123
However, with even slight genetic or structural mutations, 
these PTK change into powerful oncoproteins which can wreak cellular havoc.
122
Oncogenic 
deregulation or transforming functions acquired by PTK can principally be attributed to 
disruption or constitutive activation of one or more of the signalling pathways which are 
regulated by PTKs to ensure conservation of catalytic domains and cellular function. This 
results in activation of further signalling pathways, proteins and messengers impeding regular 
cellular processes.
122, 123
  Aberrant activity may be brought about by a variety of mechanisms; 
however, there are four main principals to oncogenesis or oncogene addiction in PTKs.  
Firstly, abnormal or over-expression of PTKs, or an over expression of its associated ligand, 
is concomitant with autocrine-paracrine stimulation which has been linked to array of human 
cancers. Overexpression of EGFR is reported in 40-80% of non-small cell lung 
cancer(NSCL) and up to 50% of primary lung cancer. EGFR and ligand over-expression is 
depicted in panel A of Figure 22, with PTKs known to be activated through that mechanism 
listed on the right. Secondly, gain of function (GOF) mutations or mutations within the 
extracellular domain of RPTKs and CTKs has been associated with several neoplasmic 
malignancies, e.g mutations in EGFR amino acids have led to uncontrolled cellular growth of 
ovarian tumours and non-small cell lung carcinoma. 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 2 – Kinases and Kinase Inhibitors 
_______________________________ 
56 
 
 
Figure 22 
Mechanisms of PTK deregulaton and oncogenic activation.
124 
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Panel B of Figure 22 shows constitutional activation of Fms-like tyrosine kinase 3 (FLT3) 
through a point mutation.Thirdly, abnormal chromosomal translocation and genomic 
rearrangements may result in the cancerous fusion of proteins and resulting in irregular 
functionality. A representation of this is CML, which arises from a reciprocal translocation 
between chromosomes 9- and 22, as highlighted in Section 2.1.2. This fusion is illustrated in 
panel C of Figure22.Lastly, in rodents and chickens, retroviral transduction of proto-
oncogenes related to a PTK leads to constitutional transitions – resulting in malignant 
activity.
122, 123,124
 With deregulation of signalling, mutation and over expression of PTKs 
playing a colossal role in the molecular pathogenesis of cancer, as well asthe wealth of 
knowledge on the enzymes themselves and their congruency as drug targets, the design and 
synthesis of kinase inhibitors as targeted therapeutic agents of the PTks has been a very 
successful and attractive endeavour for the last 20 years. 
2.2 KINASE INHIBITORS 
2.2.1Protein Kinase Inhibitors – an Overview. 
A search on Scifinder for the term “kinase inhibitor” yields ~90 000 references containing the 
word as entered and ~310 000 containing the concept. To date 26 protein kinase inhibitors 
have received FDA approval of which 17 are small molecules, with the remainder consisting 
of both anti-angiogenic and monoclonal antibody inhibitors of Ser/Thr and Tyr kinases.
125
 
Approximately 142 inhibitors, ranging over 42 different kinase targets have progressed to 
some phase of clinical assessment.
126
Although the vast majority of these are related to the 
treatment of cancer, kinase inhibition has been implicated in the remedy of an array of 
ailments inclusive of immunological, neurological, metabolic and infectious disease.
121
With 
protein kinases comprising a large share of all oncoproteins and aberrant cellular activity 
playing such a pivotal role in the pathogenesis of a myriad of diseases, it is not surprising that 
widespread interest and impetus into the targeted inactivation of this class of enzyme has 
been witnessed. This has resulted in a tremendous investment of resources, especially from 
the pharmaceutical sector, towards the development of numerous efficient strategies for 
designing potent and selective kinase inhibitorsfor suppression of these unwanted cellular 
processes and treatment of these disorders.
121, 123
 
The prominence of kinases as one of the most intensively pursued classes of drug targets may 
be attributed to a number of factors. Standing true to the adage, “kinases are responsible for 
the regulation of nearly every aspect of cellular life,” and with 518 kinases in the human 
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kinome, almost every signal transduction pathway goes via a phosphotransfer cascade, 
meaning the inactivation of this target is viable and will yield a real biological response.
124
 As 
was discussed before, the emergence of imatinib and its success displayed this aspect of 
kinase inhibition and was the herald for a proof of principle of this targeted therapy.
78
 Despite 
a high degree of similarity and preservation in the active site of kinases, highly selective 
inhibitors with positive therapeutic characteristics can and have been developed.
127
Moreover, 
and quite surprisingly, inhibition of regular cell kinase activity is well tolerated in the human 
body, allowing for the selective felling of malignant cells. This is illustrative in dasatinib, an 
inhibitor of BCR/Abl and Src tyrosine kinases and used in the treatment of imatinib resistant 
CML, which potentially inhibits all 9 members of the Src family, and possibly others, whilst 
showing minimal adverse events and a favourable side effect profile.
124
Targeting and 
inhibition of genetically mutated or activated kinases has been fortuitous in the relative ease 
of designing mechanistically relevant cellular assays, as these kinases are promptly identified 
by DNA sequencing due to their inherent anomalies. This gives a distinct advantage in 
inhibitor discovery and optmization.
124
Kinase inhibitors have shown marked success in 
clinical trials and as approved therapeutic agents. In an evaluation of 974 anticancer drugs, 
kinase inhibitors shone with a clinical attrition rate of 53% from phase I to approval, 
considerably lower in contrast to the 82% achieved for other antitumour remedies.
126
 Besides 
imatinib, exhibiting up to 80% reduction in tumour growth in chronic phase CML patients,
79
 
other FDA approved inhibitors have shownbeneficial effects in patients. Crizotinib, an 
inhibitor of an anaplastic lymphoma kinase (ALK) fusion protein linked with carcinogenesis, 
showed tumour shrinkage and growth halt in 90% of 82 patients carrying this ALKfusion 
gene.
128
Lapatinib is associated with the inhibition of two oncogenes namely, EGFR and 
HER2. Overexpression of HER2 has been shown to be conducive to breast cancer and in 
combination therapy with capecitabine, showed 51% reduction in the risk of disease 
progression.
129
Erlotinib is an inhibitor of EGFR, which is over expressed in certain malignant 
cells such as those of breast and lung carcinoma. In combination with the use of cytotoxic 
drugs, erlotinib has shown improved overall survival in patients by 19%, whilst progression 
free survival (cancer is not exacerbated) was increased by 29%, in comparison to the use of 
cytotoxic drugs alone.
130
 
However, despite the inspiring successes and advantages of this branch of targeted therapy, 
the field of kinase inhibition faces a number of challenges. These include drug resistance due 
to further mutations, lack of inhibitor selectivity and efficacy and challenges in drug target 
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validation associated with its particular disease.
124
Kinase inhibitors are very efficacious for 
patients with single genetic alteration type cancers, in contrast to those carcinomas that carry 
a large number of different mutations where treatment by kinase inhibition is limited. Thus, 
proper subject selection has become a main concern in kinase drug discovery.
126
Resistance to 
small molecule kinase inhibitors is best exemplified with gefitinib, which targets EGFR 
which is over expressed in 40-80% of NSCLC and other epithelial malignancies.
131
Tumours 
of patients that exhibited strong responses to therapy usually contained abnormalities in the 
EGFR gene. These genetic mutations were found to most frequently be either deletions in the 
amino acid chains between 747 – 750 (delL747-S752), or a point mutation - a replacement of 
one gene with another. These consist virtually always of substitution of arginine with leucine 
at codon 858 (L858R) and methionine which is substituted for threonine at position 790 
(T790M).
132
These mutations lead directly to an increase in alteration of signalling pathways 
and carcinogenesis and thus facilitate oncogenic activity. Patients with the delL747-S752 
mutation wereseen to show increased tumour susceptibilty to gefitinib, which resulted in 
interim regression of tumour growth and succesful treatment. However, following a 
remission period a second mutation was seen to develop, in this case the T790 mutation, 
which shows high level resistance to the anilinoquinazoline inhibitor. This showed that 
relapses in patients with NSCLC usually contained mutations in EGFR which conferred 
resistance to gefitinib.
132
In another example, mutations in BCR-ABL associated with imatinib 
resistance usually result in replacement of threonine with isoleucine at position 315, which  
corresponds structurally to a very similar change to that of the T790 mutation.
132
 A greater 
understanding of the mechanisms of resistance in CML has resulted in the development of a 
2
nd
 generation library of inhibitors.
133
With the advancement of large selectivity screening 
platforms, it has been shown that the majority of approved kinase inhibitors show inadequate 
selectivity and are promiscuous in targeting mulitple kinases. With the exception of lapatinib, 
this places restrictions on the applicability of late stage cancer treatment and its use as 
therapeutic agents in general.
126
Accessibility of high-resolution crystal structures 
hasmarkedly expedited the design of increasingly selective inhibitors and coupled with the 
development of allosteric and irreversible inhibitors, has done much to combat these 
issues.
134
Target validation remains problematic in kinases and has resulted in a constricted 
selection of kinase targets. More than 50% of all inhibitors in clinical evaluation targets 
kinases with already approved drugs on the market. This suggests that a proof of concept is 
necessary in kinase drug discovery. Almost the same percentage of kinases are 
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uncharacterized with nearly 25% having completely unknown function, with little to no 
explanation as to their implication in signalling pathways.
126
However, the introduction of 
specificity screening platforms and chemical probes that target a number of these unknown 
kinases have shown that current clinical and preclinical candidates display inhibitory activity 
of these kinases.
126
 The use of modern cytogenetics to identify chromosomal transformations 
and array comparative genomic hybridization techniques may also be utlized for the 
identification of new tyrosine kinase drug targets.
124
 
2.2.2Design, Synthesis and Modes of Binding. 
In modern drug discovery, advances in technology, protein ligand interactions and cellular 
based assays and screening methods, has resulted in the design, development, synthesis and 
optimization of hugely succesful anti cancer agents.
59,123
 A search for the term “kinase” in the 
protein data bank (PDB), yields 6540 crystal structure with nearly 2700 ligand hits. The 
importance of structural biology in the campaign of kinase inhibitor drug discovery is no 
more evident than in these numbers. Technological leaps in x-ray crystallography and related 
disciplines has facilitated the rapid and low cost solution of de novo compounds and 
structures, yielding important protein:drug interactions in a typically cheaper and faster 
method than that of compound synthesis and in vitro evaluation.
113b
 The world wide protein 
data bank (wwPDB) acts as a deposition for all protein related data, and thus a plethora of 
crystal structures are available for scrutiny and research. This provides structural insight into 
kinase inhibitors and their specific binding modes in the active site and assists in the 
structure-guided design of specific kinase inhibitors.
135
 Thorough profiling of kinase 
inhibitors through biochemical, cell base assays such as fluorescent polarization assay and 
nonradioactive high throughput assays, have provided insight into target validation and 
selectivity.
123
Pharmacaphore and molecular modelling, docking and structure-aided ligand 
design tools of increasing refinement have also found a place in drug design and 
optimization.
118
 The combined and cumulative usage of 2D NMR spectroscopy,in silico 
computer-assisted methods, structural biology, enzymatic and cellular based assays, 
medicinal chemistry and synthetic experimental evaluation efforts together, can defined as 
structure assisted design and optimization in modern drug discovery.
59
 
Kinase inhibitors consist of different classes which are distinguished by their mode of 
binding in the ATP active site, as well as their location in the enzyme itself. This class of 
anticancer agents can thus be divided into three types, namely: type I or ATP 
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competitive,type II or allosteric and type III or covalent inhibitors. In spite of the large 
amount of conservation in the sequencing of the ATP binding site of kinases, the majority of 
reported and approved inhibitors are ATP competitive or reversible inhibitors.
113b
 
Figure 23 
Kinase inhibitor type I and II binding modes.
121 
These type I inhibitors exploit the active conformation of the kinase. These inhibitors usually 
consist of a heterocyclic core, which serves to form weak non-covalent hydrogen 
bondacceptor/donor interactionswith the hinge binding region in the active site, as can be 
seen in Figure 23a. Furthermore, this heterocyclic system acts a scaffold for side chains 
which are used to fill the hydrophobic pockets located in the active site seen shaded in grey 
and yellow in Figure 23a. This provides further hydrophobic interactions and increases 
selectivity in the inhibitors. Examples of these inhibitors include imatinib and nilotinib. 
Type II or allosteric inhibitors in contrast, target the inactive form of the kinase, also known 
as the DFG out conformation due to the configuration of this chain.
121
 This configuration of 
the DFG out motif, from movement of the activation loop, bares a peripheral hydrophobic 
binding site flanking the ATP active site, where type II inhibitors reversibly inhibit the 
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protein kinase as illustrated in Figure 23b (the blue shaded area defines this additional 
hydrophobic binding site.)
121
Allosteric inhibitors bind outside the ATP binding site, at an 
allosteric site separate from the enzyme active site, where ligand binding takes place to effect 
kinase activity.  They are non ATP competitive as they block ATP phosphorylation remotely 
from the active site.
113b
 Allosteric inhibitors are thus highly selective as they target explicit 
binding sites that are unique to certain kinases.
121
 
The last class of kinase inhibitors, type III, are irreversible or covalent inhibitors. This class 
of drug inhibits irreversibly, by forming a covalent bond to a specific cysteine residue located 
in the ATP active site.
121
 Irreversible inhibitors, like their reversible counterparts, consist of a 
heterocyclic core or “driving group” which fulfils the same role as in reversible inhibitors, 
forming weak hydrogen bond interactions with the hinge region. However, covalent 
inhibitors carry at a designated position a suitable electrophilic functionality known as a 
“warhead.” It is this “warhead” that forms a covalent bond with a nucleophilic cysteine 
residue located inside the binding site, usually through a Michael addition reaction as an 
example. The mechanism of this covalent bond formation and structure of the irreversible 
inhibitor canertinib, which has shown activity against EGFR and HER2, can be seen on 
Figure 24 below.In this reaction the electron rich sulphur group of the cysteine residue reacts 
at the electrophilic β-carbon of the acrylamide warhead. The intermediate enolate then forms 
the 1,4- addition product.
136
 
 
 
Figure 24 
 Notable structural moieties and mechanism of covalentinhibition with Canertinib as example.
136 
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Irreversible inhibition holds a number of advantages over ATP competitive inhibition. Firstly, 
irreversible inhibitors contain the structural motifs necessary for reversible inhibition, thus 
irreversible inhibitors benefit from weak hydrogen bond interactions in the active site, as well 
as stronger covalent bond interactions. Irreversible inhibitors are not in competition with high 
endogenous concentrations of ATP in cells. This also means irreversible inhibition is 
unaffected by changes in the ATP binding affinity of the kinase through point mutations, a 
mechanism to overcome some forms of drug resistance. Irreversible inhibition has a longer 
duration of effect and has been to shown to persist in deactivation of the enzyme even after 
the free inhibitor has left circulation. Lastly, a high selectivity profile is associated with these 
inhibitors as only kinases with the appropriate cysteine residue in the correct place should 
undergo covalent bond formation and irreversible inhibition.
134b, 136
 Of the 518 kinases in the 
human kinome only 43% (or 211) have at least one cysteine residue in the ATP binding site 
spread over 27 different positions. This means that a finite number of these candidates are 
druggable, which brings about an increased chance of developing potent and selective 
inhibitors.
137
 However, promiscuity and toxicity remain the biggest challenges in the 
development of irreversible inhibitors. Selectivity, amongst not only the kinome, but also 
other cell constituents becomes an issue. However, with a vast library of inhibitor kinase co-
crystal structures, refinement of driving portions, as well as proper placement of warheads, 
has resulted in overcoming these complications.
136
 
Protein kinases and kinase inhibitor design, development and synthesis has become one of the 
most significant drug discovery categories in oncology.
126
 Technological advancements, 
developments in high throughput sequence screening for target validation and innovation in 
structural biology all aid the rational design and synthesis of novel kinase inhibitors, thereby 
increasing the viability and opportunities for drug discovery development in this field. This is 
therefore an attractive area for medicinal chemists to investigate and has become the main 
focus of many research groups. 
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CHAPTER 3 – 1
ST
 GENERATION REVERSIBLE INHIBITOR LIBRARY 
3.1 SYNTHETIC METHODOLOGY, TARGET STRATEGY AND DRIVING GROUP 
3.1.1 The Paper that started it all. 
Recently, Müller and co-workers described an innovative way to prepare mimics of naturally-
occurring kinase inhibitors, such as meriolin, by following synthetic methodology they 
developed.
138
This synthetic procedure, which can be seen in Scheme 1b, involved a one pot 
Sonogashira coupling, followed by a TMS deprotection and a copper-mediated click reaction 
to afford 1,2,3-substituted triazoles, in good yields, from the corresponding halogenated 
precursors shown as in Scheme 1a.
138
 
 
Scheme 1 
Synthetic concept and methodology used by Müller for N-Boc protected heterocycles.
138
 
 
 
           
 
 
 
 
b) 
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A library of these triazolyl NH-heterocycles was synthesized and not surprisingly, as these 
mimics contain a heterocyclic core with a hinge binding motif corresponding with reversible 
kinase inhibition, the group found that a number of the compounds were excellent inhibitors 
of pyruvate dehydrogenase lipoamide kinase isozyme 1 (PDK1). To determine whether the 
triazole moiety simply acted as a linker or retained additional functionality important for 
inhibition an analogue of the most efficacious compound was prepared whilstsubstituting the 
triazole moiety with a pyrazole ring. Interestingly, the triazole-bearing compound8f was 
shown to act as more than just a simple linker, displaying a pharmacophore character 
essential for biological activity.  It was shown that the pyrazole compound11 was 
significantly less active with an IC50 value of 2.6 µM for PDK1 compared with 0.8 µM for 
the triazole as can be seen in Figure 25.Furthermore, an isomeric compound 10 was 
synthesized, varying only in the positioning of the triazole moiety‟s carbon and nitrogen, 
which showed no activity against PDK1. A crystal structure of compound 8f with kinase 
PDK1 indicated the presence of hydrogen bond interactions between the triazole nitrogenN3 
with Thr222 and a bridging interaction between N2 and H2O and Lys111.
138
 
 
 
Figure 25 
Comparison of IC50values of PDK1 inhibition between triazole, isomeric and pyrazole compounds and 
crystal structure of compound 8f in PDK1.
138
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Heterocycles containing 1,2,3-triazole systems have been reported to possess  various 
biological activities including anti-HIV, anti-allergic, anti-fungal, anti-viral and anti-
microbial activity.
139
1,2,3-Triazole moieties have also been shown to be useful building 
blocks in chemistry and have been modified to play important roles in pharmacological 
applications due to their stability towards light, moisture, oxygen and metabolism in the 
body.
140
Moreover, these moieties have found a range of applications in industry as dyes, 
corrosion inhibitors, photographic materials and agrochemicals.
141
In 1,4-disubstituted 1,2,3-
triazoles, N2 and N3 have been shown to act as H-bond acceptors.
142, 143
Their resistance to 
hydrolytic cleavage and oxidative transformations has also earned them their ability to act as 
bioisosteres for moieties sensitive to these conditions, such as esters, thioesters, and 
thioamides.
143
Triazoles used as linkers have been shown to form planar structures, which 
would promote eligibility for the narrow ATP binding site.
144
This has generated considerable 
interest in the developmentof new and more efficient synthetic pathways for the design of a 
diverse array of 1,2,3-triazole-containing heterocycles as possible drug candidates, as well as 
investigation of their ability as pharmacophores. Thus, on this basis, it was our endeavour to 
adopt the synthetic methodology formulated by Müller and his team, to be applied to various 
halogenated heterocyclic analogues of our choosing, which also contained the important 
hinge binding motif for kinases. This would be an excellent platform to determine the 
triazole‟s ability to act as a hydrogen bond acceptor with the hinge region or within the active 
site of the target kinase and to generate a 1
st
 generation library of novel potential reversible 
inhibitors and determine their efficacy.  
3.1.2Rationale of Target Kinase: EGFR 
Lung cancer accounts for over a third of all cancer deaths and is the leading cause of death in 
men worldwide, coming second in woman only to breast cancer.
145,146
 It can be seen as a 
miscellany of diseases largely divided into two groups namely: small cell lung cancer 
(SCLC) accounting for ~20% of lung cancers and non-small cell lung cancer (NSCLC) 
comprising of the remaining ~80% of lung cancers.
146
  NSCLC is postulated to originate in 
lung epithelial cells, and is made up of a large variety and number of cellular malignancies 
such as adenocarcinoma, bronchioloalveolar, squamous, anaplastic and large-cell 
carcinomas.
146
The EGFR family or ErbB tyrosine kinase receptors, constitutes four 
homologous receptors namely: the epidermal growth factor receptor (ErbB1/EGFr/HER1), 
ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4), whose functions has been 
investigated and studied extensively.
147
 The role of EGFR driven signalling in the aetiology 
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of human canceris well known
148
 and as has been elaborated and clarified before. Over 
expression of these receptors is abundant in tumours, as well as autocrine or paracrine-
stimulated growthin malignancies.
147a
EGFR has been correlated to a multitude of cancers, 
including that of the head and neck, brain, colorectal, bladder, breast and lung.
146
 Recent 
analyses have shown that EGFR is over expressed in 62% of NSCLC patients.Also, the 
chromosomal region of EGFR, 7p12, was found to be augmented in genomic examinations. 
Additional to over expression and chromosomal transformations, the receptor ligands 
epidermal growth factor (EGF) and transforming growth factor (TGF) have also been found 
to be commonly over expressed in NSCLC. This leads to aberrant autocrine functionality and 
uncontrolled activity and growth of the receptor.
146
 Approximately 40% of patients diagnosed 
with NSCLC today are at an advanced stage. First line therapy for this disease consists of 
platinum-based combination chemotherapy; however prognosis is poor with median survival 
rates of 8-11 months, 1 year survival rates of ~35% and 2 year survival rates of 10-20% being 
reported.
145
 The treatment of NSCLC is thus an on-going struggle and new therapeutic targets 
of the molecular mechanisms that govern the growth of these malignancies are desperately 
needed. 
A range of drug discovery strategies has been developed to address this need, including  the 
use of monoclonal antibodies such as cetuximab and bevacizumab and small molecule kinase 
inhibitors such as gefitinib, erlotinib and lapatinib whose molecular structures can be seen in 
Figure 26 below. Gefitinib, a reversible inhibitor, has increased our understanding of NSCLC 
and mutations of EGFR through specific resistance mechanisms to this treatment.Erlotinib, as 
discussed before in Section 2.2.1, has shown a benefit to patients with advanced lung cancer, 
some showing complete response, whilst others only partial to the treatment.
145
 Lapatinib is 
seen as a dual tyrosine kinase inhibitor as it interrupts both the HER2 and EGFR signalling 
pathways and is used primarily for the treatment of breast cancer where it has shown marked 
success.
129
 
 
Figure 26 
Molecular structures of gefitinib, erlotinib and lapatinib. 
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Following the lead of these FDA approved drug candidates, the EGFR kinase domain would 
seem a logical and attractive target for drug discovery. For this project we would be 
collaborating with a team of German biochemists from the Technische Universiteit 
Dortmund, led by Prof. Daniel Rauh. A student in Prof. Rauh‟s group, Julian Engel, would be 
responsible for carrying out the biological assays and determining the potency and efficacy of 
our library of potential inhibitors. Julian‟s main focus of research is that of EGFR, which was 
accordingly selected as our target kinase for this project as screening could be facilitated. 
3.1.3 Choice of Heterocyclic Driving Groups and Side Chains. 
Quinoline, a heterocyclic aromatic compound, was first extracted from coal tar in 1834, 
which still remains the primary source for its industrial usage. Although the heterocycle itself 
has limited application, derivatives thereof have been shown to possess an enormous variety 
of uses in extensive fields, and italso occurs in a number of natural products and alkaloids.
149
 
A natural product derivative, quinine, and further synthetic analogues thereof such as 
chloroquine,
150
primaquine
151
 and mefloquine,
152
 have been extensively researched and found 
great success in the treatment of malaria. Biological activity of compounds containing a 
quinoline backbone has been found in anti-tuberculosis,
153
 anti-microbial,
154
 anti-
convulsant,
155
 anti-inflammatory,
156
 cardiovascular
157
 and most importantly, anticancer 
applications. Quinoline as a privileged anticancer scaffold shows activity in a number of 
different target sites such as topoisomerase I, telomerase, farnasyl transferase, Src tyrosine 
kinase, protein kinase CK-II and others.
149
 As protein tyrosine kinase inhibitors, quinoline-
based driving groups have shown potent IC50 values for a range of kinases and different types 
of cancers.
61, 158
 
Isoquinoline, a benzopyridine derivative like quinoline, was also first isolated from coal tar 
51 years after its structural isomer. This heterocycle is the structural spine of a large number 
of natural alkaloids. Isoquinoline analogues have found a variety of uses as anaesthetics, 
antihypertension agents and vasodilators.
159
 A number of derivatives have been applied in 
anti-malarial, anti-HIV, anti-tumour, anti-microbial and anti-bacterial usage.
160
 Most 
importantly, isoquinoline-derived drugs have shown protein tyrosine kinase inhibitory 
activity against a number of kinases including EGFR.
161
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Scheme 2 
Synthetic scheme illustrating choice of heterocyclic driving group, side chains and reactions. 
On the premise of these findings and research already carried out using these heterocyclic 
cores, we decided to make use of two halogenated structures of both quinoline and 
isoquinoline which can be seen in Scheme 2 above (1a-d). Following the synthetic approach 
devised by Müller, Sonogashira coupling and deprotection would afford heterocyclic alkynes 
which could subsequently undergo a copper catalysed azide alkyne cycloaddition (CuAAC) 
with appropriate azides, affording a library of reversible, 1,4 1,2,3- triazole-based potential 
kinase inhibitors.A number of molecular modelling and docking calculations were 
undertaken making use of Acclerys Discovery Studio software. The investigation visually 
showed promising results and binding modes adopted by these compounds. A number of 
hydrogen bond acceptor/donor interactions were seen between the quinoline and isoquinoline 
moieties, and the methionine and threonine hinge binding region. The choice of benzyl azide 
and 2-(azidomethyl)pyridine (Scheme 2) as suitable side azide side chain fragments to 
undergo this CuAAC was made on the grounds of simplicity, as well as potential 
hydrophobic interactions, as seen in the molecular modelling and docking calculations. As 
both moieties were predicted to fit in the hydrophobic pocket of the active site, an aromatic 
core with a flexible methyl linker for rotation was logically chosen.The addition of nitrogen 
in the pyridine moiety, and a lack thereof in the benzyl variation, would give an indication as 
to whether the heterocyclic counterpart took part in any favourable hydrogen bond 
interactions, possibly increasing efficacy and selectivity. This provided further 
encouragement for the use of these driving groups and side chain linkers for the synthesis of 
our potential reversible inhibitors. 
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3.2 SYNTHESIS OF ALKYNE FRAGMENTS 
3.2.1 Sonogashira Coupling and Silyl Deprotection. 
The palladium-catalysed coupling of aryl or vinyl halides (or triflates) with terminal 
acetylenes is generally referred to as a Sonogashira coupling reaction.
162
 Garnering its name 
from Kenkichi Sonogashira, Yasuo Tohda, and Nobue Hagihara, who first reported usage of 
the reaction in 1975,
163
 it was an extension of the work done by Heck but allowed for much 
milder conditions to be used.
162
 Nearly 30 years on, the robust Sonogashira coupling has 
transitioned to one of the most central and well established methods for sp
2–sp carbon–
carbon bond formation in organic synthesis,
162
 finding widespread application in the 
preparation of arylalkynes and conjugated enynes,a lynchpin in natural product synthesis and 
in heterocylic chemistry.
164
 This has also extended to use in the synthesis of molecular 
electronics, dendrimers and conjugated polymers or nanostructures.
162
 Conventionally, a 
copper co-catalyst is added, which provides increased reactivity, but copper-free Sonogashira 
synthetic methodology has been explored and developed.
165
 Standard Sonogashira reaction 
conditions employs some source of palladium such as PdCl2(PPh3)2 as catalyst, in 
conjunction with a co-catalytic amount of Cu(I) such as CuI, with an amine as solvent or an 
inorganic base as shown in scheme 3.
162
 
The precise mechanism for the Sonogashira coupling is not yet accurately understood, due to 
complications in analysis as two metal catalysts are present, which sheds doubt on certain 
intermediates that are formed. However, it is generally accepted that the reaction progresses 
through two separate catalytic cycles, namely the palladium and copper cycle as illustrated in 
Scheme 3. Firstly, the palladium cycle is well agreed upon as it is derived from classical 
carbon-carbon cross-coupling reactions.
166
 The cycle begins with the inactive Pd(II) catalyst, 
such as PdCl2(PPh3)2, being reduced to the active 14 electron palladium species 
[Pd(0)L2],shown as complex A in scheme 3. This complex then undergoes oxidative addition 
of the aryl or vinyl halide, which is reasoned to be the rate-limiting step of the reaction, 
forming the adduct [Pd(II)R1L2X], or complex B in Scheme 3. This adduct then undergoes 
transmetallation with the copper acetylide complex F, formed during the copper cycle, which 
in turn results in complex C after expulsion of the copper halide complex G which is 
regenerated. The trans organic ligands of complex C undergo cis/trans-isomerisation, 
yielding complex D, following subsequent reductive elimination affording the alkyne product 
and regenerating the [Pd(0)L2] catalyst.
162
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Scheme 3 
Standard Sonogashira coupling reaction conditions and catalytic cycle adapted from Chinchilla et al.
162 
In comparison to the palladium cycle, the copper cycle is unexplored and esoteric, with most 
of the mechanistic details hypothesized. It is believed that the presence of base promotes 
copper acetylide formation through the formation of an intermediateπ-alkyne copper complex 
E, which in turns makes the terminal alkyne‟s proton more acidic, resulting in the copper 
acetylide complex F which undergoes transmetallation in the palladium cycle, regenerating 
the copper halide catalyst.
162
 
The use of silyl protecting groups in organic synthesis has become a routine procedure.
167
 
The utilization of these groups in organic synthesis has extended across a wide variety of 
Complex A 
Complex B 
Complex D 
Complex C 
Complex F 
Complex E 
Complex G 
Transmetallation 
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functional groups including formation of silyl ethers in protection of hydroxyl groups, as well 
acetylene hydrogen protection. In the case of acetylene, the use of a protecting group for an 
acetylinic hydrogen is often necessary due to its acidic nature.
168
 In addition the steric bulk of 
these silane moieties prohibits catalytic hydrogenation.
169
 The use of trialkylsilylacetylenes in 
organic synthesisis convenient as they tend to be liquids or solids, as opposed to the 
unprotected gaseous counterparts.
168
 These protecting groups are frequently cleaved or 
removed through a fluoride source, the driving force of this reaction being the formation of 
the stronger Si-F bond (564.8 kJ/mol) in comparison to that of the Si-C bond (451 kJ/mol). 
Trimethylsilylacetylene (TMSA) is frequently used in Sonogashira coupling reactions with 
aryl or vinyl halides.
162
 
3.2.2 Optimization of Reaction Conditions. 
For the synthesis of our alkyne fragments, the halogenated heterocyclic scaffold of 3-
bromoquinoline (1a) was selected for optimization of this synthetic procedure. As this 
reaction sequence had not been previously applied to quinoline or isoquinoline scaffolds, the 
one pot methodology was provisionally abandoned and products were isolated and purified at 
various steps throughout the synthesis of this alkyne fragment. The reaction sequence that 
followed would entail a Sonogashira coupling of the heterocyclic halide with TMSA 
followed by in situ deprotection of the silyl protected alkyne intermediate. This was done via 
an appropriate source of fluoride, namely tetrabutyl ammonium fluoride (TBAF) as the tri-
hydrate, as can be seen in Table 1. Our first attempt entailed recreating conditions as used by 
Müller and co-workers,
138
 using appropriate inert Schlenk and degassing techniques. 
However, the yields initially obtained were poor and the results obtained by Müller could not 
be reproduced under these conditions. A number of optimization modifications were 
undertaken, including increasing the amount of catalyst and co-catalyst, the amount of base 
added, as well as the source and amount of fluoride for deprotection which can be seen 
summarized in Table 1. THF was kept as solvent and reaction times were kept constant at 12 
h for the optimization process. As can be deduced from this experimental evaluation, 
changing of the parameters afforded little profit in the yield obtained, with exception to the 
use of liquid TBAF as fluoride source and longer degassing periods. It was only after 
employing the freeze-pump-thaw cycling technique for degassing of liquids that the alkyne 
heterocyclic compound was afforded in very good yields. 
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Table 1 
Optimization of Sonogashira coupling for 3-bromoquinoline. 
 
Attempt 
PdCl2(PPh3)2 
(mol. %) 
CuI 
(mol. %) 
Et3N 
(equiv.) 
Flouride source   
(equiv.) 
Degassing 
(min)
a 
Yield 
(%) 
1 2 4 2 
TBAF.3H2O 
(1.5) 
- 37 
2 4 4 2 
TBAF.3H2O 
(1.5) 
15 50 
3 4 6 3 
TBAF.3H2O 
(2) 
30 52 
4 4 4 2 
Liquid TBAF 
(1.5) 
30 64 
5
b
 4 4 2 
Liquid TBAF 
(1.5) 
30 85 
a = Performed by passing N2 through reaction.  
b = Freeze-pump-thaw technique was also applied for degassing. 
 
This laboratory-scale technique, involves the flash freezing of the fluid to be degassed in a 
Schlenk tube usually with liquid nitrogen and the application of a vacuum thereafter. Upon 
subsequent thawing, bubbles of gas are seen to form and escape to the top head space of the 
flask. This process is typically repeated between 3-6 times until all air is removed from the 
reaction vessel and fluid.
170
 This afforded our first alkyne fragment2a in good yield. 
Subsequent 
1
H NMR spectroscopic analysis confirmed formation of 
the unprotected alkyne product. The acetylenic proton 1 was 
identified as a singlet at 3.28 ppm integrating for 1H. The aromatic 
proton peaks of 4 and 5, were seen as a triplet of doublets 
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integrating for 1H each at 7.56 and 7.63 ppm. Peaks corresponding to proton6 and3,were 
witnessed as doublets at 7.77 and 8.09 ppm, both integrating for 1. Proton 2 was seen as a 
singlet at 8.27 ppm integrating for 1H and proton 7 could also be seen as a singlet at 8.94 
ppm, integrating for 1H.   
Application of these synthetic conditions and parameters for 7-chloro-4-iodoquinoline (1b) 
did not afford the yields obtained for the 3-bromoquinoline (1a) counterpart. After 
experimentation with different sources of fluorine, including potassium fluoride (KF) and 
caesium fluoride (CsF), it was determined that the use of CsF facilitated the maximum yield 
obtained for this specific heterocycle.Similar application of the optimized synthetic 
conditions to both 4- and 5-bromoisoquinoline scaffolds (1c-d) resulted in no reaction taking 
place. 
After scouring the literature for halogenated isoquinolines and metal-mediated coupling 
reactions and further experimental evaluation, it was found that Et3N was required as solvent 
and elevated temperatures were necessary for the reaction to proceed.
171
 This afforded both 
heterocyclic alkynes 2c and 2d in very good yields. The necessity of these conditions could 
possibly be explained by the isoquinoline moieties higher pKa value of 5.46, and thus 
increased basicity, in comparison to that of the quinoline moieties pKa value of 4.85.
172
 
Studies on the basicity of these heterocycles, in both the liquid and gaseous phase, have been 
indicative of a “peri” steric effect - hindering protonation in aqueous media of both quinoline 
and acridine that is absent in isoquinoline. This is displayed in Figure 27, where the presence 
of two peri hydrogens results in a more pronounced steric hindrance effect, which in turn is 
reflected in a lower pKa value in comparison to quinoline, with one peri hydrogen, and 
pyridine with none.
172
Basicity measurements undertaken in the gas phase showed the trend of 
increasing basicity in the order pyridine < isoquinoline ~ quinoline < acridine, a complete 
reversal in the trend seen in solution.
172
 
 
Figure 27 
Peri steric effects on various heterocylic scaffolds and their corresponding pKa values in solution. 
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The solvent free values support the hypothesis of this peri steric effect. With the lack of this 
peri steric effect in the isoquinoline moiety, coordination to the copper catalyst could be 
occurring more freely, hindering formation of the π-alkyne copper complex and in turn the 
reaction itself. Furthermore, with a higher pKa value and increased basicity, the isoquinoline 
moiety could be acting as a base. The use of excesstriethylamine and increased temperatures 
in the reaction could be counteracting these factors. A summary of the final optimized 
reaction conditions for each halogenated heterocycle, as well as the best yield obtained, can 
be seen in Scheme 4. All heterocylic alkyne compounds 2a-d were fully characterized and 
product formation was confirmed through the analysis thereof. This furnished our fully 
characterized alkyne heterocycle fragment library, compounds2a-d, and allowed us to 
continue in the synthesis of the azide fragments. 
 
Scheme 4 
Optimized conditions for Sonogashira coupling and in situ deprotection for all heterocycles. 
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3.3 SYNTHESIS OF AZIDE SIDE CHAIN FRAGMENTS 
3.3.1Synthesis of benzyl azide and 2-(azidomethyl)pyridine. 
The azide side chain fragments chosen to undergo the CuAAC reaction with our already 
synthesized alkyne fragment library, consisted of benzyl azide and 2-(azidomethyl)pyridine. 
As the halogenated precursors, benzyl bromide and 2-(bromomethyl)pyridine hydrobromide, 
were commercially available and a number of literature procedures for the synthesis of these 
fragments were accessible, few complications arose.  
The conversion of benzyl bromide into benzyl azide is a well-documented, simple reaction. 
Sodium azide undergoes a simple nucleophilic substitution reaction with benzyl bromide. The 
azide group acts as the nucleophile and salt formation of NaBr is the driving force behind the 
reaction. Our reaction conditions entailed the use of acetone and water as solvents  in a 4:1 
ratio at ambient temperature, as can be seen in scheme 5.
173
 This afforded a quantitative yield 
of benzyl azide as a brown oil (3a).   
The synthesis of 2-(azidomethyl)pyridine was not as straight forward. A first attempt at the 
synthesis of this fragment using the procedures for compound 3a, afforded the product in a 
very poor yield. Further research on the literature of these compounds unearthed a procedure 
which made use of a catalytic amount of both 18-crown-6 and tetrabutylammonium iodide 
with DMF as solvent, as can be seen in Scheme 5.
174
 
 
Scheme 5 
Reaction conditions for azide fragment synthesis. 
The reaction proceeded smoothly at ambient temperature and afforded the product 3b in a 
good yield of 78%. The role of 18-crown-6 and tetrabutylammonium iodide (TBAI) in this 
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reaction is as a phase transfer catalyst. 18-crown-6 has been known to accelerate various 
substitution reactions through suppression of ion pairing.
175
 The anions, or in this case the 
azide moiety, become naked nucleophiles – increasing the nucleophilicity and reaction rate. 
FTIR analysis confirmed the successful conversion of the reaction and the presence of the 
azide moiety in both fragments, with a characteristic strong asymmetric stretch at 2089 cm
−1
 
and symmetric stretchat 1282 cm
−1
for 3a and at 2093 cm
−1
and 1270 cm
−1 
for 3b, as can be 
seen in Figure 28. 
With both our alkyne and azide fragment precursors synthesized, the synthetic path was now 
clear to attempt the CuAAC reaction to obtain a 1
st
 generation, combinatorial library of 
potential reversible kinase inhibitors from these fragments. 
Figure 28 
IR spectra of compound 3a and 3b illustrating prominent azide stretches. 
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3.4 GENERATION OF COMBINATORIAL LIBRARY FROM AZIDE AND ALKYNE 
FRAGMENTS 
3.4.1Defining “Click” Chemistry 
The term “Click” chemistry was coined by K. Barry Sharpless and his group in a landmark  
paper in 2001.
176
With particular emphasis on following the strategy adopted by nature in 
generating large molecules built from smaller components via heteroatom to carbon linkers, a 
rigorous and stringent set of criteria was defined which must be observed by a process, to fall 
within this category. Thus a click chemistry reaction is delineated and exemplified best as 
one that is modular, broad in application, affording high yields with minimal and innocuous 
by-products, stereospecific and have a high atom economy. Furthermore, the reaction should 
proceed under ambient reaction conditions, using commercially and readily available 
reagents and starting materials, in a solvent that is benign to the environment and easily 
removed with simple separation, isolation and purification.
176
 
A number of reactions have been found to satisfy these criteria exceptionally and have 
become benchmark click reactions. These include: thiol-ene click reactions,
177
 Diels-Alder 
and inverse electron demand Diels-Alder reactions,
178
 nucleophilic substitutions tostrained 
epoxides,
179
  and cycloaddition reactions such as the [4+1] cycloaddition between isonitriles 
and tetrazines
180
 and the [3+2] Huisgen 1,3-dipolar cycloadditions, frequently called “click” 
reactions, including the copper-
181
 and ruthenium-catalysed variants.
182
 
Click chemistry has found a plethora of applications in chemistry, biochemistry, 
supramolecular chemistry, polymer and materials science.
183
 This has extended to its use in 
2D gel electrophoresis, macromolecular or nanostructures,
184
 peptidomimetics or its peptide 
chains,
185
 macrocyclizations,
186
 dendrimer design,
187
 nanotechnology and drug 
discovery.
183,188
Click chemistry has also been used to label biomolecules within systems, 
through biorthogonal click reactions. This means that thesereactions possess good selectivity 
and biocompatibility,
189
 overcoming toxicity such that their participating reagents can form 
covalent bonds within abundantly functionalized biological systems - in some cases, living 
organisms.
195, 196
 This has won click chemistry world recognition as a household term for 
chemists. 
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3.4.2 The 1,4-Copper Catalysed Azide Alkyne Cycloaddition (CuAAC). 
The azide alkyne Huisgen cycloaddition has been referred to as the “cream of the crop” of 
click chemistry by Sharpless himself.
176
 In particular, the copper-catalysed cycloaddition has 
become one of the most popular and recurrently used reactions in click chemistry today.
183,188
 
It was discovered simultaneously and separately by the groups of Sharpless and Valery V. 
Fokin,
190
 as well as the Meldal group in Denmark.
191
 Whilst the Meldal group were the first 
to document and report the reaction in the synthesis of peptidotriazoles on solid support, they 
did not fully appreciate the potential of the reaction and its applicability as a click reaction. 
Sharpless on the other hand, lauded it as a reliable and robust catalytic process, bringing 
unparalleled selectivity, consistency and broad spectrum utilization in the organic synthesis 
for the formation of covalent linkers between assorted components.
190
 
 
Scheme 6 
General reaction conditions and product formed for CuAAC. 
The copper-catalysed azide alkyne cycloaddition reaction occurs between organic azides and 
terminal alkynes which are united to exclusively form 1,4-regioisomers of 1,2,3-triazoles as 
product,shown in scheme 6.
192
 Although commercial sources of copper(I) such as cuprous 
bromide or iodide may be used for the cycloaddition, the reaction has been found to proceed 
more efficiently with the use of a copper(II) source such as copper sulphate and an applicable 
reducing agent such as sodium ascorbate or ascorbic acid, as seen in scheme 6. This is due to 
Cu(I) species being unstable in aqueous solvents, which can be overcome with the addition of 
stabilising ligands. An advantage of generating the Cu(I) species in situ, whereby the Cu(II) 
complex is reduced from the +2 oxidation state to the +1, is the non-requirement of a base. If 
copper(I) sources are used directly, triethylamine (Et3N) orN,N-diisopropylethylamine 
(DIPEA) are frequently used as bases. 
This economical reaction excels in a variety of solvents.Whilst water without organic co-
solvent or a mixture of water/alcohol such as methanol, iso-proponal or tert-butanol is most 
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commonly used, organic solvents such as dimethyl sulfoxide, tetrahydrofuran, acetone, 
dimethylformamide and acetonitrile are also effective.
192
 The reaction functions ina wide pH 
range, from 4-12, with pH 7-9 yielding best results. Reactions have been shown to proceed at 
0 °C and as high as 160 °C. The isolation and purification is also simple, usually requiring 
filtration of product or extraction, avoiding laborious and time consuming chromatographical 
methods or recrystallization.
192
A huge boon of this reaction is its inertness to many of the 
most common functional groups without protection.
188
 For these reasons, it is clear to see 
why this reaction has gained such relevance and esteem in organic synthesis.  
3.4.3 Catalytic Cycle and Mechanism. 
The current proposed mechanism for the CuAAC is based on density functional theory (DFT) 
calculations undertaken by Sharpless and his group.
192
 Although there was a deficiency in 
certain aspects of chief transitions and intermediates, the study elucidated much in 
understanding, through qualitative and quantitative analysis, of the mechanistic path followed 
in this reaction as shown in Figure 29. Nevertheless, the exact DFT calculations agree and 
overlap with a number of experimental observations and evidence. These include a lower 
activation barrier calculated in comparison to related cycloadditions, which accounts for a 
dramatic increase in reaction rate observed in the CuAAC. Secondly, the regiosomer obtained 
in the experimental reaction, the 1,4-substituted variant, is predicted by DFT. Lastly, the DFT 
calculations successfully predicted the reaction to proceed with other dipoles such as nitrile 
oxides, which is observed experimentally adhering strictly to the regioselectivity. This 
enforces the mechanism put forward by Sharpless and his group.
192
 
The reaction mechanism begins with either the Cu(I) catalyst or the Cu(I) species generated 
in situ through reduction of a suitable Cu(II) pre-catalyst. This alkyne coordinates to the 
Cu(I) species, which results in the expulsion of a ligand from the copper complex and 
formation of the copper acetylide as shown in step AFigure 29. This conversion proceeds 
through the formation of a π-alkyne copper complex as has been seen in various other copper 
mediated coupling reactions.
162
Thereafter, step B involves the replacement of the previously 
expelled ligand with the coordination of the azide to the copper through the nitrogen proximal 
to the carbon forming the copper-azide-acetylide complex. Subsequent attack, in step C, from 
the distalnitrogen of the azide of the alkyne carbon bonded to R
1
 affords the six-membered 
copper(III) metallacycle. From this point the barrier for ring formation is very low, which 
furnishes the triazolyl-copper derivative through step D.  
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Figure 29 
Proposed reaction mechanism and catalytic cycle for CuAAC adapted from Sharpless et al.
192 
Subsequent release of the triazole through step E affords the 1,4-substituted 1,2,3,-triazole 
and regeneration of the copper catalyst.
192
 
3.4.4Synthetic Optimization and Generation of Library of Novel Reversible Inhibitors 
With our alkyne and azide side chain moietiesin hand, it was our intention to generate a small 
“combinatorial” library derived from these previously synthesized fragments, through the use 
of the CuAAC. As can be imagined, a large amount of literature procedures and reaction 
conditions have been reported for this reaction, which resulted in a number of experimental 
evaluation and optimization reactions being performed, in order to determine what conditions 
afforded the highest yield in the most efficient manner as can be seen in Table 2. For this, 
compound 2a and benzyl azide(3a) were selected and examined against an assortment of 
different sources of copper, including Cu(I) and Cu(II) species with reducing agents, and a 
variety of different solvents in different ratios. The reaction time was kept constant at 24h and 
all reactions were carried out at rt. 
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Table 2 
Optimization of CuAAC for compound 4a. 
 
Attempt 
Source of  
copper 
Amount  
(mol. %) 
Reducing  
agent  
Amount  
(mol. %) 
Solvents  
used 
Solvent 
 ratio 
Yield 
(%) 
1
193
 CuSO4.5H2O  2 
Sodium 
ascorbate 
5 H2O:t-BuOH 1:1 18 
2
193
 CuSO4.5H2O 5 
Sodium 
ascorbate 
5 H2O:t-BuOH 1:3 20 
3
193
 CuSO4.5H2O 5 
Sodium 
ascorbate 
5 H2O:MeOH 1:1 28 
4
194
 CuI 5 DIPEA 1 equiv. ACN - 12 
5
174
 Cu(OAc)2 10 - - H2O:t-BuOH 1:1 62 
6
174
 Cu(OAc)2 10 - - H2O:MeOH 1:4 73 
 
Our initial reactions condition were based on the one of the most popular and frequently used 
copper sources, CuSO4, with the equally as prominent sodium ascorbate as reducing agent in 
aqueous medium – a procedure which often affords quantitative yields as outlined by one of 
the co-discoverers and founder of the principle of click chemistry, Valery V. Fokin.
193
Sodium 
ascorbate, a mild reductant, is a suitable and advantageous alternative to oxygen free 
conditions as any dissolved dioxygen is reduced, eliminating the appearance of by-products 
from copper catalysed oxidative side reactions.
193
 Water is a conducive solvent for the 
formation of reactive copper acetylides, especially when formed in situ.
193
 However, as 
shown above in attempt 1-3 in Table 2, use of these reagents and conditions with a variety of 
solvents and ratios and amount of catalyst loadings afforded very poor yields. This led us to 
evaluate the use of a Cu(I) halide species in an organic solvent, such as CuI in acetonitrile 
with the use of DIPEA as base (attempt 4). However this afforded an even lower yield which 
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can be explained by the formation of oxidative by-products, which seemingly halted 
progression of the reaction and destroyed the catalyst. With this methodology, elimination of 
oxygen in the reaction vessel is a priority, but with the proclaimed robust nature of this 
reaction we sought out other synthetic conditions which would afford a reasonable yield.  
 
Scheme 7 
General reaction conditions and product formed for CuAAC.
174
 
After combing through the literature, a procedure was found which makes use of copper (II) 
acetate without inclusion of a reducing agent as devised by Zhu and co-workers.
174
 The group 
found that the CuAAC proceedswith a number of Cu(II) salts, without the need for a reducing 
agent, in readily oxidizable alcohols such as MeOH, EtOH and i-PrOH, but not t-BuOH. This 
led to the hypothesis that a Cu(I) species was generated via the reduction of the Cu(II) 
catalyst through oxidation of these alcohol solvents as shown in Scheme 7a below. However, 
the reaction was seen to proceed with a very high yield with Cu(OAc)2 in t-BuOH which is 
not inclined to oxidation. This led to the group putting forward a second postulation, that a 
Glaser-type reaction - or in the case of copper (II) acetate salts, a related Eglinton-type 
reaction, shown in Scheme 7b - was taking place. This furnished the catalytically active Cu(I) 
species, which has been shown to be generated in these reactions,
195, 196
 which in turn 
facilitated reaction of the azide alkyne cycloaddition (AAC). According to the authors,  
electron paramagnetic resonance (EPR) and absorption spectroscopy both supported these 
hypotheses.
174
 
Use of Cu(OAc)2in a mixed solvent system H2O:t-BuOH afforded a satisfactory yield and 
with replacement of MeOH a yield of 73% was found to be acceptable for the optimization of 
this reaction, as seen in Table 2. With a suitable synthetic procedure optimized, we applied 
these parameters to the rest of our heterocyclic alkyne and azide fragments in a 
“combinatorial” fashion, generating a library of clicked compounds in good yield as shown in 
Table 3.  
a) 
b) 
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Table 3 
Combinatorial library generated through CuAAC with yields. 
 
 
These novel compounds were fully characterized using 
1
H 
NMR, 
13
C NMR, FTIR spectroscopy and HRMS-TOF MS. 
This confirmed the formation of the clicked products. Showing 
compound 4aas example, both the benzylic protons and the 
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CH2 proton in the triazole ring were clearly accounted for in the 
1
H NMR spectra, with  
proton 1 showing up as a singlet at 5.61 ppm integrating for 2H and proton 2 being observed 
as a singlet at 7.86 integrating for 1H as was expected. All other protons were accounted for 
in the spectra. For the 
13
C NMR spectra, carbon1 was at 54.5 ppm and the triazole formation 
was confirmed by both carbons 2 and 3 showing on the spectra at and 129.36 and 145.49 
ppm. All other corresponding carbon peaks were accounted for. The [M+H]
+ 
ion found in the 
MS spectra was 287.1297, which matched identically with the calculated 287.1297 for 
C18H15N4. 
Through use of the CuAAC we were able to generate 8 novel, 1,4-substitued 1,2,3,-triazole 
based potential reversible kinase inhibitors. These compounds would later be sent for 
biological assays to determine efficacy and potency. With the synthetic methodology adopted 
and developed in the synthesis of our potential reversible inhibitor library, we set our sights 
on utilizing this click chemistry approach in the synthesis of potential irreversible inhibitors. 
Irreversible kinase inhibitors have been shown to possess a number of distinct advantages 
over their ATP competitive counterparts, and thus it was our endeavour to move one step 
forward in the design of potent and selective inhibitors. 
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CHAPTER 4 – 1
ST
 GENERATION IRREVERSIBLE INHIBITOR LIBRARY 
4.1 MOTIVATION, RATIONALE AND STRATEGY FOR SYNTHESIS OF IRREVERSIBLE 
INHIBITOR LIBRARY 
4.1.1 Irreversible Inhibitors – Successes and Advantages. 
The successes attained by reversible, ATP competitive kinase inhibitors as anticancer agents, 
brought drug discovery in kinase inhibition to the forefrontof the targeted therapeutic 
treatment of cancer. However, challenges met in the clinical and approved phases of these 
drugs, which include promiscuity across the widely conserved human kinome, high 
intracellular concentrations of endogenous ATP, the competitive substrate in reversible 
inhibition and resistance to prescribed drugs due to mutations in the enzyme, has sparked a  
search for alternative therapeutic mechanisms to combat these challenges.
197
A resurgence in 
the field of covalent drugs or irreversible inhibitors,
198
 has been paramount to addressing and 
overcoming these challenges. This revival has been brought on by a greater understanding of 
the advantages and disadvantages of irreversible inhibition and the approval of a number of 
potent and non-toxic covalent drugs.
199
Covalent drugs, in general, have been an extremely 
lucrative and successful class of treatment for the pharmaceutical sector, with 3 of the top ten 
selling drugs in the United States in 2009 being covalent drugs, $33 billion dollars in 
worldwide sales from the 26 covalent drugs for which there is data and the most used 
irreversible drug globally, aspirin, having 80 million tablets consumed per year in the United 
States alone.
198
 A breakdown of the 39 drugs that had received FDA approval in mid-2011 
shows that ~33% are used as anti-infectives, 20% as anti-cancer agents, 15% for 
gastrointestinal disorders and 10% and 5% for cardiovascular and central nervous system 
disorders respectively as can be seen in Figure 30. Inflammation targets make up 3% of these 
FDA approved drugs with 13% targeting other disorders.
198
This has shown irreversible 
inhibition to be a successful, proven approach in many classes of drug targets.
197
In the last 
decade, the distinct advantages of targeted, irreversible kinase inhibitors include benefits such 
as extraordinary efficacy and IC50 profiles in biological assays, success in overcoming ATP 
competition, an inherent selectivity that is exclusive to its mechanism of action and very 
importantly, an ability to retain efficacy against resistance mutations in target kinases.
197
 This 
has resulted in a number of irreversible kinase inhibitors undergoing clinical investigation 
and this field of research can be considered the vanguard of protein kinase inhibition.  
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Figure 30 
Pie chart illustrating the spread of covalent inhibitors in treatment.
198
 
With no greater PTK are these benefits greater exemplified than with EGFR. Figure 31 shows 
the chemical structure of 6 irreversible inhibitors in particular, all targeting the EGFR/HER2 
pathway and in clinical trials, that have shown the promise and potential of this mechanism of 
treatment. IC50 values in nM, based on preclinical in vitro EGFR and HER2 kinase assays, 
are indicated below each compounds name.
197, 200
Not only do these inhibitors show 
remarkable antitumour activity and efficacy in in vitro and in vivo assays, they also exhibit 
potent selectivity and the ability to overcome mutations that have sparked resistance to 
approved ATP competitive inhibitors on the market.
134b, 200-201
The compound WZ4002, as 
example, has shown remarkable selectivity in targeting the T790M specific mutation within 
the EGFR kinase domain.
201c, 201d
 This secondary mutation at the gatekeeper residue, which 
occurs by substitution of the threonine 790 amino acid with methionine, is one of the most 
common causes of resistance to known therapeutic agents.
134b
The result of this substitution is 
a bulkier side chain at the gatekeeper residue which restricts and hinders access to the active 
site by the inhibitor through sterics, thus lowering efficacy. It has also been shown that this 
mutation increases affinity for the natural substrate ATP, thus meaning an increased dosage 
of inhibitors are needed to remain competitive.
134b
 Drug discovery stratagems targeting this 
mutation through irreversible inhibition have resulted in failure due to a unacceptable toxicity 
profile which is linked to simultaneous inhibition of the wildtype EGFR.
201c
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Figure 31 
A number of irreversible inhibitors currently in clinical trials with IC50 values shown in nM.  
The wild type can be thought of as the normal or phenotypic enzyme, a product of standard 
alleles, present in the body. However, WZ4002 has shown an incredible selectivity for this 
mutated form of the EGFR kinase, being 30-100 fold more potent against EGFR T790M, and 
up to 100- fold less potent against the wildtype EGFR, in comparison to other quinazoline-
based EGFR inhibitors in vitro.
201c
With these results it is clear to see why the field of 
irreversible inhibition has generated so much interest and has opened up a dominant approach 
to identifying new classes of mutant-selective kinase inhibitors.  
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4.1.2 Rationale and Proposed Synthetic Strategy for Irreversible “Space Probing” 
Inhibitor Library. 
With the clear advantages inherent in irreversible inhibitors and synthetic methodology 
already laid out incorporating click chemistry in the design of reversible inhibitors, it was our 
endeavour to apply this to the design and synthesis of a library of irreversible inhibitors. A 
retrosynthetic analysis of possible ways of incorporating an electrophilic “warhead”, in 
combination with our already synthesized heterocyclic alkynes, led us to the azide moiety 
shown in Scheme 8. From the commercially available o-, m-and p- substituted nitrobenzyl 
bromides, a simple nucleophilic substitution reaction would afford the corresponding 
nitrobenzyl azides. These compounds would be coupled with our heterocyclic alkynes 
through click chemistry, followed by subsequentselective reduction of the aromatic nitro 
groupsto afford the aromatic amine. Coupling with acryloyl chloride in an acylation reaction, 
would present a suitable electrophile, or Michael acceptor motif, necessary for covalent bond 
formation. For the generation of our library of irreversible inhibitors, the use of the acryloyl 
amide moiety as electrophile was chosen. This was due to its ease of synthetic availability 
and its known capacity for participation in irreversible inhibition interactions, and its 
experimentally shown ability to form covalent bonds with cysteine residues.
202
 
 
Scheme 8 
Retrosynthetic breakdown of electrophilic “warhead” space probes. 
An important factor to bring to the reader‟s attention is that by utilizing ortho, meta and para 
substituted nitrobenzyl azides, a large amount of conformational space could be probed in the 
ATP binding site, increasing the chances for this electrophilic “warhead” to form a covalent 
bond with the conserved cysteine residue present in the EGFR active site – namely 
Cys797.
137
 A logical choice to make in the generation of this library of irreversible inhibitors 
would be to utilize both the copper- and its ruthenium-catalysed click counterpart.   
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Scheme 9 
Proposed synthetic route to potential irreversible inhibitors and illustration of space probing effect of 
these compounds. 
This would allow the generation of 1,4- and 1,5- substituted CuAAC and ruthenium catalysed 
azide alkyne cycloaddition (RuAAC) products respectively (see Section 4.2.2 for more 
information), affording two different regioisomers – thus expanding the conformational space 
filled and effectively augmenting the probing affect brought on by the use of o-, m- and p- 
substituted electrophiles. An illustration of the proposed synthesis for this library of space 
probing potential irreversible inhibitors can be seen in Scheme 9 above. A copper- or 
ruthenium-mediated click reaction between the quinoline and isoquinoline heterocyclic 
alkynes and synthesized azides would afford the corresponding triazole carrying an aromatic 
nitro group. Reduction of this moiety and subsequent coupling with acryloyl chloride would 
provide our fully furnished 1,4- and 1,5-, o-, m- and p-substituted library of potential 
irreversible inhibitors. To fully show the space probing effect of these compounds, and 
illustrated example is shown at the bottom of Scheme 9. This shows that for each heterocyclic 
alkyne undergoing this reaction sequence, six potential irreversible inhibitors, adopting 
unique spatial conformation and thus occupying a different volume of space in the active site, 
will be generated. This can be seen as a powerful tool for generating a large library of 
compounds targeting the cysteine residue and irreversible inhibition. The generation of the 
1,4-substituted library through CuAAC was carried out and completed by a postdoc 
researcher in our labs, Dr. Abu Taher and will not be discussed here.  
Stellenbosch University  http://scholar.sun.ac.za
Chapter 4 – 1st Generation Irreversible Inhibitor Library 
_______________________________ 
91 
 
4.2 SYNTHESIS OF LIBRARY OF 1,5- SUBSTITUTED POTENTIAL IRREVERSIBLE 
INHIBITORS. 
4.2.1 Synthesis of Nitrobenzyl Azide Fragments. 
With the heterocyclic alkynes synthesized already in hand the first step in the generation of 
the irreversible inhibitor library was to synthesize theo-, m- and p-substituted nitrobenzyl 
azide fragments. This was accomplished with relative ease as conditions used for the 
synthesis of compound 3a were utilized, affording quantitative or near quantitative yields. 
The reaction conditions and yields are summarized in Scheme 10 below.  
 
Scheme 10 
Synthesis of nitrobenzyl azide fragments 6a-c. 
Subsequent FTIR analysis confirmed the presence of the azide species in compounds 6a-c. 
As an example, compound 6ashowed acharacteristic strong asymmetric stretch at 2091 cm
−1
 
and symmetric stretchat 1254 cm
−1
. This afforded the nitrobenzyl azide fragments and 
allowed us to move on to synthesizing a combinatorial library of these fragments and the 
previously synthesized alkyne fragments, through RuAAC reactions. 
4.2.2The Ruthenium Catalysed Azide Alkyne Cycloaddition Reaction. 
Thesuccess, popularity and applicability attained by the regioselective 1,4-substituted triazole 
CuAAC reaction demanded a viable synthetic route and methodology to be crafted for its 
corresponding regioisomer, the 1,5-substituted triazole.
203
 Although synthetic procedures to 
these 1,5-substituted regioisomers are available, which include the use of stabilized 
phosphonium ylides,
204
 the addition of bromomagnesium acetylides to organic azides
205
 and 
the use of enamines with aryl azides,
206
 they lack the simplicity, scope and directness of the 
CuAAC.
182, 203
This led to the development of a ruthenium-mediated azide alkyne 
cycloaddition reaction by the groups of Fokin and Jia.
203
 By making use of ruthenium-based 
catalysts such as such as CpRuCl(PPh3)2 and Cp*RuCl(PPh3)2, the groups found a 
regioselective catalytic route to these 1,5-substituted triazoles.
207
 A notable dampener on the 
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scope of the CuAAC was its inability to catalyse cycloaddition reactions on internal alkynes. 
In contrast to the CuAAC, the group of Fokin found that these ruthenium catalysts were 
indeed able to induce cycloaddition on both terminal and internal alkynes.
203
 Weinreb et 
al.,
208
 investigated the synthesis of these 1,4,5-substituted triazole products with some 
interesting results as well as the group of Huang and co-workers,
207
 who deduced that the 
factors governing the regioselectivity of the reaction are due to electronic effects of the 
substituents. Although a number of ruthenium based catalysts and their activity in promoting 
the cycloaddition have been investigated, η5-pentamethylcyclopentadienyl ruthenium 
[Cp*RuCl] variants have been shown to be the most successful in doing this. These include 
Cp*RuCl(PPh3)2, the cyclooctadiene variant Cp*RuCl(COD)and [Cp*RuCl]4. The 
effectiveness of these complexes can be attributed to stabilisation of higher oxidation states 
of the ruthenium centre by the electron rich Cp* ligand, evident in complexes lacking this 
ligand showing little to no effect in driving the cycloaddition forward. Aprotic solvents are 
well tolerated including toluene, THF, dioxane, benzene and DMF, with a temperature range 
from ambient to 110°C. Interestingly, the presence of water in the reaction flask usually did 
not affect the catalytic activity of the complexes, leading to the conclusion that incredibly dry 
conditions are not necessary.
182
Scheme 11 gives an outline of the general synthetic 
procedures used and products afforded from this reaction. The RuAAC has found 
applicability in synthesis of glycoconjugate carbonic anhydrase inhibitors,
209
 mimics of 
vancomycin
210
 and other synthetic applications such as one pot reaction methods.
211
 
Scheme 11 
General reaction conditions and products formed for the RuAAC. 
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4.2.2Catalytic Cycle and Mechanism. 
Ruthenium-mediated catalytic transformations of alkynes have been well established in the 
literature and confirmation of the existence of intermediates such as ruthenium(II) 
acetylides,
212
 vinylidenes
213
 and ruthenametallacyclic complexes
214
 have been presented.
203
  
This and a number of DFT calculation projects have laid the ground work to deciphering the 
mechanism of the RuAAC. This includes work done by the Fokin group,
182
 and most recently 
an investigation done by Tüzün from Istanbul.
215
 The mechanistic proposal outlined by these 
groupswhich proceeds via a 6-membered ruthenacycle intermediate, is supported by the DFT 
calculation data observed. This proposed mechanism is shown in Figure 32.The catalysts 
ability to be involved in both terminal and internal alkynes, suggests it is unlikely that a 
ruthenium acetylide is present in the catalytic cycle. The specific catalysts that are most 
competent in this cycloaddition point to [Cp*RuCl] being the catalytically active species, a 
hypothesis supported by a lower catalytic activity seen in both the [Cp*RuBr] and [Cp*RuI], 
whilst removal of the anionic chloride through Ag
+
, to form [Cp*Ru]
+
 cationic 
complexes,results in complete loss of activity.
182
 
 
Figure 32 
Proposed reaction mechanism and catalytic cycle for RuAAC adapted from Sharpless et al.
182 
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The group hypothesized that the reaction mechanism begins with displacement of the 
spectator ligands to form an activated complex as shown in step A of Figure 32. This 
complex is converted, via oxidative coupling of the alkyne and azide, to the ruthenacycle 
illustrated by step B in Figure 32. The regioselectivity is determined by this step or the first 
new carbon-nitrogen bond formed, which can be seen as a nucleophilic attack of the activated 
alkyne at the electrophilic terminal nitrogen of the azide.  Computational studies support the 
irreversible configuration of this ruthenacycle. Subsequent reductive elimination (step C) 
releases the 1,5 substituted triazole product and the catalyst is regenerated in as shown in step 
D. DFT studies also indicate that the reductive elimination is the rate determining step in the 
catalytic cycle.
182
 
4.2.3 Synthetic Optimization and Generation of Library of Novel Irreversible Inhibitors 
With both the heterocyclic alkyne fragments (2a-d)and the newly synthesized nitrobenzyl 
azide fragments (6a-c) in hand, the synthesis of the exclusively 1,5-substituted, RuAAC-
mediated library of potential irreversible kinase inhibitors could be undertaken. For this 
purpose, the catalyst Cp*RuCl(COD) was chosen and purchased for all reactions on the 
grounds that it is the most labile catalyst, with the cyclooctadiene group being more easily 
displaced than say that of  the phosphine ligands, and proceeds in the least demanding 
reaction conditions.
182
 Following suit as was previously done in the synthetic endeavours of 
our reversible library, the coupling between the heterocyclic alkyne 2a and ortho substituted 
nitrobenzyl azide 6a was chosen to be optimized, as can be seen in Table 4. The 
Cp*RuCl(COD) has been shown to be active at catalytic amounts of 2 mol. % at ambient 
temperatures producing high yields and 100% regioselectivity.
182
Thus our first reaction 
conditions implemented a minimum amount of catalyst at rt with anhydrous tertrahydrofuran 
as solvent. Careful consideration was taken to keep conditions inert and a period of 45min of 
degassing with nitrogen was implemented. This however, resulted in very poor yields which 
were solely attributed to the incomplete consumption of both starting reagents as deteremined 
by TLC. The reaction was seen not to proceed to completion, and after 24h the reaction was 
stopped and both the starting materials were salvaged and the product isolated. This meant 
that whilst we were not losing both our heterocyclic alkyne and azide fragment reagents, the 
amount of product afforded in this reaction was unacceptable (<20%). Thus it was decided to 
make use of more catalyst in the second attempt2, but againto no avail, it was seen to have 
little effect on the yield and more importantly not successful in driving the reaction to 
completion.  
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Table 4 
Optimization of RuAAC for compound 7a. 
 
Attempt
182
 Cp*RuCl(COD) (mol. %) Solvent Temp (°C) Yield(%) 
1 2 THF
a 
rt 18 
2 4 THF
a
 rt 19 
3 4 THF
b
 rt 23 
4 4 Dioxane
a
 rt 18 
5 4 Toluene
a
 Gradually to 80 71 
6 4 Toluene
a
 80 85 
a = Nitrogen was passed through reaction for 45min for degassing                                                                                                   
b = Freeze-pump-thaw technique and nitrogen was passed through for 45min for degassing of 
reaction.  
At this point we investigated whether or not the catalyst was being deactivated due to 
contaminants such as molecular oxygen or water in the reaction flask and so a freeze-pump-
thaw technique, in combination with passing nitrogen through the reaction, was applied for 
attempt 3. 
This had little effect on the yield and the next variable to investigate was that of solvents. 
Attempt 4 saw the utilization of anhydrous dioxane, which resulted in a lower yield than that 
obtained for attempt 3 – the main culprit still being incompletion of the reaction. Finally it 
was decided to make use of a high boiling point solvent and by increasing the temperature of 
the reaction, give external energy to drive the reaction to completion.  For this purpose, 
toluene was chosen as solvent and the reaction was gradually heated to 80°C, starting at rt in 
20°C increments every hour for attempt 5. Satisfyingly, this resulted in the reaction going to 
completion and a good yield of 71% being obtained for the reaction. The reason we delayed 
with  increasing the temperature to allow it to go to completion, was that the Cp*RuCl(COD) 
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catalyst has specificallybeen shown to proceed better at ambient conditions and that elevated 
temperatures are actually detrimental to the reaction, resulting in deactivation, decomposition 
and low yields.
182
 Interestingly, this was not the case for our reactions and the final attempt 6 
kept the temperature of the reaction constant at 80°C from start to finish, resulting in our 
optimized yield of 85% for compound 7a. These reaction conditions were then applied to the 
rest of the heterocyclic alkynes 2a-d and our o-, m- and p- substituted nitrobenzyl azides 6a-
c, the results of which are summarized below in Table 5.  
Table 5 
Summary of synthesis of 1,5- substituted triazole compounds 7a-l. 
 
It is interesting to note that the products formed from the isoquinoline alkynes resulted in far 
lower yields than those products built from the quinoline alkynes. A number of control 
reactions, changing the solvent, temperature and the use of freeze-pump-thaw techniques, 
similar to those done in the optimization reactions, were undertaken to determine whether 
these had any effect on the yield. As was the case with our optimization results, the reactions 
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did not proceed to completion with a lowering of the temperature and other variables altered 
only worsened the afforded yield. The difference in yields between these two scaffolds could 
be attributed to coordinative and basic effects of the isoquinoline driving group as discussed 
in Section 3.2.2. In the end the yields obtained were very good for the quinoline backbone 
products and acceptable for those containing isoquinoline as the driving group. 
The compounds synthesized were fully characterized using 
1
H 
NMR, 
13
C NMR, FTIR spectroscopy and HRMS-TOF MS. This 
confirmed the synthesis thereof. Using compound 7a, as 
example,
1
H NMR spectroscopic analysis showed the benzylic 
peak of protons 1 at 6.07 ppm integrating for 2H and proton2 in 
the triazole ring being witnessed as a singlet at 8 ppm integrating for 1H, as was expected. 
All other protons were accounted for in the spectra. 
13
C NMR spectroscopy also confirmed 
product formation as the benzylic carbon 1was witnessed at 49.6 ppmand both triazole 
carbons2 and 3 were seen at 129.6 and 136.1 ppm respectively. The remaining carbon peaks 
were all accounted for in the spectrum.MS analysis and spectra showed the [M+H]
+
 ion as 
332.1156,which correlates well with the calculated 332.1147 for C18H14N5O2. 
Confirmation of the synthesis of both the 1,4- and 1,5-
regioisomers was gained through comparison of the peaks 
obtained in both the 
1
H NMR and 
13
C NMR spectra of the 
appropriate CuAAC analogues synthesized by Dr. Abu 
Taher, and the library synthesized through the RuAAC. 
For example, the triazole proton 4 of the analogue of compound 7a, shown above on the left, 
was observed at 8.17 ppm, a notable shift from that seen for proton 2 of compound 7a (8.00 
ppm). A similar trend was observed for all compounds synthesized and on the basis of these 
findings, it was deduced that both the 1,4- and 1,5-regioisomer series had been synthesized. It 
should be noted that these correlations do not confirm which regioisomer is which; however, 
there is significant literature precedent concerning the regiochemical outcomes of CuAAC 
and RuAAC reactions.
190, 203
It is thus our assumption that the 1,4-regiosomer was furnished 
through the CuAAC reaction, whilst the 1,5-regiosomer was provided under the  RuAAC 
conditions. It should also be noted that 2D NMR spectroscopy, such as Nuclear Overhauser 
effect spectroscopy (NOESY), or the obtaining of a crystal structure, could be used to 
confirm the absolute structure of each click reaction.  
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This afforded a range of 1,5-substituted triazole compounds that were ready to have the 
electrophilic warhead moiety incorporatedfor irreversible inhibition introduced.  
4.2.4 Reduction of Aromatic Nitro and Addition of Acryl Amide Moiety to Clicked 
Compounds. 
With the formation of our twelve 1,5-substituted 1,2,3-triazole-based core driving portions, 
with o-, m- and p- substituted aromatic nitro groups attached to them, the next step in the 
synthesis of the library of potential irreversible kinase inhibitors would be the introduction of 
the electrophilic warhead or Michael acceptor moiety. This would enable the inhibitors to 
potentially undergo a Michael addition reaction with the nucleophilic cysteine residue present 
in the kinase active site. This would involve two synthetic steps, namely the reduction of the 
aromatic nitro group followed by a subsequent acylation reaction with acryloyl chloride. 
A trove of synthetic methods is known for the reduction of nitroarenes using a variety of 
reagents, catalysts and reaction conditions. These include the use of catalytic hydrogenation 
by making use of palladium on activated charcoal and a source of hydrogen,
216
platinum(IV) 
oxide,
217
Raney nickel,
218
 stannous or tin(II) chloride
219
 and zinc
220
 or iron in aqueous 
media.
221
This left us with a variety of options in the reduction of theo-, m- and p- substituted 
nitro group on each clicked compound. Once again to remain consistent the compound 7a 
was chosen for optimization reactions for this synthetic procedure. Our synthetic endeavours 
resulted in the use of a couple of different reagents and conditions in the reduction of this 
aromatic group. A summary of these experimental efforts can be seen below in Table 6. 
Table 6 
Optimization of reduction of aromatic nitro compound 7a. 
 
Attempt Catalyst (mol. %) Secondary Reducing agent (equiv.) Solvent 
Yield(
%) 
1
222
 Raney Nickel (10) NaBH4(2) EtOH
 
14 
2 Pd/C (5) H2 DCM 81 
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For attempt 1, we synthesized our own Raney nickel following a procedure set out by 
Mozingo.
223
 The use of this reducing agent in tandem with NaBH4 as outlined by Litvi´c and 
co-workers,
222
 resulted in a very poor yield and discouraged us from further use of these 
reducing agents. Our next choice of reductant system, in attempt 2, made use of palladium on 
activated charcoal with hydrogen gas. DCM was chosen as solvent purely for solubility issues 
and the reaction was seen to proceed smoothly and effectively with a simple filtration through 
Celite required for product isolation. This afforded the aniline in a good yield and became our 
choice for the further reduction of all aromatic nitro groups.  
It was deemed unnecessary to purify the product obtained after reduction, due to the lack of 
formation of by-products and simple isolation procedure, and thus the acylation reaction was 
performed directly on the aromatic amine afforded after reduction. The reaction of acryloyl 
chloride with triethylamine as base in DCM, proceeded smoothly with acceptable yields 
between 56 and 66%. It is important to note that the yields obtained were calculated over two 
steps. As this reaction afforded our final product, it was seen as redundant to labour further 
on optimization of the reaction conditions. The formal reaction conditions used for both the 
aromatic nitro reduction and acylation reaction can be seen below in Table 7, as well as a full 
summary of yields obtained over the two steps for products 8a-l.  
A full characterisation of all synthesized compounds was 
completed. The spectral data obtained from this confirmed the 
formation of our desired products. With compound 8a as 
example, analysis of the 
1
H NMR spectra obtained clearly showed 
the ethylene protons 1 and 2both as doublets of doublets at 6.12 
and 5.64 ppm respectively, each integrating for 1H. The 3
rd
 
ethylene proton 3was also witnessed as a doublet of doublets at 
6.28 ppm integrating for 1H. The amide proton 4could be seen far downfield at 9.84 ppm 
integrating for the required 1H. Lastly, the benzyl protons of 5were observed as a singlet at 
5.77 ppm, integrating for 2H and indicative of the triazole and driving portions still being 
attached to the molecule. All other protons were accounted for in the spectra. The 
13
C NMR 
spectrum for compound 8aclearly showed the benzyl carbon of 5 at 48.8 ppm and that of 
carbon 6 further downfield at 163.4 ppm. All other carbons were observed as expected in the 
spectra. Finally, the HRMS spectra for compound 8a showed agreement between the [M+H]
+
 
ion 356.1510 and that calculated for C21H18N5O as 356.1511. 
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Table 7 
Reaction conditions and yields obtained for products 8a-l. 
 
This afforded our twelve potential irreversible kinase inhibitors and furnished our 1
st
 
generation library of potential irreversible inhibitors. With both a 1
st
 generation library of 
eight reversible and twelve 1,5-substituted potential irreversible inhibitors synthesized and 
another twelve 1,4-substituted irreversible inhibitors synthesized by Dr. Abu Taher, we were 
ready to send these compounds to our collaborators at the Technische Universiteit Dortmund 
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in Germany for biological screening. The assays results could determine efficacy, selectivity 
and other important factors and data that could be analysed to provide further knowledge on 
these potential kinase inhibitors. Further use of molecular modelling could be used to 
rationalize the results obtained and determine where the most feasible and profitable synthetic 
modifications could be made in the possible synthesis of a 2
nd
 generation library based on the 
most efficacious potential inhibitors. The methods and results of these biological assays will 
be discussed in full in the following chapter.   
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CHAPTER 5 – BIOLOGICAL EVALUATION OF SYNTHESIZED 
POTENTIAL KINASE INHIBITORS AND CONCLUSIONS 
5.1 BIOLOGICAL SCREENING METHODOLOGY 
5.1.1 Professor Daniel Rauh’s Research Focus – Fluorescent Labelling in Kinases. 
Professor Daniel Rauh is the head of chemical biology at the Technische Universiteit 
Dortmund and has filled this post since the end of 2010. With nearly 70 publications in 
journals such as Nature Chemistry, Nature Chemical Biology, Nature Genetics, Journal of the 
American Chemistry Society and the American Chemistry Society Chemical Biology, he has 
distinguished himself in his field. His research focus is mainly on the development of 
biological assays for protein kinases and phosphatases, which is why we have been privileged 
to collaborate with him and his group. Prof. Rauh‟s group were the first to develop detection 
methods in biological assays called fluorescent labels in kinases (FLiK) or the FLiK 
approach,
224
 and for their phosphatase counterparts florescent labels in phosphatases 
(FLiP).
225
 
The active reversible phosphorylation of a protein kinase may change the enzyme 
conformation and thus its state of activity towards further phosphorylation or biological 
processes.
226
 Important residues in this reversible process are the conserved triplet of the 
activation loop in the kinase domain, consisting of aspartate (D), phenylalanine (F), and 
glycine (G) residues – making up the DFG motif. This can be seen on the right of Figure 33. 
The aspartate residue (D) in particular, plays a catalytic role in phosphate transfer.
118
 Two 
important conformations protein kinases may adopt is the DFG-out, or inactive state, and the 
DFG-in or active state. The reversible transition between these two conformations is 
controlled by the rotational movement of the aspartate residue (D), accompanied by 
corresponding rotation of both the adjacent phenylalanine (F) and glycine (G) residues. In the 
DFG-out conformation the aspartate residue (D) is rotated out of the ATP binding pocket, 
exposing a large hydrophobic pocket for ligands or inhibitors to utilize.
118
 For the DFG-in 
conformation the opposite is true, with the aspartate residue (D) moving back into the ATP 
active site. This reversible process is illustrated on the left side of Figure 33.  
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Figure 33 
Ilustration of reversible conformational transition of kinases and the DFG motif.
224 
Certain inhibitors make use of, and in doing so stabilize, a specific conformation of a protein 
kinase for ligand binding. Type II, or allosteric inhibitors and type III, non ATP competitive 
or irreversible inhibitors – shown in blue - make use of and stabilize the inactive or DFG-out 
conformational state,whilst classicATP competitive, reversible or Type I inhibitors – shown 
in yellow - make use of and stabilize the DFG-in or active state.
226
 It is this precise 
mechanism and conformational preference and stabilization of the protein kinase by ligands 
and inhibitors that the FLiK biological assay exploits.  
The FLiK assay makes use of the environmentally sensitive, thiol-reactive fluorophore 
acrylodan, which is attached to a specific site of the target kinase – shown as a green and red 
sphere in the DFG-out and DFG-in conformation respectively in Figure 33 above. During 
ligand or inhibitor binding, the protein kinase undergoes a conformational change. This 
conformational change and stabilization brought on by the inhibitor binding, produces an 
alteration in the microenvironment, which may change the solvent shell of the fluorophore 
acrylodan, seen as a change between the red and green sphere illustrated in Figure 33. This 
alteration is witnessed as a significant change in itsemission spectra, which is characterised 
by two emission maxima (λem,max) at ∼470 and ∼510 nm. Conformational transitions bring 
about changes in the total intensity of these two emission maxima relative to each other, 
resulting in an attractive ratiometric fluorescence readout, which has been shown to be 
superior to its monochromic counterpart.
224,226
The FLiK assay is thus a conformation-specific 
binding assay and has been shown to be viable for a number of kinases including p38α 
kinase,
227
 abl
228
 and cSrc,
229
 to name a few. This methodology has been used in high 
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throughput screening and in cooperation with the pharmaceutical industry,
226
 and is 
especially significant when deducing the relative binding modes and specificity of potent 
inhibitors. The ratiometric fluorescence readout explained above is also made use of in 
activity-based assays for kinases. 
5.1.2 Methodology Used in Screening of Reversible and Irreversible Inhibitors against 
EGFR. 
For the biological assays and IC50 values determined for our compounds, a student in Prof. 
Rauh‟s group, Julian Engel, made use of the HTRF KinEASE-TK assay from Cisbio. For our 
specific biological screening, this technique involved use of the wildtype form of the kinase 
and the two medicinally relevant mutant deviants, more specifically the inhibitor-sensitizing 
mutation EGFR Leu858Arg (L858R) and the double mutant drug resistant variant, EGFR 
Leu858Arg-Thr790Met (L858R_T790M). As a control reaction these kinases were each 
incubated in the presence or absence of our potential reversible and irreversible inhibitors, 
followed by the addition of a biotinylated poly Glu-Tyr substrate peptidewhich is 
phosphorylated by the EGFR kinase. Completion of the reaction allows for subsequent 
introduction of an antiphosphotyrosine antibody labelled with europium cryptate, and 
streptavidin which is labelled with a fluorophoreXL665. The fluorescence resonance energy 
transfer or FRET is then measured between europium cryptate and XL665 to quantify the 
phosphorylation of the substrate peptide. This allows for a control experiment and value for 
kinase activity and following this, ATP concentrations were set at their respective Km values 
(30 μM for the EGFR-WT, 60 μM for EGFR-L858R, and 30 μM for EGFR-L858R_T790M). 
Our synthesized inhibitors were then preincubated with the specific kinase and peptide for 2h, 
where after ATP was added to initiate the reaction and the fluorescence of these samples 
were documented at 620 nm (Eu-labelled antibody) and 665 nm (XL665 labelled 
streptavidin) 60 μs after excitation at 317 nm by a Tecan Safire plate reader. The quotient of 
these two readings, done in an eight fold dilution series and carried out in triplicate, were then 
plotted against inhibitor concentrations and fitted to a Hill 4-parameter equation to determine 
relevant IC50 values.
230
 The principle of the FRET analysis, using the attachedeuropium 
cryptate andstreptavidin groups, as well as the data acquired and an example of IC50 value 
determination in these biological assays is shown in Figure 34.   
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Figure 34 
Principle of FRET analysis as well as IC50 value through use of this technique and plotting of 8-fold 
dilution series. 
Gefitinib and WZ4002 were used as control groups for the kinase inhibitory activity tests and 
in determination of the IC50 values. A total of 33 inhibitors were sent to our collaborators and 
the kinase inhibitory activity results against the EGFR wildtype, L858R and L858R_T790M 
mutation can be seen in Figure 35.  
5.2 RESULTS AND DISCUSSION 
The biological screening yielded a few important and interesting results.The first point is 
evident in the screen against the wildtype. Whilst the control inhibitors exhibit very potent 
inhibition of the wildtype EGFR kinase at low concentrations, it is encouraging to see that 
our synthesized inhibitors showed little to no activity against the phenotypic kinase, even 
athigh concentrations of 50μM. This can be interpreted as a very good result as high 
inhibitory activity against the wildtype kinase is usually linked to a high toxicity profile, as it 
targets the unmutated form of the kinase. 
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Figure 35 
Kinase inhibitory activity results against wildtype, L858R and L858R_T790M mutation EGFR kinases. 
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Looking at both mutated forms of the EGFR kinase and the biological screening data, it is 
encouraging to see that not only are the inhibitors active, but in the case of the L858R screen, 
a number compounds including AT5, HL58 (8c), AT1 and LH4 (4d) are seen to be similarly 
active to the FDA approved drug gefitinib, used specifically for treatment of breast and lung 
cancer as an EGFR inhibitor. This is also the case for the double mutant variant 
L858R_T790M, where compounds HL60 (8b), AT5 and AT1 show comparable activity to 
the control group. An important conclusion to draw from this data is that whilst our 
synthesized inhibitors are not effective in inhibiting the wildtype variant, they show promise 
and efficacy against the mutant strains. This indicates a positive selectivity profile for our 
inhibitors, in contrast to that found for gefitinib and WZ4002, which show activity across the 
board for all the EGFR screens. This shows promise for our synthesized inhibitors as a high 
selectivity and moderate to good inhibition trend and profile was witnessed.  
Table 8 
 IC50 values in μM of most efficacious and selective synthesised inhibitors.  
 
From these results corresponding IC50 values were derived for each of our inhibitors. A 
summary of the most efficacious and selective inhibitors is show in Table 8.Whilst the IC50 
values of these compounds are not inside of the nanomolar range and cannot compete with 
WZ4002, a number of interesting conclusions and future work can be derived from these 
results. Compound AT5,highlighted in red in Table 8, was shown to be the most efficacious 
inhibitor of those synthesized, in this case by Dr Taher. This was based on the isoquinoline 
scaffold with the 1,4-substituted regioisomer of the triazoleand the Michael acceptor in the 
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ortho positionand thus an irreversible inhibitor. AT5 showed good inhibitoryactivity and an 
excellent selectivity profile for the mutated kinases. Its IC50 value was comparable to gefitinib 
and lower in the case of the double mutant variant. The very impressive selectivity could be 
investigated further with molecular modeling, as well as the determination of whether 
synthetic tweaking to the molecule could result in a lower IC50 value whilst still retaining the 
selectivity. Compound LH4, highlighted in green in Table 8, was a reversible inhibitor 
synthesized in this project and showed slightly higher IC50 values, yet retained the selectivity 
seen for compound AT5. With further investigation into this compound through molecular 
modeling, a suitable position for an electrophilic warhead to be placed on the molecule could 
be found, perhaps increasing its efficacy. Lastly, compounds HL58 (7c) and HL60 (7b) 
showed remarkable selectivity for the L858R and L858R_T790M mutations alone 
respectively. This is highlighted in blue in Table 8. The use of molecular modelling to further 
determine the differences in selectivity and their binding modes is definitely a venture worth 
pursuing.  
5.3 CONCLUSIONS 
The aim of this project was to synthesize a library of reversible and potential irreversible 
kinase inhibitors. This project has seen the synthesis of 20 of the 32 potential inhibitors 
includingeight reversible inhibitors, compounds 4a-d and 5a-d, as well as twelve irreversible 
inhibitors, compounds 8a-l. The synthesis of these compounds made use of palladium, copper 
and ruthenium metal-mediated chemistry including Sonogashira coupling reactions, CuAAC 
and RuAAC.All novel compounds were fully characterized using a range of analytical 
techniques. 
Biological screening assays against the wildtype, and two mutant forms of the EGFR kinase – 
L858R and L858R_T790m – were undertaken by our collaborators at the Techniese 
Universiteit Dortmund in Germany. The potential kinase inhibitors synthesized showed good 
inhibitory activity and a favourable selectivity profile for both the mutated strains of the 
EGFR kinase. Compound AT5 showed the greatest inhibitory activity and was the most 
efficacious inhibitor with an IC50 value of 4.53 and 1.85 μM L858R and L858R_T790M 
mutants respectively. This inhibitor shows greater activity against the double mutant variant 
L858R_T790M than the FDA approved drug, gefitinib. Compound AT5is exceedingly 
selective towards the mutant forms of the EGFR kinase as it is essentially non-active against 
the EGFR wild type. Compound LH4(4d), shows similar efficacy, being slightly less potent, 
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and a similar selectivity profile. Compounds HL58 (7c) and HL60 (7b) showed selectivity 
for the L858R and L858R_T790M mutation respectively.  
With the encouraging results obtained from the biological screening assays, molecular 
modelling and docking studies could be undertaken to determine the synthetic alterations that 
are required to generate a 2
nd
 generation library of compounds. Based on compound AT5, 
LH4(4d),HL58 (7c) and HL60 (7b),this library would build on the inherent selectivity of 
these molecules for the mutant EGFR kinase variations and explore the origin of this 
selectivity. This could possibly lead to more potent inhibitors with an even higher selectivity 
profile. 
The synthetic methodology developed in this project could also be utilized in the synthesis of 
possible biological space and cysteine probes. With the synthesis of these probes, large 
libraries could potentially be synthesized quickly and efficiently, allowing for a large scale, 
broad range kinase screening. 
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 CHAPTER 6 – FUTURE WORK 
6.1 FUTURE WORK 
6.1.1 2
nd
 Generation Library Based on Compound AT5. 
Molecular modelling calculations and docking studies were undertaken to postulate the 
specific binding mode of AT5,andinspection of the conformation adopted by the compound 
provided insight into possible synthetic modifications. Scrutiny of the inhibitor in the active 
site and its adopted spatial arrangement revealed two possible sites for further investigation 
shown in Figure 36 below. The first of these promising sites is the introduction of another, 
secondary hydrogen bond interaction with the hinge region at Glu791.  
 
Figure 36 
Illustration of possible sites for further synthetic investigation and modification. 
GLN791 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 6 – Future Work 
_______________________________ 
111 
 
As can be seen in Figure 36, there is a considerable amount of space between the carbon 
alpha to the nitrogen of the isoquinoline ring and the carbonyl bond of GLN791. This space, 
whilst large enough to warrant the introduction of a functional group, is also small enough to 
maintain a hydrogen bond effect. Thus we hypothesize the introduction of a hydrogen bond 
donor group, such as a hydroxyl or amine moiety at this position of the isoquinoline driving 
group, could result in higher efficacy and selectivity for member of a 2
nd
 generation library. 
Secondly, on the right side of the scaffold there exists a large open hydrophobic pocket, 
shown by a yellow caged sphere in Figure 36. It is our belief that functionalizing the 
isoquinoline core at relevant positions to extened into this hydrophobic pocket would increase 
the inhibitor selectivity profile and possibly the potency.  
To test this hypothesis docking calculations were undertaken with a large group of potential 
second generation inhibitors. These included the addition of the amine and hydroxyl hinge 
binding motif ortho to the isoquinoline nitrogen at R1, as well as various functional groups on 
position R2 and R3 of the isoquinoline ring in different combinations. This included a methyl, 
ethyl, methoxy and cyano functional group for possible space filling. The results were 
promising and showed the highest score and visual impression with the groups illustrated in 
Figure 37 below. The synthesis of a 2
nd
 generation library could thus yield compounds with 
increased efficacy and selectivity profiles for these irreversible inhibitors.  
 
Figure 37 
Possible structures for 2
nd
 generation library of AT5. 
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6.1.2 Biological Space Filling and Cysteine Targeting Probes. 
As was shown in the proposed synthesis of our irreversible compounds in Section 4.1.2, the 
benefits of using a benzyl azide with an o-, m- and p- substituted functional group, which 
would later become an electrophilic warhead capable of forming covalent bond interactions 
with the cysteine residue in the active site, is a largely untapped potential biological probe. If 
the synthetic methodology and route developed and employed in our synthesis of irreversible 
inhibitors were to be shortened and simplified to have the o-, m- and p- substituted 
electrophilic warhead already in place on the benzyl azide moiety, as shown in Scheme 12 
below, this would open the door to a vast number of possibilities that these moieties could be 
used as biological probes of the kinase active site. Through the use of both CuAAC and 
RuAAC click chemistry as we have shown in our synthesis, a potentially wide ranging library 
could probe a significant amount of space in the active site; in addition, this library could be 
synthesized simply and effectively. 
 
Scheme 12 
Proposed synthetic plan for use of biological space probes to generate a large library of compounds. 
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This could be done by propargylation, or the addition of an alkyne group to heterocycles or 
driving groups that are known to form hydrogen bond interactions effectively with the hinge 
region of kinases, followed by subsequent coupling through both the 1,4-substituted CuAAC 
and the 1,5-substituted RuAAC with the o-, m- and p- substituted electrophilic warhead 
moieties as shown in Scheme 12.  This would generate a large number of different spatial and 
space probing conformations from one heterocycle or driving group and thus a large library 
of potential irreversible inhibitors targeting the cysteine residue across a broad panel of 
kinases. From this library biological assays will hopefully lead to a few compounds that show 
high efficacy and selectivity for a certain kinase, and further synthetic modifications could 
result in an extremely potent and selective inhibitor. 
Furthermore, if a certain compound generated through the use of this synthetic methodology 
shows promise by displaying high efficacy and potent selectivity, a simple and effective way 
to give an indication of whether or not this is through covalent bond formation with the 
cysteine residue would be to synthesize an analogue of the compound with the saturated 
propionamide probe derivative as shown in Scheme 13. This will afford critical information 
on whether or not the compounds inhibit irreversibly or not, as a large drop in the efficacy of 
the compound would be expected without the neccasary Michael acceptor moiety. With the 
use of these both of these biological probes a large amount of information regarding the 
targeting of the cysteine residue, chemical space probed in the active site of the kinase as well 
as the type of inhibition that is undertaken by these synthesized compound will be afforded.  
 
Scheme 13 
Proposed synthetic method for insight into compounds mechanism of inhibition.
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CHAPTER 7 – EXPERIMENTAL 
7.1 GENERAL PROCEDURES 
7.1.1 Purification of solvents and reagents. 
Chemicals used in these experiments were purchased from Merck or Sigma Aldrich. Solvents 
used for chromatographic purposes were distilled by means of conventional distillation 
procedures. Solvents used for reaction purposes were dried over the appropriate drying agents 
and then distilled under N2gas. Tetrahydrofuran was distilled from sodium metal, using 
benzophenone as indicator. Dichloromethane, dichloroethane, dimethylformamide and 
acetonitrile were distilled from calcium hydride. Ethanol was distilled from magnesium 
turnings and iodine. Diethyl ether was bought with a ≥98% purity grade from Sigma Aldrich 
and then dried on activated 3Å molecular sieves.Other reagents requiring purification were 
purified according to standard procedures. 
7.1.2 Chromatography 
Thin layer chromatography was performed using Merck silica gel 60 F254 coated on 
aluminium sheets. Visualization was performed with a UV lamp, using iodine on silica, or by 
spraying with a Cerium Ammonium Molybdate (CAM) or ninhydrin (NIN) or potassium 
permanganate (KMnO4) solution followed by heating. 
All column chromatography was performed on Merck silica gel 60 (particle size 0.040-0.063 
mm) using one of or combinations of petroleum ether,EtOAc, toluene, dichloromethane, 
ethanol and/orMeOH as a solvent. 
7.1.3 Spectroscopic and physical data 
NMR spectra (
1
H, 
13
C) were recorded on a 300 MHz Varian VNMRS  
(75 MHz for 
13
C), a 400 MHz Varian Unity Inova (101 MHz for 
13
C), or a 600 MHz Varian 
Unity Inova (150 MHz for 
13C). Chemical shifts (δ) are reported in ppm and J-values are 
given in Hz. Chemical shifts were recorded using the residual solvent peak or external 
reference.  All spectra were obtained at 25 °C unless otherwise reported.  Data was processed 
using MestReNova.   
Mass spectrometry was performed on a Waters SYNAPT G2. Infrared spectra were recorded 
on a Thermo Nicolet Nexus 470 by means of Attenuated Total Reflectance (ATR) mode. 
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Melting points were obtained using a Gallenkamp Melting Point Apparatus and are 
uncorrected. 
7.1.4 Other general procedures 
All reactions were performed under a positive pressure of 5.0 gradeN2 or Ar unless water was 
used as a solvent. The glassware was flame-dried while under vacuum before being purged 
with N2 gas. Condensers were pre-dried at 120 °C for a minimum of two hours. Standard 
Schlenk techniques were employed when necessary. 
Solvents were removed in vacuo, where we arereferring to removal of the solvent using a 
rotary evaporator followed by removal of trace amounts of solvent using a high vacuum 
pump at ca. 0.08 mm Hg. 
7.2 SYNTHESIS PERTAINING TO CHAPTER 3. 
7.2.1 Compounds 2a-b. 
General Procedure for Sonogashira Coupling of Quinoline Alkynes 
A dry Schlenk tube was evacuated under high vacuum and filled with Ar (3×). To this 
Schlenk tube was added by syringe, under Ar, in anhydrous THF (15 mL). The solvent was 
then degassed by 3 - 5 cycles of freeze-pump-thaw technique. The solvent was subsequently 
degassed for 15 min with Ar purge. This was followed by the addition of the catalysts, 
PdCl2(PPh3)2(4 mol. %) and CuI (4 mol. %), under positive pressure Ar. Et3N (2 equiv) was 
then added by syringe and the mixture was allowed to stir for 5 min.  Following this, 
trimethylsilylacetylene (TMSA) (1.5 equiv) was added by syringe. A colour change from 
yellow to black was witnessed, indicating the consumption of the catalyst and that the 
reaction was working. The reaction mixture was allowed to stir at rt, under N2, for up to 6 h 
or until complete consumption of the starting materials (monitored by TLC). This resulted in 
the intermediate TMS-protected quinoline alkyne, requiring no characterisation or 
purification, which allowed for in situ deprotection. To the reaction mixture was added 
liquidTBAF - or CsF - (1.5 equiv.), which was then left to stir for 0.5 h until the deprotection 
was complete (monitored by TLC). The reaction mixture was then filtered through Celite, 
followed by removal of the Et3Nin vacuo. The reaction mixture was then diluted with EtOAc 
(30 mL) and washed with a saturated NH4Cl solution (60 mL). The layers were then 
separated and the organic layer was rinsed with a saturated solution of brine (50 mL), dried 
over MgSO4 and filtered. After removal of the solvents in vacuo, the residue was purified by 
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flash column chromatography over silica gel eluted first with EtOAc and hexane 
(EtOAc:Hexane, 5:95) and then (EtOAc:Hexane, 60:40). This afforded the pure product as a 
white solid. The details for the compounds synthesized are described below.  
3-ethynylquinoline - 2a 
Scale: 3-bromoquinoline (800 mg, 3.84 mmol) 
This compound was synthesized following the general procedure for 
Sonogashira coupling of quinoline alkynes. The compound was purified by silica gel column 
chromatography, eluted first with EtOAc and hexane (EtOAc:Hexane, 5:95) and then 
(EtOAc:Hexane, 60:40). This afforded the pure product as a white solid (500 mg, 3.26 mmol, 
85%).  
Rf = 0.3 (EtOAc:Hexane, 5:95) ; Mp 73-75 °C; IR (ATR, cm
-1
):3159(s, stretch, –C≡C–H), 
2092(w, stretch, –C≡C–), 1120 (s, stretch, C–N); 1H NMR (400 MHz, CDCl3) δ 8.94 (d, J = 
2.1 Hz, 1H, ArH), 8.28 (d, J = 1.9 Hz, 1H, ArH), 8.12 – 8.05 (m, 1H, ArH), 7.79 – 7.75 (m, 
1H, ArH), 7.73 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H, ArH), 7.56 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H, 
ArH), 3.28 (s, 1H, CCH); 
13
C NMR (101 MHz,CDCl3) δ 152.4 (ArC), 147.2 (ArC), 139.4 
(ArC), 130.5 (ArC), 129.6 (ArC), 127.7 (ArC), 127.5 (ArC), 127.1 (ArC), 116.4 (ArC), 
81.1(CCH), 80.6 (CCC); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C11H8N: 154.0657; 
found: 154.0657 
7-chloro-4-ethynylquinoline - 2b 
Scale: 7-chloro-4-iodoquinoline (1500 mg, 5.18 mmol) 
This compound was synthesized following the general procedure for 
Sonogashira coupling of quinoline alkynes. However,CsF (1.2 equiv) was 
used as the deprotecting agent for the synthesis of this compound. The compound was 
purified by silica gel column chromatography, eluted first with EtOAc and hexane 
(EtOAc:Hexane, 5:95) and then (EtOAc:Hexane, 60:40). This afforded the pure product as a 
white solid (603 mg, 3.21 mmol, 62%). 
Rf = 0.33 (EtOAc:Hexane, 5:95) ; Mp 109-111 °C; IR (ATR, cm
-1
):3170 (s, stretch, –C≡C–
H), 2097(w, stretch, –C≡C–), 1151 (s, stretch, C–N); 1H NMR (400 MHz, CDCl3) δ 8.87 (d, 
J = 4.4 Hz, 1H,ArH), 8.19 (t, J = 8.6 Hz, 1H,ArH), 8.11 (d, J = 2.0 Hz, 1H,ArH), 7.56 (dd, J 
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= 8.9, 2.1 Hz, 1H,ArH), 7.52 (d, J = 4.4 Hz, 1H,ArH), 3.68 (s, 1H,CCH); 
13
C NMR (101 
MHz,CDCl3) δ 150.8 (ArC), 148.4 (ArC), 136.1 (ArC), 128.8 (ArC), 128.8 (ArC), 128.5 
(ArC), 127.3 (ArC), 126.4 (ArC), 124.6 (ArC), 87.1 (CCH), 78.9 (CCC); HRMS-TOF MS 
ES+: m/z [M+H]
+
 calcd for C11H7ClN: 188.0267; found: 188.0265 
7.2.2 Compounds 2c-d. 
General procedure for Sonogashira coupling of isoquinoline alkynes 
A dry Schlenk tube was evacuated under high vacuum and filled with Ar (3×). To this 
Schlenk tube was added by syringe, under Ar, anhydrous Et3N (15 mL). The solvent was then 
degassed by 3 to 5 cycles of freeze-pump-thaw technique. The solvent was subsequently 
degassed for 15 min with Ar purge. This was followed by the addition of the catalysts, 
PdCl2(PPh3)2(4 mol. %) and CuI (4 mol. %), under positive pressure Ar. The reaction mixture 
was then allowed to stir for 5 min. Following this, TMSA (1.5 equiv) was added by syringe. 
The reaction mixture was placed in an oil bath heated to 65 °C and a colour change from 
yellow to black was witnessed, indicating the consumption of the catalyst and that the 
reaction was working. The reaction mixture was allowed to stir at 65 °C, under N2, for up to 8 
h or until complete consumption of the starting materials (monitored by TLC). This resulted 
in the intermediate TMS-protected quinoline alkyne, requiring no characterisation or 
purification, which allowed for in situ deprotection. To the reaction mixture was added liquid 
TBAF (1.5 equiv.), which was then left to stir for 0.5 h until the deprotection was complete 
(monitored by TLC). The reaction mixture was then filtered through celite, followed by 
removal of the Et3Nin vacuo. The reaction mixture was then diluted with EtOAc (30 mL) and 
washed with a saturated ammonium chloride solution (60 mL). The layers were then 
separated and the organic layer was rinsed with a saturated solution of brine (50 mL), dried 
over MgSO4 and filtered. After removal of the solvents in vacuo, the residue was purified by 
flash column chromatography over silica gel eluted first with EtOAc and hexane 
(EtOAc:Hexane, 5:95), then (EtOAc:Hexane, 60:40). This afforded the pure product as a 
brown solid.The details for the compounds synthesized are described below.  
4-ethynylisoquinoline - 2c 
Scale: 4-bromoisoquinoline (800 mg, 3.84 mmol) 
 This compound was synthesized following the general procedure for 
Sonogashira coupling of isoquinoline alkynes. The compound was purified by 
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silica gel column chromatography, eluted first with EtOAc and hexane (EtOAc:Hexane, 5:95) 
and then (EtOAc:Hexane, 60:40). This afforded the pure product as a brown solid (491 mg, 
3.22 mmol, 84%).  
Rf = 0.31 (EtOAc:Hexane, 5:95); Mp 70-72 °C; IR (ATR, cm
-1
):3157(s, stretch, –C≡C–H), 
2086 (w, stretch, –C≡C–), 1166 (s, stretch, C–N); 1H NMR (400 MHz, CDCl3) δ 9.21 (s, 
1H,ArH), 8.72 (d, J = 4.9 Hz, 1H,ArH), 8.25 (dd, J = 8.4, 0.7 Hz, 1H,ArH), 7.98 (t, J = 7.6 
Hz, 1H,ArH), 7.82 – 7.74 (m, 1H,ArH), 7.65 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H,ArH), 3.55 (s, 
1H,CCH); 
13
C NMR (101 MHz,CDCl3) δ 152.7 (ArC), 147.4 (ArC), 136.0 (ArC), 131.4 
(ArC), 128.1 (ArC), 128.1 (ArC), 127.8 (ArC), 125.0 (ArC), 114.9 (ArC), 84.6 (CCH), 79.0 
(CCC); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C11H8N: 154.0657; found: 154.0656 
5-ethynylisoquinoline - 2d 
Scale: 5-bromoisoquinoline (600 mg, 2.88 mmol) 
This compound was synthesized following the general procedure for 
Sonogashira coupling of isoquinoline alkynes. The compound was purified by 
silica gel column chromatography, eluted first with EtOAc and hexane (EtOAc:Hexane, 5:95) 
and then (EtOAc:Hexane, 60:40). This afforded the pure product as a brown solid (390 mg, 
2.54 mmol, 88%). 
Rf = 0.31 (EtOAc:Hexane, 5:95) ; Mp 79-81 °C; IR (ATR, cm
-1
):3185 (s, stretch, –C≡C–H), 
2098(w, stretch, –C≡C–), 1145 (s, stretch, C–N); 1H NMR (400 MHz, CDCl3) δ 9.26 (s, 
1H,ArH), 8.61 (s, 1H,ArH), 8.09 (s, 1H,ArH), 8.01 – 7.93 (m, 1H,ArH), 7.90 (d, J = 5.0 Hz, 
1H,ArH), 7.54 (s, 1H,ArH), 3.52 (s, 1H,CCH); 
13
C NMR (101 MHz,CDCl3) δ 152.7 (ArC), 
144.0 (ArC), 136.4 (ArC), 135.2 (ArC), 128.7 (ArC), 128.3 (ArC), 126.8 (ArC), 119.3 (ArC), 
118.8 (ArC), 83.4 (CCH), 80.2 (CCC); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for 
C11H8N: 154.0657; found: 154.0655 
7.2.2 Compounds 3a-b. 
     (azidomethyl)benzene - 3a 
To a stirred solution of benzyl bromide (1.39 mL, 11.7 mmol) in a 
water/acetone mixture (50 mL, 1:4) was added NaN3 (1.14g, 17.5 mmol, 1.5 
equiv.) The resulting suspension was then stirred at rt, under N2, for 24 h. The acetone was 
removed under reduced pressure and then diluted with DCM (30 mL) and deionised water 
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(30 mL) and the organic layer was separated. The aqueous layer was extracted with aliquots 
of DCM (3 × 20 mL) and the combined organic layers were then rinsed with a saturated 
solution of brine (50 mL), dried over MgSO4 and filtered. The solvent was removed under 
reduced pressure and the product 4a (1.55g, 10.7 mmol) was afforded in quantitative yield as 
a yellow oil. The product 3a was sufficiently pure to use without further work up or 
purification. FTIR analysis was used to confirm product formation which correlated well with 
the literature.
173
 
IR (ATR, cm
-1
): 2089 (s, assym. stretch, N3), 1252 (s, symm. stretch, N3) 
 2-(azidomethyl)pyridine - 3b 
A dry, 2-neck round-bottomed flask charged with 2-(bromomethyl)pyridine 
hydrobromide (1.20 g, 4.74 mmol), 18-crown-6 (cat.) and 
tetrabutylammonium iodide (cat.) was evacuated under high vacuum and filled with Ar(3×). 
DMF (2 mL) was added through a septum by syringe, under positive pressure (Ar) and to this 
stirred solution was added diisopropylethylamine (1 mL). Lastly, NaN3 (0.30g, 4.7 mmol, 1.2 
equiv.) was added and the solution was left to stir at rt, under N2, for 24 h. The solution was 
then diluted with EtOAc (20 mL), rinsed with basic brine (20 mL×3, pH > 10) followed by 
washing with an NH4Cl solution (30 mL, 1M). The organic layer was then dried over MgSO4 
and filtered. The solvent was removed under reduced pressure to afford the pure product 4b 
as a yellow-brown oil (496mg, 3.35 mmol, 78%). The product 3bwas sufficiently pure to use 
without further work up or purification. FTIR analysis confirmed product formation which 
correlated well with the literature.
174
 
IR (ATR, cm
-1
): 2093 (s, assym. stretch, N3), 1270 (s, symm. stretch, N3).  
7.2.2 Compounds 4a-d. 
General procedure for the copper-mediated azide alkyne cycloaddition reactions 
(CuAAC) 
A dry, 2-neck round bottom flask charged with alkyne (1 equiv) and azide (1.2 equiv) was 
evacuated under high vacuum and filled with Ar(3×). A solution of MeOH/water (30 mL, 
2:1) was added through a septum by syringe, under positive pressure (Ar). To this stirred 
solution was added copper acetate hydrate (10 mol. %) and the solution was left to stir at rt, 
under N2, for 36h or until complete consumption of the starting material (monitored by TLC). 
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The MeOH was removed under reduced pressure and the reaction mixture was diluted with 
EtOAc (30 mL) and washed with an NH4Cl solution (60 mL, 1 M). The layers were then 
separated and the aqueous layer was washed with successive portions of EtOAc (3×20 mL). 
The combined organic layers were then rinsed with a saturated solution of brine (60 mL), 
dried over MgSO4 and filtered. After removal of the solvents in vacuo, the residue was 
purified by flash column chromatography over silica gel, eluted first with EtOAc and hexane 
(EtOAc:Hexane, 60:40), followed by MeOH and EtOAc (MeOH:EtOAc, 5:95). This afforded 
the pure product as a white solid.The details for the compounds synthesized are described 
below. 
3-(1-benzyl-1H-1,2,3-triazol-4-yl)quinoline - 4a 
Scale: 3-ethynylisoquinoline (0.1 g, 0.65 mmol) 
This compound was synthesized following the general 
procedure for CuAAC. The compound was purified by silica 
gel column chromatography, eluted first with EtOAc and 
hexane (EtOAc:Hexane, 60:40), followed by MeOH and EtOAc (MeOH:EtOAc, 5:95). This 
afforded the pure product as a white solid (0.14g, 0.47 mmol, 73%). 
Rf = 0.31 (EtOAc:Hexane, 60:40); Mp 157-159 °C; IR (ATR, cm
-1
):3064 (s, stretch,  =C–
H), 2922 (m, stretch, CH2),1046 (s, stretch, C–N), 813 (s, oop, C–H);
1
H NMR (300 MHz, 
CDCl3) δ 9.26 (s, 1H,ArH), 8.61 (d, J = 2.0 Hz, 1H,ArH), 8.09 (d, J = 8.4 Hz, 1H,ArH), 7.86 
(s, 1H, CCHN), 7.84 (dd, J = 8.2, 1.1 Hz, 1H,ArH), 7.69 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H,ArH), 
7.54 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H,ArH), 7.47 – 7.29 (m, 5H,ArH), 5.61 (s, 2H, CH2); 13C 
NMR (75 MHz,CDCl3) δ 148.4 (ArC), 147.9 (ArC), 145.5 (NCCH), 134.5 (ArC), 132.0 
(ArC), 129.7 (ArC), 129.4 (ArC), 129.3 (CCHN), 129.1 (ArC), 128.3 (ArC), 128.2 (ArC), 
128.0 (ArC), 127.3 (ArC), 123.9 (ArC), 120.1 (ArC), 54.5 (CH2); HRMS-TOF MS ES+: 
m/z [M+H]
+
 calcd for C18H15N4: 287.1297; found: 287.1297 
4-(1-benzyl-1H-1,2,3-triazol-4-yl)-7-chloroquinoline - 4b 
Scale: 7-chloro-4-ethynylquinoline (0.10 g, 0.53 mmol) 
This compound was synthesized following the general 
procedure for CuAAC. The compound was purified by silica gel 
column chromatography, eluted first with EtOAc and hexane 
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(EtOAc:Hexane, 60:40), followed by MeOH and EtOAc (MeOH:EtOAc, 5:95). This afforded 
the pure product as a white solid (0.12 g, 0.29 mmol, 55%). 
Rf = 0.32 (EtOAc:Hexane, 60:40); Mp 123-127 °C;IR (ATR, cm
-1
):3071 (s, stretch,  =C–H), 
2920 (m, stretch, CH2),1054 (s, stretch, C–N), 824 (s, oop, C–H); 
1
H NMR (300 MHz, 
CDCl3) δ 8.91 (d, J = 4.5 Hz, 1H,ArH), 8.61 (d, J = 9.1 Hz, 1H,ArH), 8.14 (d, J = 2.2 Hz, 
1H,ArH), 7.86 (s, 1H, CCHN), 7.57 – 7.51 (m, 2H,ArH), 7.47 – 7.34 (m, 5H,ArH), 5.67 (s, 
2H, CH2);
13
C NMR (75 MHz,CDCl3) δ 151.1 (ArC), 149.6 (ArC), 145.3 (NCCH), 136.2 
(ArC), 135.7 (ArC), 134.3 (ArC), 129.5 (CCHN), 129.3 (ArC), 129.0 (ArC), 128.4 (ArC), 
128.3 (ArC), 127.6 (ArC), 124.1 (ArC), 123.3 (ArC), 120.5 (ArC), 54.7 (CH2);HRMS-TOF 
MS ES+: m/z [M+H]
+
 calcd for C18H14N4Cl: 321.0907; found: 321.0904 
4-(1-benzyl-1H-1,2,3-triazol-4-yl)isoquinoline - 4c 
 Scale: 4-ethynylisoquinoline (0.10 g, 0.65 mmol) 
This compound was synthesized following the general procedure for 
CuAAC. The compound was purified by silica gel column 
chromatography, eluted first with EtOAc and hexane 
(EtOAc:Hexane, 60:40), followed by MeOH and EtOAc 
(MeOH:EtOAc, 5:95). This afforded the pure product as a white solid (0.12 g, 0.33 mmol, 
51%). 
Rf = 0.31 (EtOAc:Hexane, 60:40); Mp 111-113 °C;IR (ATR, cm
-1
):3069 (s, stretch,  =C–H), 
2925 (m, stretch, CH2),1059 (s, stretch, C–N), 827 (s, oop, C–H); 
1
H NMR (400 MHz, 
DMSO-d6) δ 9.34 (s, 1H,ArH), 8.85 (s, 1H,ArH), 8.78 (s, 1H,ArH), 8.62 (d, J = 8.5 Hz, 
1H,ArH), 8.22 (d, J = 8.1 Hz, 1H,ArH), 7.87 (t, J = 7.7 Hz, 1H,ArH), 7.76 (t, J = 7.5 Hz, 
1H,ArH), 7.46 – 7.39 (m, 4H,ArH, CCHN), 7.39 – 7.32 (m, 1H,ArH), 5.75 (s, 2H, CH2);13C 
NMR (101 MHz, DMSO-d6) δ 152.6 (ArC), 143.3 (NCCH), 142.4 (ArC), 135.9 (ArC), 
132.3 (ArC), 131.3 (CCHN), 128.8 (ArC), 128.2 (ArC), 128.2 (ArC), 128.0 (ArC), 127.6 
(ArC), 124.5 (ArC), 121.4 (ArC), 53.1 (CH2);HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for 
C18H15N4: 287.1297; found: 287.1293 
5-(1-benzyl-1H-1,2,3-triazol-4-yl)isoquinoline - 4d 
 Scale: 5-ethynylisoquinoline (0.10 g, 0.65 mmol) 
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This compound was synthesized following the general procedure for CuAAC. The compound 
was purified by silica gel column chromatography, eluted first with EtOAc and hexane 
(EtOAc:Hexane, 60:40), followed by MeOH and EtOAc (MeOH:EtOAc, 5:95). This afforded 
the pure product as a white solid (0.13 g, 0.33 mmol, 51%). 
Rf = 0.30 (EtOAc:Hexane, 60:40); Mp 131-132 °C; IR (ATR, cm
-1
):3103 (s, stretch,  =C–
H), 2925 (m, stretch, CH2),1071 (s, stretch, C–N), 831 (s, oop, C–H); 
1
H NMR (400 MHz, 
DMSO-d6) δ 9.38 (s, 1H,ArH), 8.81 (s, 1H,ArH), 8.57 (d, J = 6.0 Hz, 1H,ArH), 8.46 (d, J = 
6.0 Hz, 1H,ArH), 8.16 (d, J = 8.0 Hz, 1H,ArH), 8.08 (d, J = 7.2 Hz, 1H,ArH), 7.76 (t, J = 7.7 
Hz, 1H,ArH), 7.41 (dd, J = 8.5, 5.3 Hz, 4H,ArH,CCHN), 7.36 (dd, J = 8.8, 3.0 Hz, 1H,ArH), 
5.73 (s, 2H, CH2); 
13
C NMR (101 MHz, DMSO-d6) δ 153.0 (ArC), 144.9 (NCCH), 143.7 
(ArC), 135.9 (ArC), 132.3 (ArC), 131.5 (ArC), 130.5 (CCHN), 128.8 (ArC), 128.7 (ArC), 
128.2 (ArC), 128.0 (ArC), 127.2 (ArC), 126.7 (ArC), 124.3 (ArC), 118.1 (ArC), 53.1 (CH2); 
HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C18H15N4: 287.1297; found: 287.1292 
7.2.3 Compounds 5a-d. 
3-[1-(pyridin-2-ylmethyl)-1H-1,2,3-triazol-4-yl]quinoline - 5a 
Scale: 3-ethynylisoquinoline (0.10 g, 0.65 mmol) 
This compound was synthesized following the general 
procedure forCuAAC. The compound was purified by silica 
gel column chromatography, eluted first with EtOAc and 
hexane (EtOAc:Hexane, 60:40), followed by MeOH and EtOAc (MeOH:EtOAc, 5:95). This 
afforded the pure product as a white solid (0.13 g, 0.36 mmol, 56%). 
Rf = 0.24 (EtOAc:Hexane, 60:40); Mp 137-139 °C; IR (ATR, cm
-1
):3131 (s, stretch,  =C–
H), 2918 (m, stretch, CH2),1045 (s, stretch, C–N), 844 (s, oop, C–H); 
1
H NMR (400 MHz, 
DMSO-d6) δ 9.41 (d, J = 2.1 Hz, 1H,ArH), 8.91 (s, 1H,ArH), 8.81 (d, J = 1.8 Hz, 1H,ArH), 
8.57 (d, J = 4.7 Hz, 1H,ArH), 8.04 (dd, J = 7.8, 4.5 Hz, 2H,ArH), 7.85 (td, J = 7.7, 1.8 Hz, 
1H,ArH), 7.78 – 7.72 (m, 1H,ArH), 7.63 (t, J = 7.5 Hz, 1H,ArH), 7.43 – 7.39 (m, 
1H,ArH,CCHN), 7.37 (dd, J = 7.5, 4.9 Hz, 1H,ArH), 5.83 (s, 2H, CH2); 
13
C NMR (101 
MHz, DMSO-d6) δ 154.8 (ArC), 149.5 (ArC), 148.2 (ArC), 147.1 (ArC), 143.9 (NCCH), 
137.4 (ArC), 130.9 (CCHN), 129.6 (ArC), 128.8 (ArC), 128.3 (ArC), 127.6 (ArC), 127.2 
(ArC), 124.0 (ArC), 123.4 (ArC), 123.2 (ArC), 122.4 (ArC), 54.7 (CH2); HRMS-TOF MS 
ES+: m/z [M+H]
+
 calcd for C17H14N5: 287.1249; found: 287.1250 
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7-chloro-4-[1-(pyridin-2-ylmethyl)-1H-1,2,3-triazol-4-yl]quinoline - 5b 
Scale: 7-chloro-4-ethynylquinoline (0.10 g, 0.53 mmol) 
This compound was synthesized following the general 
procedure for CuAAC. The compound was purified by silica gel 
column chromatography, eluted first with EtOAc and hexane 
(EtOAc:Hexane, 60:40), followed by MeOH and EtOAc 
(MeOH:EtOAc, 5:95). This afforded the pure product as a white solid (0.12 g, 0.36 mmol, 
68%). 
Rf = 0.23 (EtOAc:Hexane, 60:40); Mp 122-123 °C; IR (ATR, cm
-1
):3120 (s, stretch,  =C–
H), 2980 (m, stretch, CH2),1048 (s, stretch, C–N), 840 (s, oop, C–H);
1
H NMR (400 MHz, 
CDCl3) δ 8.93 (d, J = 4.5 Hz, 1H,ArH), 8.65 – 8.61 (m, 2H,ArH), 8.21 (s, 1H,CCHN), 8.14 
(d, J = 2.2 Hz, 1H,ArH), 7.75 (td, J = 7.7, 1.8 Hz, 1H,ArH), 7.61 (d, J = 4.5 Hz, 1H,ArH), 
7.54 (dd, J = 9.1, 2.2 Hz, 1H,ArH), 7.37 (d, J = 7.8 Hz, 1H,ArH), 7.31 (ddd, J = 7.6, 4.9, 1.0 
Hz, 1H,ArH), 5.78 (s, 2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 153.9 (ArC), 151.2 (ArC), 
150.2 (ArC), 149.6 (ArC), 145.2 (NCCH), 137.7 (ArC), 136.3 (ArC), 135.7 (ArC), 129.0 
(CCHN), 128.3 (ArC), 127.6 (ArC), 124.2 (ArC), 124.1 (ArC), 123.9 (ArC), 123.0 (ArC), 
120.5 (ArC), 56.0 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C17H13N5: 322.0854; 
found: 322.0851 
 4-[1-(pyridin-2-ylmethyl)-1H-1,2,3-triazol-4-yl]isoquinoline - 5c 
Scale: 4-ethynylisoquinoline (0.10 mg, 0.65 mmol) 
This compound was synthesized following the general procedure 
forCuAAC. The compound was purified by silica gel column 
chromatography, eluted first with EtOAc and hexane 
(EtOAc:Hexane, 60:40), followed by MeOH and EtOAc 
(MeOH:EtOAc, 5:95). This afforded the pure product as a white solid (0.13 mg, 0.45 mmol, 
69%).  
Rf = 0.23 (EtOAc:Hexane, 60:40); Mp 110-112 °C; IR (ATR, cm
-1
):3120 (s, stretch,  =C–
H), 2920 (m, stretch, CH2),1049 (s, stretch, C–N), 840 (s, oop, C–H); 
1
H NMR (400 MHz, 
CDCl3) δ 9.25 (s, 1H,ArH), 8.72 (s, 1H,ArH), 8.63 (d, J = 4.2 Hz, 1H,ArH), 8.56 (d, J = 8.5 
Hz, 1H,ArH), 8.09 (s, 1H,CCHN), 8.01 (d, J = 8.2 Hz, 1H,ArH), 7.78 – 7.70 (m, 2H,ArH), 
Stellenbosch University  http://scholar.sun.ac.za
Chapter 7 – Experimental 
_______________________________ 
124 
 
7.64 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H,ArH), 7.34 (d, J = 7.8 Hz, 1H,ArH), 7.32 – 7.27 (m, 
1H,ArH), 5.79 (s, 2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 154.3 (ArC), 153.1 (ArC), 150.1 
(ArC), 144.9 (NCCH), 143.0 (ArC), 137.6 (ArC), 133.6 (ArC), 131.2 (CCHN), 128.1 (ArC), 
127.6 (ArC), 125.1 (ArC), 123.7 (ArC), 123.3 (ArC), 122.8 (ArC), 56.0 (CH2); HRMS-TOF 
MS ES+: m/z [M+H]
+
 calcd for C17H13N5: 287.1249; found: 287.1242 
5-[1-(pyridin-2-ylmethyl)-1H-1,2,3-triazol-4-yl]isoquinoline - 5d 
Scale: 5-ethynylisoquinoline (0.10 g, 0.65 mmol) 
This compound was synthesized following the general procedure for 
CuAAC. The compound was purified by silica gel column 
chromatography, eluted first with EtOAc and hexane (EtOAc:Hexane, 
60:40), followed by MeOH and EtOAc (MeOH:EtOAc, 5:95). This 
afforded the pure product as a white solid (0.12g, 0.43 mmol, 66%). 
Rf = 0.22 (EtOAc:Hexane, 60:40); Mp 128-130 °C; IR (ATR, cm
-1
):3130 (s, stretch,  =C–
H), 2929 (m, stretch,CH2),1050 (s, stretch, C–N), 824 (s, oop, C–H); 
1
H NMR (300 MHz, 
CDCl3) δ 8.63 (d, J = 3.4 Hz, 1H,ArH), 8.34 (s, 1H,ArH), 8.08 (s, 1H,CCHN), 7.98 (t, J = 
7.6 Hz, 2H,ArH), 7.74 (td, J = 7.7, 1.7 Hz, 1H,ArH), 7.69 – 7.60 (m, 1H,ArH), 7.40 – 7.26 
(m, 2H,ArH), 5.78 (s, 2H, CH2); 
13
C NMR (75 MHz,CDCl3) δ 154.3 (ArC), 153.0 (ArC), 
150.1 (ArC), 146.3 (ArC), 143.9 (NCCH), 137.6 (ArC), 133.6 (ArC), 130.9 (CCHN), 128.6 
(ArC), 127.3 (ArC), 127.0 (ArC), 123.7 (ArC), 123.2 (ArC), 122.8 (ArC), 56.0 (CH2); 
HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C17H13N5: 287.1249; found: 287.1247 
7.3 SYNTHESIS PERTAINING TO CHAPTER 4. 
7.3.1 Compounds 6a-c. 
General Procedure for Synthesis of Nitrobenzyl Azides 
To a stirred solution of nitrobenzyl bromide (1 equiv) in a round bottom flask, in a 
water/acetone mixture (50 mL, 1:4) was added NaN3 (1.5 equiv.) The resulting suspension 
was then stirred at rt, under N2, for 24 h. The acetone was removed under reduced pressure 
and then diluted with DCM (30 mL) and deionised water (30 mL) and the organic layer was 
separated. The aqueous layer was extracted with aliquots of DCM (3×10 mL) and the 
combined organic layers were then rinsed with a saturated solution of brine (50 mL), dried 
over MgSO4 and filtered. The solvent was removed under reduced pressure to afford the 
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product which was sufficiently pure to use without further work up or purification. FTIR 
analysis was used to confirm product formation. 
1-(azidomethyl)-2-nitrobenzene - 6a 
 Scale: 2-nitrobenzyl bromide (1.00 g, 4.62 mmol) 
This compound was synthesized following the general procedure nitrobenzyl 
azides. This afforded the pure product in quantitative yield as a brown oil (0.82 g, 4.26 
mmol). 
Rf = 0.64 (EtOAc:Hexane, 60:40); IR (ATR, cm
-1
):3074 (s, stretch, ArC–H),2916 (m, 
stretch, CH2), 2091 (s, assym. stretch, N3), 1523 (s, assym. stretch, N-O), 1254 (s, symm. 
stretch, N3) 
1-(azidomethyl)-3-nitrobenzene - 6b 
Scale: 3-nitrobenzyl bromide (1.00 g, 4.62 mmol) 
This compound was synthesized following the general procedure nitrobenzyl 
azides. This afforded the pure product as a brown oil (0.81 g, 4.53 mmol, 
98%). 
 Rf = 0.54 (EtOAc:Hexane, 60:40); IR (ATR, cm
-1
):3072 (s, stretch, ArC–H), 2970 (m, 
stretch, CH2),2091 (s, assym. stretch, N3), 1523 (s, assym. stretch, N-O), 1252 (s, symm. 
stretch, N3) 
1-(azidomethyl)-4-nitrobenzene - 6c 
Scale: 4-nitrobenzyl bromide (1.00 g, 4.62 mmol) 
This compound was synthesized following the general procedure 
nitrobenzyl azides.  This afforded the pure product as a white solid (0.81 g, 4.52 mmol, 98%).  
Rf = 0.46 (EtOAc:Hexane, 10:90); IR (ATR, cm
-1
):3079 (s, stretch, ArC–H), 2920(m, 
stretch, CH2),2093 (s, assym. stretch, N3), 1515 (s, assym. stretch, N-O), 1251 (s, symm. 
stretch, N3) 
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7.3.1 Compounds 7a-l. 
General procedure for the ruthenium-mediated azide alkyne cycloaddition reactions 
(RuAAC) 
A dry Schlenk tube was evacuated under high vacuum and filled with Ar(3×). To this 
Schlenk tube was added by syringe, under Ar, anhydrous toluene (15 mL). The solvent was 
subsequently degassed for 1 h with Ar purge. After degassing, the catalyst Cp*RuCl(COD) (4 
mol. %) and alkyne4a-d (1 equiv) were added under positive pressure Ar and the mixture was 
allowed to stir for 5 min under Ar. Following this, the azide6a-c (1.2 equiv) was also added 
under positive pressure Ar. In all reactions the alkyne was added first, followed by the azide. 
The reaction mixture was then placed in an oil bath heated to 80 °C and was allowed to stir 
under N2 for 24 h or until complete consumption of starting materials (monitored by TLC). 
The reaction mixture was then absorbed directly onto silica gel and purified by flash column 
chromatography over silica gel eluting with EtOAc and hexane (EtOAc:Hexane, 70:30) to 
yield the pure product as a yellow/orange brown solid.The details for the compounds 
synthesized are described below. 
3-[1-(2-nitrobenzyl)-1H-1,2,3-triazol-5-yl]quinoline - 7a 
Scale: 3-ethynylquinoline (0.15 g, 0.98 mmol) 
This compound was synthesized following the general 
procedure for RuAAC. The compound was purified by silica 
gel column chromatography, eluted with EtOAc and hexane 
(EtOAc:Hexane, 70:30). This afforded the pure product as a yellow brown solid (0.28 g, 0.83 
mmol, 85%. 
Rf = 0.45 (EtOAc:Hexane, 70:30); Mp 99-101 °C; IR (ATR, cm
-1
):3110 (s, stretch, ArC–H), 
2963(m, stretch, CH2),1520 (s, assym. stretch, N-O), 1122 (s, stretch, C–N), 855 (s, oop, C–
H); 
1
H NMR (400 MHz, CDCl3) δ 8.77 (d, J = 2.3 Hz, 1H,ArH), 8.16 (dd, J = 8.2, 1.3 Hz, 
1H,ArH), 8.12 (dd, J = 8.4, 0.8 Hz, 1H,ArH), 8.07 (d, J = 2.2 Hz, 1H,ArH), 8.00 (s, 
1H,CCHN), 7.84 – 7.76 (m, 2H,ArH), 7.67 – 7.58 (m, 2H,ArH), 7.56 – 7.48 (m, 1H,ArH), 
6.87 (dd, J = 7.8, 1.0 Hz, 1H,ArH), 6.07 (s, 2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 148.9 
(ArC), 148.3 (ArC), 147.0 (ArC), 136.1 (NCCH), 135.9 (ArC), 134.7 (ArC), 134.3 (ArC), 
131.5 (CCHN), 131.3 (ArC), 129.6 (ArC), 129.6 (ArC), 128.9 (ArC), 128.2 (ArC), 128.1 
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(ArC), 127.2 (ArC), 125.8 (ArC), 119.8 (ArC), 49.6 (CH2); HRMS-TOF MS ES+: m/z 
[M+H]
+
 calcd for C18H14N5O2: 332.1147; found: 332.1156 
3-[1-(3-nitrobenzyl)-1H-1,2,3-triazol-5-yl]quinoline - 7b  
Scale: 3-ethynylquinoline (0.15 g, 0.98 mmol) 
This compound was synthesized following the general 
procedure for RuAAC. The compound was purified by silica 
gel column chromatography, eluted with EtOAc and hexane 
(EtOAc:Hexane, 70:30). This afforded the pure product as a 
yellow brown solid (0.30 g, 0.9 mmol, 92%) 
Rf = 0.45 (EtOAc:Hexane, 70:30); Mp 142-144 °C; IR (ATR, cm
-1
):3070 (s, stretch, ArC–
H), 2901(m, stretch, CH2),1521 (s, assym. stretch, N-O), 1125 (s, stretch, C–N), 837 (s, oop, 
C–H); 1H NMR (400 MHz, CDCl3) δ 8.78 (d, J = 2.2 Hz, 1H,ArH), 8.15 (d, J = 9.1 Hz, 
2H,ArH), 8.05 (d, J = 2.1 Hz, 1H,ArH), 7.99 – 7.94 (m, 1H,ArH), 7.93 (s, 1H,CCHN), 7.82 
(m, 2H,ArH), 7.69 – 7.61 (m, 1H,ArH), 7.55 – 7.42 (m, 2H,ArH), 5.72 (s, 2H, CH2); 13C 
NMR (101 MHz,CDCl3) δ 149.1 (ArC), 148.6 (ArC), 148.3 (ArC), 137.1 (NCCH), 136.4 
(ArC), 135.4 (ArC), 134.5 (ArC), 133.3 (ArC), 131.4 (CCHN), 130.4 (ArC), 129.7 (ArC), 
128.3 (ArC), 128.1 (ArC), 127.1 (ArC), 123.7 (ArC), 122.39 (ArC), 119.92 (ArC), 51.4 
(CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C18H14N5O2: 332.1147; found: 
332.1152 
3-[1-(4-nitrobenzyl)-1H-1,2,3-triazol-5-yl]quinoline - 7c 
Scale: 3-ethynylquinoline (0.15 g, 0.98 mmol) 
This compound was synthesized following the general 
procedure for RuAAC. The compound was purified by 
silica gel column chromatography, eluted with EtOAc 
and hexane (EtOAc:Hexane, 70:30). This afforded the pure product as a brown solid (0.27g, 
0.82 mmol, 83%) 
Rf = 0.43 (EtOAc:Hexane, 70:30); Mp 144-146 °C; IR (ATR, cm
-1
):3060 (s, stretch, ArC–
H), 2912(m, stretch, CH2),1508 (s, assym. stretch, N-O), 1141 (s, stretch, C–N), 836 (s, oop, 
C–H); 1H NMR (400 MHz, CDCl3) δ 8.77 (d, J = 2.3 Hz, 1H,ArH), 8.16 (dt, J = 9.1, 2.4 Hz, 
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3H,ArH), 8.00 (t, J = 4.1 Hz, 1H,ArH), 7.94 (s, 1H,CCHN), 7.83 (ddd, J = 8.4, 6.9, 1.5 Hz, 
1H,ArH), 7.78 (dd, J = 8.0, 0.6 Hz, 1H,ArH), 7.64 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H,ArH), 7.29 – 
7.28 (m, 1H,ArH), 7.27 – 7.25 (m, 1H,ArH), 5.72 (s, 2H, CH2); 13C NMR (101 MHz,CDCl3) 
δ 149.0 (ArC), 148.3 (ArC), 148.1 (ArC), 142.1 (ArC), 136.3 (NCCH), 135.5 (ArC), 134.5 
(ArC), 131.4 (CCHN), 129.7 (ArC), 128.3 (ArC), 128.1 (ArC), 128.1 (ArC), 127.1 (ArC), 
124.4 (ArC), 119.9 (ArC); 51.5 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for 
C18H14N5O2: 332.1147; found: 332.1150 
7-chloro-4-[1-(2-nitrobenzyl)-1H-1,2,3-triazol-5-yl]quinoline - 7d 
Scale: 7-chloro-4-ethynylquinoline (0.15 g, 0.8 mmol) 
This compound was synthesized following the general 
procedure for RuAAC. The compound was purified by silica 
gel column chromatography, eluted with EtOAc and hexane 
(EtOAc:Hexane, 70:30). This afforded the pure product as an 
orange brown solid (0.23 g, 0.64 mmol, 81%) 
Rf = 0.46 (EtOAc:Hexane, 70:30); Mp 173-175 °C; IR (ATR, cm
-1
):3148 (s, stretch, ArC–
H), 2901(m, stretch, CH2),1524 (s, assym. stretch, N-O), 1244 (s, stretch, C–N), 882 (s, oop, 
C–H);1H NMR (400 MHz, CDCl3) δ 8.93 (d, J = 4.1 Hz, 1H,ArH), 8.19 (s, 1H,ArH), 8.01 
(d, J = 8.0 Hz, 1H,ArH), 7.96 (s, 1H,CCHN), 7.51 (m, 5H,ArH), 7.19 (d, J = 4.1 Hz, 
1H,ArH), 6.94 (d, J = 7.6 Hz, 1H,ArH), 5.90 (d, J = 50.3 Hz, 2H, CH2); 
13
C NMR (101 
MHz,CDCl3) δ 150.9 (ArC), 149.1 (ArC), 147.2 (ArC), 136.7 (NCCH), 135.3 (ArC), 134.3 
(ArC), 133.9 (ArC), 133.0 (ArC), 130.5 (CCHN), 129.7 (ArC), 129.7 (ArC), 129.5 (ArC), 
129.3 (ArC), 125.7 (ArC), 125.6 (ArC), 124.8 (ArC), 122.3 (ArC), 49.6 (CH2); HRMS-TOF 
MS ES+: m/z [M+H]
+
 calcd for C18H13ClN5O2:  366.0758; found: 366.0759 
7-chloro-4-[1-(3-nitrobenzyl)-1H-1,2,3-triazol-5-yl]quinoline - 7e 
Scale: 7-chloro-4-ethynylquinoline (0.15 g, 0.8 mmol) 
This compound was synthesized following the general 
procedure for RuAAC. The compound was purified by 
silica gel column chromatography, eluted with EtOAc 
and hexane (EtOAc:Hexane, 70:30). This afforded the 
pure product as an orange brown solid (0.24 g, 0.66 mmol, 83%) 
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Rf = 0.48 (EtOAc:Hexane, 70:30); Mp 176-178 °C; IR (ATR, cm
-1
):3076 (s, stretch, ArC–
H), 2961(m, stretch, CH2),1524 (s, assym. stretch, N-O), 1259 (s, stretch, C–N), 819 (s, oop, 
C–H); 1H NMR (400 MHz, CDCl3) δ 8.99 (d, J = 4.0 Hz, 1H,ArH), 8.22 (s, 1H,ArH), 8.09 
(d, J = 7.9 Hz, 1H,ArH), 7.94 (s, 1H,CCHN), 7.71 (s, 1H,ArH), 7.47 (d, J = 8.6 Hz, 1H,ArH), 
7.39 (t, J = 7.9 Hz, 1H,ArH), 7.33 (d, J = 8.9 Hz, 1H,ArH), 7.28 (d, J = 7.6 Hz, 1H,ArH), 
7.21 (d, J = 4.0 Hz, 1H,ArH), 5.52 (s, 2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 150.8 
(ArC), 148.9 (ArC), 148.4 (ArC), 136.8 (NCCH), 136.2 (ArC), 135.3 (ArC), 133.6 (ArC), 
133.2 (ArC), 130.1 (CCHN), 129.4 (ArC), 129.3 (ArC), 125.7 (ArC), 124.8 (ArC), 123.7 
(ArC), 122.7 (ArC), 122.6 (ArC), 51.7 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for 
C18H13ClN5O2: 366.0758; found: 366.07.57 
7-chloro-4-[1-(4-nitrobenzyl)-1H-1,2,3-triazol-5-yl]quinoline - 7f 
Scale: 7-chloro-4-ethynylquinoline (0.15 g, 0.8 mmol) 
This compound was synthesized following the general 
procedure for RuAAC. The compound was purified by 
silica gel column chromatography, eluted with EtOAc and 
hexane (EtOAc:Hexane, 70:30). This afforded the pure 
product as a brown solid (0.24 g, 0.65 mmol, 82%) 
Rf = 0.46 (EtOAc:Hexane, 70:30); Mp 181-189 °C; IR (ATR, cm
-1
):3115 (s, stretch, ArC–
H), 2903(m, stretch, CH2),1516 (s, assym. stretch, N-O), 1285 (s, stretch, C–N), 856 (s, oop, 
C–H); 1H NMR (400 MHz, CDCl3) δ 8.94 (d, J = 4.1 Hz, 1H,ArH), 8.21 (s, 1H,ArH), 8.04 
(d, J = 8.4 Hz, 2H,ArH), 7.92 (s, 1H,CCHN), 7.47 (d, J = 8.5 Hz, 1H,ArH), 7.33 (d, J = 8.9 
Hz, 1H,ArH), 7.11 (t, J = 8.1 Hz, 1H,ArH), 7.05 (d, J = 8.3 Hz, 2H,ArH), 5.49 (s, 2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 150.8 (ArC), 149.0 (ArC), 148.0 (ArC), 141.2 (ArC), 136.8 
(NCCH), 135.31 (ArC), 133.3 (ArC), 133.2 (ArC), 129.5 (CCHN), 129.4 (ArC), 128.5 (ArC), 
125.7 (ArC), 124.8 (ArC), 124.2 (ArC), 122.5 (ArC), 51.7 (CH2); HRMS-TOF MS ES+: 
m/z [M+H]
+
 calcd for C18H13ClN5O2: 366.0758; found: 366.0759 
4-[1-(2-nitrobenzyl)-1H-1,2,3-triazol-5-yl]isoquinoline - 7g 
Scale: 4-ethynylisoquinoline (0.15 g, 0.98 mmol) 
This compound was synthesized following the general procedure 
for RuAAC. The compound was purified by silica gel column 
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chromatography, eluted with EtOAc and hexane (EtOAc:Hexane, 70:30). This afforded the 
pure product as a yellow brown solid (0.16 g, 0.5 mmol, 54%) 
Rf = 0.44 (EtOAc:Hexane, 70:30); Mp 129-131 °C; IR (ATR, cm
-1
):3055 (s, stretch, ArC–
H), 2961(m, stretch, CH2),1523 (s, assym. stretch, N-O), 1260 (s, stretch, C–N), 861 (s, oop, 
C–H); 1H NMR (400 MHz, CDCl3) δ 9.32 (s, 1H,ArH), 8.27 (s, 1H,ArH), 8.07 (dt, J = 7.1, 
3.0 Hz, 1H,ArH), 8.01 – 7.93 (m, 2H,ArH,CCHN), 7.78 – 7.65 (m, 2H,ArH), 7.55 (td, J = 
7.7, 1.2 Hz, 1H,ArH), 7.50 (dd, J = 8.1, 6.2 Hz, 1H,ArH), 7.46 – 7.37 (m, 1H,ArH), 6.89 (d, J 
= 7.3 Hz, 1H,ArH), 5.83 (s, 2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 154.9 (ArC), 147.1 
(ArC), 143.0 (ArC), 135.7 (NCCH), 134.3 (ArC), 133.8 (ArC), 132.2 (ArC), 131.1 (CCHN), 
129.4 (ArC), 129.3 (ArC), 128.6 (ArC), 128.5 (ArC), 125.5 (ArC), 123.4 (ArC), 118.1 (ArC), 
49.3 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C18H14N5O2: 332.1147; found: 
332.1150 
4-[1-(3-nitrobenzyl)-1H-1,2,3-triazol-5-yl]isoquinoline - 7h 
Scale: 4-ethynylisoquinoline (0.15 g, 0.98 mmol) 
This compound was synthesized following the general 
procedure for RuAAC. The compound was purified by silica 
gel column chromatography, eluted with EtOAc and hexane 
(EtOAc:Hexane, 70:30). This afforded the pure product as an 
orange brown solid (0.17 g, 0.51 mmol, 55%) 
Rf = 0.44 (EtOAc:Hexane, 70:30); Mp 131-133 °C;IR (ATR, cm
-1
):3034 (s, stretch, ArC–
H), 2916(m, stretch, CH2),1525 (s, assym. stretch, N-O), 1161 (s, stretch, C–N), 907 (s, oop, 
C–H); 1H NMR (400 MHz, CDCl3) δ 9.35 (s, 1H,ArH), 8.32 (s, 1H,ArH), 8.09 – 8.04 (m, 
1H,ArH), 7.97 (ddd, J = 8.0, 2.1, 1.4 Hz, 1H,ArH), 7.90 (s, 1H,CCHN), 7.64 (m, 2H,ArH), 
7.52 (t, J = 1.7 Hz, 1H,ArH), 7.33 (t, J = 7.8 Hz, 1H,ArH), 7.27 (ddd, J = 12.6, 7.0, 4.7 Hz, 
2H,ArH), 5.50 (s, 2H, CH2);
13
C NMR (101 MHz,CDCl3) δ 154.9 (ArC), 148.2 (ArC), 144.1 
(ArC), 136.4 (NCCH), 135.8 (ArC), 134.4 (ArC), 133.8 (ArC), 133.0 (ArC), 132.0 (ArC), 
130.0 (CCHN), 128.5 (ArC), 128.5 (ArC), 123.5 (ArC), 123.3 (ArC), 122.9 (ArC), 118.4 
(ArC), 51.7 (CH2);HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C18H14N5O2: 332.1147; 
found: 332.1145 
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4-[1-(4-nitrobenzyl)-1H-1,2,3-triazol-5-yl]isoquinoline - 7i 
Scale: 4-ethynylisoquinoline (0.15 g, 0.98 mmol) 
This compound was synthesized following the general procedure for 
RuAAC. The compound was purified by silica gel column 
chromatography, eluted with EtOAc and hexane (EtOAc:Hexane, 
70:30). This afforded the pure product as an orange brown solid 
(0.18 g, 0.55 mmol, 60%) 
Rf = 0.43 (EtOAc:Hexane, 70:30); Mp 214-216 °C; IR (ATR, cm
-1
):3140 (s, stretch, ArC–
H), 2935(m, stretch, CH2),1517 (s, assym. stretch, N-O), 1163 (s, stretch, C–N), 928 (s, oop, 
C–H); 1H NMR (400 MHz, CDCl3) δ 9.38 (s, 1H,ArH), 8.32 (s, 1H,ArH), 8.05 (t, J = 12.7 
Hz, 1H,ArH), 7.96 (d, J = 8.7 Hz, 2H,ArH), 7.91 (s, 1H,CCHN), 7.66 (m, 2H,ArH), 7.29 (d, 
J = 8.1 Hz, 1H,ArH), 7.02 (d, J = 8.7 Hz, 2H,ArH), 5.50 (s, 2H, CH2); 
13
C NMR (101 
MHz,CDCl3) δ 154.8 (ArC), 147.8 (ArC), 144.1 (ArC), 141.5 (ArC), 135.8 (NCCH), 134.36 
(ArC), 133.1 (ArC), 132.0 (CCHN), 128.6 (ArC), 128.5 (ArC), 128.5 (ArC), 124.0 (ArC), 
123.4 (ArC), 51.6 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C18H14N5O2: 
332.1147; found: 332.1147 
5-[1-(2-nitrobenzyl)-1H-1,2,3-triazol-5-yl]isoquinoline - 7j 
Scale: 5-ethynylisoquinoline (0.1 g, 0.65 mmol) 
This compound was synthesized following the general procedure for 
RuAAC. The compound was purified by silica gel column 
chromatography, eluted with EtOAc and hexane (EtOAc:Hexane, 
70:30). This afforded the pure product as an orange brown solid (0.11 
g, 0.34 mmol, 53%)  
Rf = 0.29 (EtOAc:Hexane, 80:20); Mp 194-196 °C; IR (ATR, cm
-1
):3128 (s, stretch, ArC–
H), 2922(m, stretch, CH2),1524 (s, assym. stretch, N-O), 1105 (s, stretch, C–N), 869 (s, oop, 
C–H); 1H NMR (400 MHz, CDCl3) δ 9.35 (s, 1H,ArH), 8.52 (s, 1H,ArH), 8.13 (d, J = 8.2 
Hz, 1H,ArH), 7.95 (d, J = 6.1 Hz, 2H,ArH,CCHN), 7.65 (t, J = 7.7 Hz, 1H,ArH), 7.61 – 7.50 
(m, 2H,ArH), 7.43 (t, J = 7.8 Hz, 1H,ArH), 7.28 (s, 1H,ArH), 7.00 (d, J = 7.7 Hz, 1H,ArH), 
5.83 (s, 2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 153.2 (ArC), 147.3 (ArC), 144.5 (ArC), 
135.3 (NCCH), 135.2 (ArC), 134.6 (ArC), 134.2 (ArC), 132.6 (ArC), 130.9 (ArC), 130.4 
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(CCHN), 129.7 (ArC), 129.4 (ArC), 126.8 (ArC), 125.3 (ArC), 123.2 (ArC), 117.1(ArC), 
77.36 (ArC), 49.0 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C18H14N5O2: 
332.1147; found: 332.1151 
5-[1-(3-nitrobenzyl)-1H-1,2,3-triazol-5-yl]isoquinoline - 7k 
Scale: 5-ethynylisoquinoline (0.15 g, 0.98 mmol) 
This compound was synthesized following the general procedure 
for RuAAC. The compound was purified by silica gel column 
chromatography, eluted with EtOAc and hexane (EtOAc:Hexane, 
70:30). This afforded the pure product as an orange brown solid 
(0.18 g, 0.53 mmol, 54%) 
Rf = 0.3 (EtOAc:Hexane, 80:20); Mp 130-132 °C; IR (ATR, cm-1):3074 (s, stretch, ArC–
H), 2904(m, stretch, CH2),1522 (s, assym. stretch, N-O), 1105 (s, stretch, C–N), 832 (s, oop, 
C–H); 1H NMR (400 MHz, CDCl3) δ 9.37 (s, 1H), 8.45 (d, J = 5.4 Hz, 1H,ArH), 8.19 (t, J = 
9.9 Hz, 1H,ArH), 8.00 (d, J = 7.9 Hz, 1H,ArH), 7.85 (s, 1H,CCHN), 7.74 – 7.64 (m, 
1H,ArH), 7.53 (d, J = 7.2 Hz, 2H,ArH), 7.40 – 7.30 (m, 1H,ArH), 7.27 (d, J = 5.9 Hz, 
1H,ArH), 7.14 (d, J = 5.8 Hz, 1H,ArH), 5.47 (s, 2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 
152.8 (ArC), 148.2 (ArC), 143.8 (ArC), 136.5 (NCCH), 135.3 (ArC), 134.8 (ArC), 134.4 
(ArC), 133.8 (ArC), 133.3 (ArC), 130.7 (CCHN), 130.0 (ArC), 127.0 (ArC), 123.5 (ArC), 
123.4 (ArC), 122.8 (ArC), 117.3 (ArC), 51.6 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 
calcd for C18H14N5O2: 332.1147; found: 332.1145 
5-[1-(4-nitrobenzyl)-1H-1,2,3-triazol-5-yl]isoquinoline - 7l 
Scale: 5-ethynylisoquinoline (0.15 g, 0.98 mmol) 
This compound was synthesized following the general procedure for 
RuAAC. The compound was purified by silica gel column 
chromatography, eluted with EtOAc and hexane (EtOAc:Hexane, 
70:30). This afforded the pure product as an orange brown solid 
(0.20 g, 0.58 mmol, 60%) 
Rf = 0.3 (EtOAc:Hexane, 80:20); Mp 169-171 °C;IR (ATR, cm
-1
):3123 (s, stretch, ArC–H), 
2961(m, stretch, CH2),1515 (s, assym. stretch, N-O), 1258 (s, stretch, C–N), 793 (s, oop, C–
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H);
1
H NMR (400 MHz, CDCl3) δ 9.37 (s, 1H,ArH), 8.49 (d, J = 5.3 Hz, 1H,ArH), 8.16 (d, J 
= 8.2 Hz, 1H,ArH), 7.98 (t, J = 9.3 Hz, 2H,ArH), 7.87 (s, 1H,CCHN), 7.65 (t, J = 7.7 Hz, 
1H,ArH), 7.44 (t, J = 9.5 Hz, 1H,ArH), 7.19 (d, J = 5.8 Hz, 1H,ArH), 7.02 (d, J = 8.5 Hz, 
2H,ArH), 5.46 (s, 2H, CH2);
13
C NMR (101 MHz,CDCl3) δ 153.0 (ArC), 147.9 (ArC), 144.1 
(ArC), 141.6 (ArC), 135.3 (NCCH), 134.7 (ArC), 134.6 (ArC), 133.2 (ArC), 130.5 (CCHN), 
128.5 (ArC), 126.9 (ArC), 124.0 (ArC), 123.3 (ArC), 117.3 (ArC), 51.51 (CH2); HRMS-
TOF MS ES+: m/z [M+H]
+
 calcd for C18H14N5O2: 332.1147; found: 332.1146 
7.3.2 Compounds 8a-l. 
General Procedure for Reduction of Aromatic Nitro Groups and Acylation with 
Acryloyl Chloride 
To a 2 neck round bottom flask was added a solution of the aromatic nitro "clicked" 
compound7a-l (1 equiv) in anhydrous DCM (15 mL) under N2. A hydrogen ballon was 
attached to one neck and Pd/C (10 mol. % on C) (5 mol. %) was added to the reaction 
mixture. The N2 was evacuated through a tap on the other neck, creating a hydrogen 
atmosphere in the reaction vessel under atmospheric pressure. The resulting suspension was 
then stirred at rt for 6 hours or until complete reduction of the nitro moiety to the amine 
(monitored by TLC). The reaction mixture was then filtered through Celite and the solvent 
was removed under reduced pressure to afford the product as a white foam, which was 
sufficiently pure to use without further purification. To a dry round bottom flask was then 
directly added a solution of the crude reduced aromatic amine (1 equiv) in anhydrous DCM 
(15 mL) under N2. The reaction mixture was placed in an ice bath and  cooled to  0 °C, where 
after Et3N (12 equiv) was added slowly by syringe and allowed to stir for 5 min. Acryloyl 
chloride (1.2 equiv) was then added drop-wise and a colour change from colourless to yellow 
was seen immediately. The ice bath was then removed and the reaction mixture was allowed 
to stir at rt for up to 4 hours or until complete consumption of the starting material (monitored 
by TLC). After removal of the solvent in vacuo, the residue was purified by flash column 
chromatography over silica gel, eluting first with EtOAc and hexane (EtOAc:Hexane, 90:10), 
then EtOAc. This afforded the pure product as a white foam/solid. 
N-{2-{[5-(quinolin-3-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8a 
Scale: 3-(1-(2-nitrobenzyl)-1H-1,2,3-triazol-5-yl)quinoline (200 mg, 
0.604 mmol) 
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This compound was synthesized following the general procedure for reduction of aromatic 
nitro and acylation with acryloyl chloride. The compound was purified by silica gel column 
chromatography, eluted first with EtOAc and hexane (EtOAc:Hexane, 90:10) and then 
EtOAc. This afforded the pure product as a white foam (131 mg, 0.37 mmol, 61%) 
Rf = 0.44 (EtOAc:Hexane, 90:10); Mp 185-187 °C; IR (ATR, cm
-1
):3247 (m, stretch, N–H), 
3120 (s, stretch, ArC–H), 1652 (s, stretch,–C=C–), 1208 (s, stretch, C–N), 803 (s, oop, C–H); 
1
H NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H, NH), 8.94 (d, J = 2.2 Hz, 1H, ArH), 8.40 (d, 
J = 2.1 Hz, 1H, ArH), 8.24 (s, 1H,CCHN), 8.05 (d, J = 8.3 Hz, 1H, ArH), 7.96 (d, J = 8.4 Hz, 
1H, ArH), 7.88 – 7.78 (m, 1H, ArH), 7.68 (t, J = 7.1 Hz, 1H, ArH), 7.39 – 7.22 (m, 2H, ArH), 
7.11 (t, J = 7.5 Hz, 1H, ArH), 6.73 (d, J = 7.3 Hz, 1H, ArH), 6.28 (s, 1H, CCHC), 6.12 (dd, J 
= 17.1, 2.0 Hz, 1H, CCH2), 5.77 (s, 2H, CH2), 5.70 – 5.59 (m, 1H, CCH2); 
13
C NMR (101 
MHz, DMSO-d6) δ 163.5 (HNCO), 149.3 (ArC), 147.1 (ArC), 135.2 (NCCH), 135.0 (ArC), 
135.0 (ArC), 133.9 (ArC), 131.2 (CCCH2), 130.7 (CCHN), 130.5 (ArC), 128.7 (ArC), 128.5 
(ArC), 128.3 (ArC), 127.5 (ArC), 127.4 (ArC), 126.8 (CCH2), 126.8 (ArC), 126.0 (ArC), 
125.7 (ArC), 119.96 (ArC), 48.83 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for 
C21H18N5O: 356.1511; found: 356.1510 
N-{3-{[5-(quinolin-3-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8b 
Scale: 3-(1-(3-nitrobenzyl)-1H-1,2,3-triazol-5-yl)quinoline (200 mg, 
0.604 mmol) 
This compound was synthesized following the general procedure for 
reduction of aromatic nitro and acylation with acryloyl chloride. The 
compound was purified by silica gel column chromatography, eluted 
first with EtOAc and hexane (EtOAc:Hexane, 90:10) and then EtOAc. 
This afforded the pure product as a white foam (132 mg, 0.37 mmol, 
62%) 
Rf = 0.44 (EtOAc:Hexane, 90:10); Mp 122-124 °C; IR (ATR, cm
-1
):3259 (m, stretch, N–H), 
1667 (s, stretch,–C=C–), 1202 (s, stretch, C–N), 747 (s, oop, C–H);1H NMR (400 MHz, 
DMSO-d6) δ 10.12 (s, 1H, NH), 8.95 (d, J = 2.2 Hz, 1H, ArH), 8.51 (dd, J = 9.0, 1.9 Hz, 1H, 
ArH), 8.21 (d, J = 8.7 Hz, 1H,CCHN), 8.05 (d, J = 8.5 Hz, 1H, ArH), 7.97 (t, J = 7.2 Hz, 1H, 
ArH), 7.90 – 7.79 (m, 1H, ArH), 7.68 (t, J = 7.4 Hz, 1H, ArH), 7.55 (d, J = 8.3 Hz, 1H, ArH), 
7.39 (s, 1H, ArH), 7.21 (t, J = 7.9 Hz, 1H, ArH), 6.94 – 6.72 (m, 1H, CCHC), 6.46 – 6.30 (m, 
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1H, CCH2), 6.29 – 6.13 (m, 1H, CCH2), 5.88 – 5.62 (m, 3H, CH2); 
13
C NMR (101 MHz, 
DMSO-d6) δ 163.1 (HNCO), 149.3 (ArC), 147.2 (ArC), 139.5 (NCCH), 136.5 (ArC), 135.6 
(ArC), 134.8 (ArC), 134.2 (ArC), 131.7  (CCCH2), 130.7 (CCHN), 129.2 (ArC), 128.8 (ArC), 
128.5 (ArC), 127.6 (ArC), 127.0 (ArC), 126.8 (CCH2), 122.0 (ArC), 120.0 (ArC), 118.7 
(ArC), 117.5 (ArC), 51.5 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for C21H18N5O: 
356.1511; found: 356.1520 
N-{4-{[5-(quinolin-3-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8c 
Scale: 3-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-5-yl)quinoline (200 mg, 
0.604 mmol) 
This compound was synthesized following the general procedure for 
reduction of aromatic nitro and acylation with acryloyl chloride. 
The compound was purified by silica gel column chromatography, 
eluted first with EtOAc and hexane (EtOAc:Hexane, 90:10) and 
then EtOAc. This afforded the pure product as a white foam (134 
mg, 0.38 mmol, 62%) 
Rf= 0.43 (EtOAc:Hexane, 90:10); Mp 178-180 °C; IR (ATR, cm
-1
):3239 (m, stretch, N–H), 
1679 (s, stretch,–C=C–), 1254 (s, stretch, C–N), 790 (s, oop, C–H); 1H NMR (400 MHz, 
DMSO-d6) δ 10.12 (s, 1H, NH), 8.95 (d, J = 2.2 Hz, 1H, ArH), 8.54 (d, J = 2.1 Hz, 1H, 
ArH), 8.19 (s, 1H,CCHN), 8.06 (d, J = 8.5 Hz, 1H, ArH), 8.00 (d, J = 8.1 Hz, 1H, ArH), 7.84 
(t, J = 7.0 Hz, 1H, ArH), 7.69 (t, J = 7.5 Hz, 1H, ArH), 7.54 (d, J = 8.5 Hz, 2H, ArH), 7.01 
(d, J = 8.5 Hz, 2H, ArH), 6.37 (dd, J = 17.0, 10.1 Hz, 1H, CCHC), 6.21 (dd, J = 17.0, 2.0 Hz, 
1H, CCH2), 5.79 (s, 2H, CH2), 5.76 – 5.69 (m, 1H, CCH2); 
13
C NMR (101 MHz, DMSO-d6) 
δ 163.1 (HNCO), 149.4 (ArC), 147.2 (ArC), 138.6 (NCCH), 135.6 (ArC), 134.7 (ArC), 134.2 
(ArC), 131.7  (CCCH2), 130.8 (ArC), 130.6 (CCHN), 128.8 (ArC), 128.5 (ArC), 127.7 (ArC), 
127.6 (ArC), 127.0 (ArC), 126.8 (CCH2), 120.1 (ArC), 119.4 (ArC), 51.3 (CH2); HRMS-
TOF MS ES+: m/z [M+H]
+
 calcd for C21H18N5O: 356.1511; found: 356.1521 
N-{2-{[5-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8d 
Scale: 7-chloro-4-(1-(2-nitrobenzyl)-1H-1,2,3-triazol-5-
yl)quinoline (140 mg, 0.38 mmol) 
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This compound was synthesized following the general procedure for reduction of aromatic 
nitro and acylation with acryloyl chloride. The compound was purified by silica gel column 
chromatography, eluted first with EtOAc and hexane (EtOAc:Hexane, 90:10) and then 
EtOAc. This afforded the pure product as a white foam (90 mg, 0.23 mmol, 61%) 
Rf = 0.41 (EtOAc:Hexane, 90:10); Mp 154-156 °C; IR (ATR, cm
-1
):3249 (m, stretch, N–H), 
1665 (s, stretch,–C=C–), 1186 (s, stretch, C–N), 876 (s, oop, C–H); 1H NMR (400 MHz, 
CDCl3) δ 9.09 (s, 1H, NH), 9.03 (d, J = 4.3 Hz, 1H, ArH), 8.25 (d, J = 1.9 Hz, 1H, ArH), 
7.89 (t, J = 8.3 Hz, 1H, ArH), 7.85 (s, 1H,CCHN), 7.46 (dd, J = 8.9, 2.0 Hz, 1H, ArH), 7.28 – 
7.25 (m, 3H, ArH), 6.79 (t, J = 7.4 Hz, 1H, ArH), 6.47 (t, J = 3.7 Hz, 1H, ArH), 6.46 – 6.40 
(m, 1H, CCHC), 6.31 (d, J = 7.4 Hz, 1H, CCH2), 5.85 (d, J = 10.8 Hz, 1H, CCH2), 5.30 (s, 
2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 164.3 (HNCO), 150.9 (ArC), 148.9 (ArC), 137.0 
(NCCH), 136.9 (ArC), 135.1 (ArC), 133.5 (ArC), 133.2 (ArC), 131.4  (CCCH2), 130.4 
(CCHN), 130.2 (ArC), 129.4 (ArC), 129.3 (ArC), 128.2 (ArC), 125.9 (CCH2), 125.1 (ArC), 
124.94 (ArC), 123.05 (ArC), 50.1 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 calcd for 
C21H17ClN5O: 390.1122; found: 390.1120 
N-{3-{[5-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8e 
Scale: 7-chloro-4-(1-(3-nitrobenzyl)-1H-1,2,3-triazol-5-
yl)quinoline (190 mg, 0.52 mmol) 
This compound was synthesized following the general 
procedure for reduction of aromatic nitro and acylation with 
acryloyl chloride. The compound was purified by silica gel 
column chromatography, eluted first with EtOAc and hexane 
(EtOAc:Hexane, 90:10) and then EtOAc. This afforded the 
pure product as a white foam (113 mg, 0.29 mmol, 56%  
Rf = 0.41 (EtOAc:Hexane, 90:10); Mp 128-131 °C;IR (ATR, cm
-1
):3271 (m, stretch, N–H), 
2920(m, stretch, CH2), 1668 (s, stretch,–C=C–), 1169 (s, stretch, C–N), 877 (s, oop, C–H); 
1
H NMR (400 MHz, CDCl3) δ 8.94 (s, 1H, NH), 8.16 (s, 1H, ArH), 7.88 (d, J = 24.5 Hz, 
1H,CCHN), 7.65 (s, 1H, ArH), 7.48 – 7.36 (m, 2H, ArH), 7.35 – 7.27 (m, 1H, ArH), 7.18 (d, 
J = 4.3 Hz, 1H, ArH), 7.15 – 6.99 (m, 2H, ArH), 6.56 (t, J = 7.9 Hz, 1H, ArH), 6.45 – 6.35 
(m, 1H, CCHC), 6.29 – 6.15 (m, 1H, CCH2), 5.75 (d, J = 10.3 Hz, 1H, CCH2), 5.40 (d, J = 
20.4 Hz, 2H, CH2);
13
C NMR (101 MHz,CDCl3) δ 163.6 (HNCO), 150.8 (ArC), 149.6 
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(ArC), 148.8 (ArC), 138.6 (NCCH), 136.5 (ArC), 135.3 (ArC), 135.1 (ArC), 133.6  (CCCH2), 
131.0 (CCHN), 129.6 (ArC), 129.1 (ArC), 129.0 (ArC), 128.3 (ArC), 126.0 (CCH2), 125.1 
(ArC), 123.4 (ArC), 122.9 (ArC), 120.0 (ArC), 119.0 (ArC), 52.6 (CH2); HRMS-TOF MS 
ES+: m/z [M+H]
+
 calcd for C21H17ClN5O: 390.1122; found: 390.1118 
N-{4-{[5-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8f 
Scale: 7-chloro-4-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-
5-yl)quinoline (190 mg, 0.52 mmol) 
This compound was synthesized following the 
general procedure for reduction of aromatic nitro and 
acylation with acryloyl chloride. The compound was 
purified by silica gel column chromatography, eluted 
first with EtOAc and hexane (EtOAc:Hexane, 90:10) and then EtOAc. This afforded the pure 
product as a white foam (116 mg, 0.30 mmol, 57%) 
Rf = 0.4 (EtOAc:Hexane, 90:10); Mp 161-173 °C;IR (ATR, cm
-1
):3287 (m, stretch, N–H), 
2850(m, stretch, CH2), 1675 (s, stretch,–C=C–), 1242 (s, stretch, C–N), 877 (s, oop, C–H); 
1
H NMR (400 MHz, CDCl3) δ 8.92 (s, 1H, NH), 8.19 (t, J = 6.1 Hz, 1H, ArH), 7.85 (s, 
1H,CCHN), 7.47 (d, J = 8.5 Hz, 1H, ArH), 7.43 (dd, J = 8.9, 1.6 Hz, 1H, ArH), 7.36 (d, J = 
8.0 Hz, 2H, ArH), 7.30 (d, J = 8.9 Hz, 1H, ArH), 7.12 (d, J = 4.2 Hz, 1H, ArH), 6.79 (d, J = 
8.3 Hz, 2H, ArH), 6.42 (d, J = 16.8 Hz, 1H, CCHC), 6.24 (dd, J = 16.8, 10.2 Hz, 1H, CCH2), 
5.77 (d, J = 10.2 Hz, 1H, CCH2), 5.36 (s, 2H, CH2);
13
C NMR (101 MHz,CDCl3) δ 163.6 
(HNCO), 150.8 (ArC), 148.9 (ArC), 138.3 (NCCH), 136.5 (ArC), 135.2 (ArC), 133.7 (ArC), 
133.0  (CCCH2), 131.0 (CCHN), 130.2 (ArC), 129.2 (ArC), 129.1 (ArC), 128.57 (ArC), 
128.42 (ArC), 126.0 (CCH2), 125.1 (ArC), 122.7 (ArC), 120.1v, 52.4 (CH2);HRMS-TOF 
MS ES+: m/z [M+H]
+
 calcd for C21H17ClN5O: 390.1122; found: 390.1111 
N-{2-{[5-(isoquinolin-4-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8g 
Scale: 4-(1-(2-nitrobenzyl)-1H-1,2,3-triazol-5-yl)isoquinoline (108 
mg, 0.33 mmol) 
This compound was synthesized following the general procedure for 
reduction of aromatic nitro and acylation with acryloyl chloride. The 
compound was purified by silica gel column chromatography, eluted 
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first with EtOAc and hexane (EtOAc:Hexane, 90:10) and then EtOAc. This afforded the pure 
product as a white foam (68 mg, 0.19 mmol, 59%) 
Rf = 0.24 (EtOAc:Hexane, 90:10); Mp 189-191 °C; IR (ATR, cm
-1
):3224 (m, stretch, N–H), 
2919(m, stretch, CH2), 1673 (s, stretch,–C=C–), 1205 (s, stretch, C–N), 749 (s, oop, C–H); 
1
H NMR (400 MHz, CDCl3) δ 9.43 (s, 1H, NH), 8.41 (s, 1H, ArH), 8.13 (d, J = 7.9 Hz, 1H, 
ArH), 7.92 (d, J = 7.8 Hz, 1H, ArH), 7.84 (s, 1H,CCHN), 7.76 – 7.63 (m, 2H, ArH), 7.28 (d, 
J = 8.3 Hz, 1H, ArH), 7.22 (d, J = 7.2 Hz, 1H, ArH), 6.76 (t, J = 7.4 Hz, 1H, CCHC), 6.55 – 
6.44 (m, 2H, ArH), 6.34 (d, J = 7.4 Hz, 1H, CCH2), 5.84 (dd, J = 8.9, 2.3 Hz, 1H, CCH2), 
5.28 (s, 2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 164.3 (HNCO), 155.0 (ArC), 144.5 (ArC), 
137.1 (NCCH), 135.5 (ArC), 134.6 (ArC), 133.4 (ArC), 132.2 (ArC), 131.6  (CCCH2), 130.4 
(CCHN), 130.2 (ArC), 128.5 (ArC), 128.4 (ArC), 127.9 (ArC), 125.3 (CCH2), 124.9 (ArC), 
124.8 (ArC), 123.6 (ArC), 118.2 (ArC), 49.7 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 
calcd for C21H18N5O: 356.1511; found: 356.1515 
N-{3-{[5-(isoquinolin-4-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8h 
Scale: 4-(1-(3-nitrobenzyl)-1H-1,2,3-triazol-5-yl)isoquinoline (131 
mg, 0.4 mmol) 
This compound was synthesized following the general procedure 
for reduction of aromatic nitro and acylation with acryloyl 
chloride. The compound was purified by silica gel column 
chromatography, eluted first with EtOAc and hexane 
(EtOAc:Hexane, 90:10) and then EtOAc. This afforded the pure 
product as a white foam (91 mg, 0.26 mmol, 64%) 
Rf = 0.24 (EtOAc:Hexane, 90:10); Mp 126-128 °C;IR (ATR, cm
-1
):3266 (m, stretch, N–
H),1667 (s, stretch,–C=C–), 1207 (s, stretch, C–N), 747 (s, oop, C–H); 1H NMR (400 MHz, 
CDCl3) δ 9.32 (s, 1H, NH), 8.29 (d, J = 5.0 Hz, 1H, ArH), 8.08 – 8.02 (m, 2H, ArH), 7.85 (s, 
1H,CCHN), 7.68 – 7.59 (m, 2H, ArH), 7.54 (d, J = 8.0 Hz, 1H, ArH), 7.35 – 7.30 (m, 1H, 
ArH), 7.10 (s, 1H, ArH), 7.02 (t, J = 7.9 Hz, 1H, ArH), 6.52 (d, J = 7.7 Hz, 1H, ArH), 6.38 
(dd, J = 16.9, 1.4 Hz, 1H, CCHC), 6.24 (dd, J = 16.9, 10.1 Hz, 1H, CCH2), 5.72 (dd, J = 10.1, 
1.4 Hz, 1H, CCH2), 5.37 (s, 2H, CH2);
13
C NMR (101 MHz,CDCl3) δ 163.7 (HNCO), 154.6 
(ArC), 144.2 (ArC), 138.7 (NCCH), 135.5 (ArC), 135.4 (ArC), 134.6 (ArC), 133.1 (ArC), 
131.9 (CCCH2), 131.2 (CCHN), 129.5 (ArC), 128.3 (ArC), 128.3 (ArC), 128.0 (ArC), 123.7 
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(CCH2), 123.4 (ArC), 120.0 (ArC), 119.0 (ArC), 118.7 (ArC), 52.4 (CH2);HRMS-TOF MS 
ES+: m/z [M+H]
+
 calcd for C21H18N5O: 356.1511; found: 356.1511 
N-{4-{[5-(isoquinolin-4-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8i 
Scale: 4-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-5-
yl)isoquinoline (155 mg, 0.47 mmol) 
This compound was synthesized following the general 
procedure for reduction of aromatic nitro and acylation 
with acryloyl chloride. The compound was purified by 
silica gel column chromatography, eluted first with 
EtOAc and hexane (EtOAc:Hexane, 90:10) and then EtOAc. This afforded the pure product 
as a white foam (95 mg, 0.27 mmol, 57%) 
Rf = 0.26 (EtOAc:Hexane, 90:10); Mp 179-181 °C;IR (ATR, cm
-1
):3224 (m, stretch, N–H), 
2960(m, stretch, CH2), 1681 (s, stretch,–C=C–), 1250 (s, stretch, C–N), 752 (s, oop, C–H); 
1
H NMR (400 MHz, CDCl3) δ 9.36 (s, 1H, NH), 8.25 (s, 1H, ArH), 8.09 (dd, J = 17.8, 11.4 
Hz, 2H, ArH), 7.86 (s, 1H,CCHN), 7.74 – 7.63 (m, 2H, ArH), 7.36 (d, J = 6.8 Hz, 3H, ArH), 
6.76 (t, J = 13.9 Hz, 2H, ArH), 6.47 – 6.21 (m, 2H, CCHC, CCH2), 5.73 (d, J = 10.1 Hz, 1H, 
CCH2), 5.42 – 5.28 (m, 2H, CH2);
13
C NMR (101 MHz,CDCl3) δ 163.7 (HNCO), 154.6 
(ArC), 144.17 (ArC), 138.3 (NCCH), 135.5 (ArC), 134.6 (ArC), 132.9 (ArC), 132.0 
(CCCH2), 131.2 (CCHN), 130.3 (ArC), 128.6 (ArC), 128.4 (ArC), 128.3 (ArC), 128.2 (ArC), 
128.1 (ArC), 123.7 (CCH2), 120.1 (ArC), 118.7 (ArC), 52.2 (CH2);HRMS-TOF MS ES+: 
m/z [M+H]
+
 calcd for C21H18N5O: 356.1511; found: 356.1516 
N-{2-{[5-(quinolin-5-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8j 
Scale: 5-(1-(2-nitrobenzyl)-1H-1,2,3-triazol-5-yl)isoquinoline (140 mg, 
0.42mmol) 
This compound was synthesized following the general procedure for 
reduction of aromatic nitro and acylation with acryloyl chloride. The 
compound was purified by silica gel column chromatography, eluted with 
EtOAc and MeOH (EtOAc:MeOH, 95:5). This afforded the pure product 
as a white foam (91 mg, 0.26 mmol, 61%) 
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Rf = 0.38 (EtOAc:MeOHl, 95:5) ; Mp 193-195 °C;IR (ATR, cm
-1
):3222 (m, stretch, N–H), 
1673 (s, stretch,–C=C–), 1245 (s, stretch, C–N), 827 (s, oop, C–H); 1H NMR (400 MHz, 
CDCl3) δ 9.39 (s, 2H, NH), 8.49 (s, 1H, ArH), 8.19 (dd, J = 22.3, 7.6 Hz, 1H, ArH), 7.97 (d, 
J = 7.6 Hz, 1H, ArH), 7.83 (s, 1H,CCHN), 7.75 (t, J = 7.6 Hz, 1H, ArH), 7.66 – 7.57 (m, 1H, 
ArH), 7.26 (t, J = 7.7 Hz, 1H, ArH), 7.08 (d, J = 5.6 Hz, 1H, ArH), 6.75 (t, J = 7.3 Hz, 1H, 
CCHC), 6.49 (q, J = 17.2 Hz, 2H, ArH), 6.23 (d, J = 7.2 Hz, 1H, CCH2), 5.84 (t, J = 12.6 Hz, 
1H, CCH2), 5.28 (d, J = 12.7 Hz, 2H, CH2);
13
C NMR (101 MHz,CDCl3) δ 164.3 (HNCO), 
153.2 (ArC), 144.7 (ArC), 137.3 (NCCH), 135.1 (ArC), 134.9 (ArC), 134.9 (ArC), 133.4 
(ArC), 131.65 (CCCH2), 130.6 (CCHN), 130.3 (ArC), 130.3 (ArC), 128.0 (ArC), 126.8 
(CCH2), 125.1 (ArC), 124.8 (ArC), 123.1 (ArC), 117.3 (ArC), 49.7 (CH2);HRMS-TOF MS 
ES+: m/z [M+H]
+
 calcd for C21H18N5O: 356.1511; found: 356.1515 
N-{2-{[5-(quinolin-5-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8k 
Scale: 5-(1-(3-nitrobenzyl)-1H-1,2,3-triazol-5-yl)isoquinoline (150 mg, 
0.45 mmol) 
This compound was synthesized following the general procedure for 
reduction of aromatic nitro and acylation with acryloyl chloride. The 
compound was purified by silica gel column chromatography, eluted 
with EtOAc and MeOH (EtOAc:MeOH, 95:5). This afforded the pure 
product as a white foam (93 mg, 0.26 mmol, 58%) 
Rf = 0.37 (EtOAc:MeOH, 95:5); Mp 134-136 °C;IR (ATR, cm
-1
):3262 (m, stretch, N–H), 
2960(m, stretch, CH2), 1611 (s, stretch,–C=C–), 1257 (s, stretch, C–N), 792 (s, oop, C–H); 
1
H NMR (400 MHz, CDCl3) δ 9.30 (s, 1H, NH), 8.40 (s, 1H, ArH), 8.10 (d, J = 8.3 Hz, 1H), 
7.83 (s, 1H,CCHN), 7.65 (t, J = 7.7 Hz, 1H, ArH), 7.57 – 7.47 (m, 2H, ArH), 7.36 (d, J = 8.0 
Hz, 1H, ArH), 7.14 – 7.02 (m, 3H, ArH), 6.58 (d, J = 7.8 Hz, 1H, ArH), 6.40 (d, J = 16.9 Hz, 
1H, CCHC), 6.21 (dd, J = 16.8, 10.2 Hz, 1H, CCH2), 5.76 (d, J = 10.2 Hz, 1H, CCH2), 5.34 
(s, 2H, CH2);
13
C NMR (101 MHz,CDCl3) δ 163.5 (HNCO), 152.9 (ArC), 144.1 (ArC), 
138.4 (NCCH), 135.6 (ArC), 135.1 (ArC), 134.9 (ArC), 134.5 (ArC), 133.2 (ArC), 131.1 
(CCCH2), 130.1 (CCHN), 129.5 (ArC), 128.6 (ArC), 128.2 (ArC), 126.9 (CCH2), 123.7 
(ArC), 123.6 (ArC), 119.8 (ArC), 119.2 (ArC), 117.4 (ArC), 52.4 (CH2);HRMS-TOF MS 
ES+: m/z [M+H]
+
 calcd for C21H18N5O: 356.1511; found: 356.1512 
N-{2-{[5-(quinolin-5-yl)-1H-1,2,3-triazol-1-yl]methyl}phenyl}acrylamide - 8l 
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Scale: 5-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-5-yl)isoquinoline 
(140 mg, 0.42 mmol) 
This compound was synthesized following the general 
procedure for reduction of aromatic nitro and acylation with 
acryloyl chloride. The compound was purified by silica gel 
column chromatography, eluted with EtOAc and MeOH 
(EtOAc:MeOH, 95:5).  This afforded the pure product as a white foam (99 mg, 0.28 mmol, 
66%) 
Rf = 0.36 (EtOAc:MeOH, 95:5); Mp 196-198 °C; IR (ATR, cm
-1
):3274 (m, stretch, N–H), 
2960(m, stretch, CH2), 1664 (s, stretch,–C=C–), 1256 (s, stretch, C–N), 760 (s, oop, C–H); 
1
H NMR (400 MHz, CDCl3) δ 9.33 (s, 1H, NH), 8.45 (d, J = 5.8 Hz, 1H, ArH), 8.12 (d, J = 
8.3 Hz, 1H, ArH), 7.82 (s, 1H,CCHN), 7.65 (dd, J = 18.5, 11.2 Hz, 1H, ArH), 7.51 (s, 1H, 
ArH), 7.46 (d, J = 6.6 Hz, 1H, ArH), 7.34 (d, J = 8.1 Hz, 2H, ArH), 7.13 (d, J = 5.9 Hz, 1H, 
ArH), 6.78 (d, J = 8.4 Hz, 2H, ArH), 6.42 (d, J = 16.8 Hz, 1H, CCHC), 6.30 – 6.17 (m, 1H, 
CCH2), 5.84 – 5.71 (m, 1H, CCH2), 5.32 (s, 2H, CH2); 
13
C NMR (101 MHz,CDCl3) δ 153.1 
(HNCO), 144.5 (ArC), 138.1 (NCCH), 135.1 (ArC), 134.8 (ArC), 134.4 (ArC), 133.0 (ArC), 
131.1 (CCCH2), 130.6 (CCHN), 130.1 (ArC), 128.6 (ArC), 128.3 (ArC), 126.7 (CCH2), 
123.7 (ArC), 120.0 (ArC), 117.4 (ArC), 52.1 (CH2); HRMS-TOF MS ES+: m/z [M+H]
+
 
calcd for C21H18N5O: 356.1511; found: 356.151 
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